

Part I: General Information

Date Prepared: May 7, 2021

Name: David J. Kuter

Office address: Hematology Division
Suite 118, Room 110
Massachusetts General Hospital
Zero Emerson Place
Boston, MA 02114
617-726-8033

Home Address: 16 Prospect Street
Reading, Massachusetts 01867

E:mail: dkuter@MGH.harvard.edu

FAX: 617-724-6801

Place of Birth: Fond du Lac, Wisconsin

Education:

1971 A.B.	Harvard College, Cambridge, Massachusetts
1976 D. Phil.	Magdalen College, Oxford University, Oxford, England (Biochemistry)
1978 M.D.	Harvard Medical School, Boston, Massachusetts

Post-doctoral Training:

Internship and Residency:

1978-1979	Intern, Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts
1979-1980	Assistant Resident, Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts
1980-1981	Senior Resident, Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts
1983	Chief Resident, Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts

Clinical and Research Fellowships:

1978-1981	Clinical Fellow in Medicine, Harvard Medical School, Boston, Massachusetts
-----------	---

1981-1983	Research Fellow in Medicine, Harvard Medical School, Boston, Massachusetts
1981-1984	Fellow, Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts
1984-1994	Visiting Scientist and Post-doctoral Fellow, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA

Licensure and Certification:

1980	Massachusetts License
1981	American Board of Internal Medicine (Sept. 16, 1981)
1984	American Board of Internal Medicine, Subspecialty Board in Hematology (Nov. 13, 1984)
1985	American Board of Internal Medicine, Subspecialty Board in Medical Oncology (Nov. 19, 1985)

Academic Appointments:

1975-1978	Teaching Fellow, Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts
1983-1991	Instructor in Medicine, Harvard Medical School, Boston, Massachusetts
1984-1994	Visiting Scientist, Department of Biology, Whitaker College, Massachusetts Institute of Technology, Cambridge, Massachusetts
1991-2001	Assistant Professor of Medicine, Harvard Medical School, Boston, Massachusetts
1991-2009	Member of the Affiliated Faculty of the Harvard-MIT Division of Health Sciences and Technology
2001-2008	Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts
2008-	Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Hospital or Affiliated Institution Appointments:

1981-1983	Clinical and Research Fellow in Medicine, Massachusetts General Hospital, Boston, Massachusetts
1983-1984	Chief Resident in Medicine, Massachusetts General Hospital, Boston, Massachusetts
1984-1988	Assistant in Medicine, Massachusetts General Hospital, Boston, Massachusetts
1988-1993	Assistant Physician, Massachusetts General Hospital, Boston, Massachusetts

1993-1998	Associate Physician, Massachusetts General Hospital, Boston, Massachusetts
1995-	Director of Clinical Hematology, Massachusetts General Hospital, Boston, Massachusetts
1998-	Physician, Massachusetts General Hospital, Boston, Massachusetts

Major Administrative Responsibilities:

1995-	Director of Clinical Hematology, Massachusetts General Hospital, Boston, Massachusetts
2000-	Director Partner's Clinical Hematology Program, MGH-BWH-DFCI, Boston, Massachusetts

Major Committee Assignments:

Massachusetts General Hospital:

1983-1984	Quality Assurance Board (member)
1985-1986	Staff Associates Subcommittee on Practice Organization (member)
1983	Internship Selection Committee,
1985-1986,	Department of Medicine (member)
1989-1995	
1988-1989	Committee on Research (member)
1989-1994	Minority Affairs Committee (member)
1990-	Transfusion Committee (member)
1990-1991	Blood Bank Director Search Committee (member)
1991-1992	Bone Marrow Transplantation Search Committee (member)
1993	Hematology Laboratory Director Search Committee (member)
1995-	MGH-DFCI Fellowship Selection Committee (member)
2000-2003	MGH Anticoagulation Committee (member)
2008-2020	MGH Anticoagulation Guidelines Committee (chairman)
2012-	MGH Oncology Drugs Stewardship Committee (member)
2013-2020	MGH Antithrombosis Stewardship Committee (chairman)

National:

1995-1998	American Society of Hematology Scientific Subcommittee on Platelets (member)
-----------	--

1996	Working Group on Thrombopoietin. National Heart, Lung, Blood Institute. National Institutes of Health, Bethesda, MD (member)
2000	Working Group on Clinical Research in Transfusion Medicine/Hemostasis. National Heart, Lung, Blood Institute. National Institutes of Health, Bethesda, MD (member)
2001-2003	American Society of Hematology Scientific Subcommittee on Hematopoietic Growth Factors (member)
2002-	Steering Committee, NIH Network for Transfusion Medicine and Hemostasis (member)
2003-	Publications Committee, NIH Network for Transfusion Medicine and Hemostasis (Chairman)
2003-2005	ITP Sub-committee, NIH Network for Transfusion Medicine and Hemostasis (Chairman)
2004	American Society of Hematology Scientific Subcommittee on Hematopoietic Growth Factors (Chairman)
2005	American Society of Hematology Scientific Subcommittee on Hematopoietic Growth Factors (Chairman)
2004-2015	Heparin-induced Thrombocytopenia Subcommittee, NIH Network for Transfusion Medicine and Hemostasis (Chairman)
2006-	Platelet Disorder Support Association, Medical Advisory Board (Member)
2006-2007	American Society of Hematology Committee on Training Programs (Member)
2009	National Institute of Health, NHLBI, External Panel, State of the Science – Hemostasis/Thrombosis (Member)
2016-2019	American Society of Hematology, ITP Guidelines Committee (Member)
2016-	National Blood Clot Alliance, Medical and Scientific Advisory Board (MASAB) (Member)
2017-2021	American Society of Hematology, ASH Awards Committee (Member)
2018-	American Society of Hematology, ASH Mentor Award Study Section (Member)
2021-	American Society of Hematology, ASH Awards Committee (Vice-Chairman)

International:

2006-	Steering Committee (Member), OGT 918-001 Study (A phase IV, open-label, non-comparative, multi-center study to evaluate the long term efficacy, safety and tolerability of oral miglustat as a maintenance after a switch from Enzyme Replacement Therapy (ERT) in adult patients with stable Type I Gaucher Disease
2008-2009	International ITP Guidelines Group (Member)
2008-2017	NCCN Myeloid Growth Factors Panel (Member)
2008-	Steering Committee (Chairman), AC-056B501 Study (A multi-center, retrospective cohort study to describe outcomes of miglustat therapy in Type I Gaucher Disease patients followed-up between 2003 and 2008
2008	International Working Group on ITP Standardization (Member)
2010	Data Safety Monitoring board (Chairman), E5501-G000-202, A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy, Safety, and Population Pharmacodynamics of Once-Daily Oral E5501 Tablets Used up to 7 Days in Subjects with Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures.
2010-2013	Romiplostim Bone Marrow Committee (Chairman), for all Amgen post-marketing studies.
2015-2019	ASH Guideline Panel on Immune Thrombocytopenia (Member)
2017-2021	Independent Monitoring Committee for PRN1008-010 (NCT03395210) An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura (Co-Chairman).
2018-2019	International Working Group on ITP Standardization (Co-Chairman)

Professional Societies:

1986- American Society of Hematology-- Member

1993-2012 International Society for Experimental Hematology -- Member

Editorial Boards:

1987 Editorial Board, Cancer Manual (8th Edition), American Cancer Society, Massachusetts Division
 1993 Editorial Board, Cancer Manual (9th Edition), American Cancer Society, Massachusetts Division
 1983- Reviewer, *Blood*
 1983- Reviewer, *The New England Journal of Medicine*
 1983- Reviewer, *Transfusion*
 2004-2007 Editor, Hematology section, *First Consult*
 2012-2014 Reviewer, Faculty of 1000
 2012- Sub-editor, Hematology, Merck Manuals

Awards and Honors:

1971 Summa cum laude, Harvard College, Cambridge, MA
 1971 Phi Beta Kappa
 1971-1974 Rhodes Scholar (Wisconsin and Magdalen)
 1981-1982 American Cancer Society Regular Clinical Fellowship
 2000 Joseph R. Bove Transfusion Medicine Visiting Professor, Yale University School of Medicine, New Haven, CT (March 20-21)
 2001 Geller Memorial Lecture, Dept of Medicine, South Nassau Community Hospital, Oceanside, NY
 2002 2002 Partners in Excellence Award, Massachusetts General Hospital, Boston, MA
 2003 Visiting Professorship, Drexel University College of Medicine, Philadelphia, PA
 2006 Visiting Professorship, Drexel University College of Medicine, Philadelphia, PA
 2007 13th Joseph R. Bove Transfusion Medicine Visiting Professor New Haven, CT (November 26-27)
 2007 Boston Best Doctors 2007 – Hematology/Oncology
 2007 The Jane Grier Memorial Prize – Recognizing Excellence in Hematology-Oncology Teaching, MGH Cancer Center, Boston, MA
 2008 The Robert Hettig Lectureship in Hematology, Department of Medicine, Baylor School of Medicine, Houston, TX
 2008 The Joseph E. Sokal Memorial Lectureship, Duke University Medical Center, Durham, NC
 2008 The Douglas Family Foundation Prize – Recognizing Excellence in Hematology-Oncology Research, MGH Cancer Center, Boston, MA
 2010 The Cooper Visiting Professorship, North Shore Medical Center, Salem, MA
 2010 The Douglas Family Foundation Prize – Recognizing

	Excellence in Hematology-Oncology Research, MGH Cancer Center, Boston, MA
2010	Visiting Professor, Yamagata University Medical Society, Yamagata, Japan
2011	The Michael Binari Lecture on Anticoagulation, Mt Auburn Hospital, Cambridge, MA
2011	2011 Top Doctor Hematology
2012	Visiting Professor, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2012	2012 Partners in Excellence Individual Award, Massachusetts General Hospital, Boston, MA
2012	2012 Top Doctor Hematology
2013	The 100 Award, MGH Cancer Center, Boston, MA
2013	2013 Top Doctor Hematology
2013	Ernest Beutler Prize, American Society of Hematology
2016	The Eighth Annual Arthur Haut, M.D. Lecture, University of Arkansas College of Medicine
2018	The Alfred Hospital Whole Time Medical Specialists Visiting Professor, The Alfred Hospital, Melbourne, Australia
2019	2019 Partners in Excellence Award, Partners Healthcare, Intravenous Immunoglobulin (IVUG) Shortage Workgroup
2019	2019 Partners in Excellence Award, Partners Healthcare, Intravenous Heparin Shortage Working Group

Part II: Research, Teaching, and Clinical Contributions

A. Narrative Report

My clinical efforts are directed toward malignant and benign hematology problems. I am especially interested in complex coagulation issues, the use of anticoagulants, unusual disorders of platelets, myeloma, and myeloproliferative diseases. My clinical and research interests are united around problems of low or high platelet counts. In addition I serve as the main referral center for the medical treatment of patients with Gaucher's Disease.

My clinical interests above guide my clinical research efforts. We conduct research trials on the treatment of patients with Gaucher's Disease with Cerezyme and Zavesca. In addition, we are a major site for trials using thrombopoietin (PEG-rHuMGDF, rHuTPO, AMG-531, eltrombopag) and have done many of the pivotal studies in the use of PEG-rHuMGDF in stimulating platelet donors to provide increased apheresis yields as well as with AMG-531 in increasing the platelet count in patients with ITP. We were also a major center for the study of the new erythropoietin, darbepoetin alpha, in stimulating red blood cell production in patients with cancer. I also participate in a large number of clinical trials in multiple myeloma and helped develop the new drug bortezomib. I lead one clinical research team looking at the incidence, biochemical mechanism of, and treatment for thrombosis in malignancy and a second group that is doing clinical trials in heparin-induced thrombocytopenia (HIT). The former will soon start a randomized, placebo-controlled trial in

patients with limited stage small cell lung cancer to see if enoxaparin sodium increases survival. The latter is about to start the only randomized, controlled trial in the treatment of HIT (comparing fondaparinux to direct thrombin inhibitors).

My basic science interests revolve around the biology and molecular biology of thrombopoietin and platelets, especially as related to clinical disorders of platelet production, such as idiopathic thrombocytopenic purpura and essential thrombocythemia. One program serves as a worldwide reference laboratory for measuring thrombopoietin and antibodies to thrombopoietin. A second program analyzes the mechanism of action of several new thrombopoietin small molecule mimetics. A third program has identified the mechanism and role of apoptosis in platelet viability. My major new activity has been to use microarray and proteomics methods to identify novel genes that distinguish essential thrombocythemia platelets from normal platelets. Several genes (such as cyclin G1) have been found that are markedly altered in ET platelets and give some clue as to the underlying pathophysiology.

My teaching efforts are directed toward training the Hematology/Oncology fellows in hematology and running the HST 080 Hematology Course. For the 14 Hematology/Oncology fellows, I direct the Hematology Clinic and Conference and supervise the fellows when they admit patients to the hospital. Weekly microscope rounds, direct bedside teaching, and formal lecturing are done on all hematology topics. I also ran the HST 080 Hematology Course (1994-2009): this involves organizing all lectures, giving one-quarter of the lectures, teaching all of the problems sets, and writing the camel each year for 35-40 students (April-May, 48 contact hours).

At the national level I have served on numerous committees of the American Society of Hematology and help run the NIH-Transfusion Medicine and Hemostasis (TMH) Network. I have organized several international hematology symposia each year for the past decade and lecture on many hematology topics throughout North American, Europe, Africa, South America, Asia and Australia.

B. Funding Information: (Note: funding end-dates not available for all studies and for these funding will continue until drug is approved)

For Research

1985-1988	American Cancer Society	PI
	Career Development Award: The regulation of platelet production.	
1995-1997	AMGEN	PI
	The interaction of thrombopoietin with platelets and endothelial cells.	
1996-1997	Upjohn-Pharmacia	PI
	Thromboembolism and malignancy - therapy, recurrence rate and the role of warfarin.	
1989-1993	Roberts Pharmaceutical Co	PI
	An open protocol for the use of anagrelide for patients with thrombocythemia.	

1993-2006	Genzyme Corporation	PI	Clinical and molecular studies in Gaucher's Disease.
1995-2000	NIH/RO1	PI	The molecular physiology of thrombopoietin.
1995-2000	AMGEN	PI	Clinical studies on thrombocytopenic patients.
1996-1999	Cypress Bioscience	PI	Effectiveness of Prosorba column immunoadsorption vs. intravenous IVIG in patients with steroid-refractory ITP.
1996-2000	AMGEN	PI	A randomized, placebo-controlled, blinded study of the safety and efficacy of PEG-MGDF in normal platelet donors (MGDF-961001).
1996-2000	AMGEN	PI	A placebo-controlled, blinded, safety and efficacy trial of platelet apheresis product collected in MGDF-961001 (MGDF-961003).
1995-2000	AMGEN	PI	A long-term follow-up study of participants enrolled in Amgen-sponsored MGDF trials (MGDF-961004).
1998-2000	Cypress Bioscience	PI	Prospective, randomized, multi-center, blinded, controlled, multiple dose study of IPM safety and efficacy in thrombocytopenic patients with active bleeding.
1998-2002	NIH/RO1	PI	The molecular and cellular mechanisms of platelet viability.
1998-2001	Kirin Brewing Co	PI	Thrombopoietin and the thrombopoietin receptor, MPL, in pathological conditions of altered platelet production
1998-2000	AMGEN	PI	Sequencing the TPO gene and molecular characterization of the antibody to TPO in normal

volunteers with thrombocytopenia after multiple injections of PEG-rHuMGDF

1999-2002	AMGEN	PI	A dose-finding study of novel erythropoiesis stimulating-protein (NESP) administered subcutaneous injection for treatment for anemia in subjects with solid tumors receiving multicycle chemotherapy
1999-2001	Pharmacia-Upjohn	Co-PI	Randomized, double-blind, placebo-controlled trial of recombinant human thrombopoietin administered to patients with solid tumors or lymphomas who are receiving myelosuppressive treatment regimens requiring platelet transfusion support
1999-2001	Pharmacia-Upjohn	Co-PI	A phase III randomized, double-blind, placebo-controlled study to evaluate the effects of Fragmin in preventing catheter-related complications when given daily to cancer patients with central venous catheters
1999-2001	Hoechst	Co-PI	A multicenter study of a 24 hour intravenous infusion of HMR 1275 in fludarabine-refractory or intolerant B-cell chronic lymphocytic leukemia
2000-2002	Kirin	PI	Thrombopoietin and the thrombopoietin receptor, MPL, in pathological disorders – assay development
2000-2004	IDEC	PI	A phase II, randomized, open-label, multiple-dose, dose-finding, safety and clinical activity study of IDEC-131 in patients with chronic, refractory immune thrombocytopenic purpura
2000-2001	Millennium	Site PI	A phase II, open label, randomized study of two doses of PS-341 alone or in combination with dexamethasone in patients with multiple myeloma who have failed to respond or relapsed following front-line therapy
2001-2005	EntreMed	Site PI	A phase 2, open label, safety and efficacy study of 2-methoxyestradiol (2ME2) administered orally to patients with plateau phase or relapsed multiple myeloma.

2002-2002	AMGEN	PI	A randomized, open-label study of darbepoetin alfa using fixed and weight-based dosing for the treatment of anemia in subjects with non-myeloid malignancies receiving multi-cycle chemotherapy
2002-2005	Millennium	Site PI	An international, multi-center, randomized, open-label study of PS-341 versus high-dose dexamethasone in patients with relapsed or refractory multiple myeloma
2002-2005	Millennium	Site PI	An international, non-comparative, open-label study of PS-341 administered to patients with multiple myeloma who experienced relapsed or progressive disease after receiving at least four previous treatment regimens or experienced progressive disease after receiving dexamethasone in Millennium Protocol M34101-039
2002-2005	Millennium	PI	Genomic analysis of platelets from patients with essential thrombocythemia
2002-2004	MDS Proteomics	PI	Proteomic studies of essential thrombocythemia
2002-2004	PLIVIA	PI	Studies on Plivia PLD-117, a novel thrombopoietic factor
2002-2005	Surgical Sealants, Inc	PI	Development of radio adsorption immuno detection (RAID) assay for detecting IgG antibody to bovine albumin and cross-linked bovine albumin
2002-2004	Pharmacia	PI	Detection of antibodies to recombinant human thrombopoietin, rHuTPO, in human serum and Rhesus serum
2002-2004	ALZA Corp	Site PI	A multi-center randomized study of vincristine, doxil, and dexamethasone vs vincristine, doxorubicin, and dexamethasone in patients with multiple myeloma
2002-2003	AMGEN	PI	An open-label, dose-finding study evaluating the safety and efficacy of Amgen Megakaryopoiesis Protein 2 [AMP2(AMG 531)] in thrombocytopenic subjects with immune

thrombocytopenic purpura (ITP)

2002-2002	Genentech	PI	A randomized, double-blind, placebo-controlled phase III trial of Rituxan in adult patients receiving best supportive care for chronic splenectomy-refractory idiopathic autoimmune thrombocytopenic purpura (ITP)
2002-2004	Pharmacia	Co-PI	A trial of dalteparin low molecular weight heparin for primary prophylaxis of venous thromboembolism in brain tumour patients
2002-2007	Genzyme	PI	A multicenter, randomized, dose frequency study of the safety and efficacy of cerezyme infusions every four weeks versus every two weeks in the maintenance therapy of patients with Type 1 Gaucher Disease
2002-2012	NIH-UO1	PI	Studies of rHuTPO in ITP and of rVIIIa in liver disease. We are one of the core 14 centers in the NIH Transfusion Medicine and Hemostasis (TMH) Network
2004-	AMGEN	PI	An open-label study evaluating the safety and efficacy of long-term dosing of AMG531 in thrombocytopenic subjects with ITP
2004-2006	ALEXION	PI	A hemoglobin stabilization and transfusion reduction efficacy and safety clinical investigation, randomized, multi-center, double-blind, placebo-controlled study using eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) (TRIUMPH Study)
2005-2006	ALEXION	PI	Safety in hemolytic PNH patients treated with eculizumab: a multi-center, open-label research design study (SHEPHERD Study)
2005-2007	ALEXION	PI	A phase III, open-label, extension study of eculizumab in patients with transfusion dependent, hemolytic paroxysmal nocturnal hemoglobinuria (PNH) who have participated in the Triumph, Shepherd, or X03-001 Studies
2005-2007	AMGEN	PI	

	A randomized, placebo-controlled study evaluating the efficacy and safety of AMG 531 treatment of thrombocytopenic subjects with ITP prior to splenectomy	
2005-2007	AMGEN	PI
	A randomized, placebo-controlled study evaluating the efficacy and safety of AMG 531 treatment of thrombocytopenic subjects with ITP refractory to splenectomy	
2005-2007	Pfizer	PI
	Analysis of hypercoagulable states associated with malignant gliomas	
2005-2009	GSK	Co-PI
	Fondaparinux anticoagulation in the treatment of HIT (FAITH Study)	
2005-2007	Millennium	Site-PI
	An open-label, randomized study of Velcade/Melphalan/Prednisone vs Melphalan/Prednisone in subjects with previously untreated multiple myeloma	
2005-2007	Millennium	Site-PI
	Phase III trial of Velcade (bortezomib) in patients with previously untreated multiple myeloma	
2005-2012	NIH=NHLBI (TMH Network)	PI
	Heparin induced thrombocytopenia observational study of thrombosis (The HOT Trial)	
2005-2012	NIH -NHLBI (TMH Network)	PI
	Determination of the optimal prophylactic platelet dose strategy to prevent bleeding in thrombocytopenic patients	
2005-2012	NIH (TMH Network)	Co-PI
	A multi-center, randomized, controlled trial of fresh frozen plasma or no therapy prior to invasive hepato-biliary procedures (The SHIP Trial)	
2005-2009	NIH-NHLBI RO1 HL082889	PI
	A proteogenomic analysis of platelets in patients with essential thrombocythemia	
2007-2009	AMGEN	PI
	Platelet proteomic and platelet aggregation studies on platelets from patients with ITP	

2011-2017	EISAI	PI	A Phase III, multicenter, randomized, double-blind, active-controlled, parallel-group trial with an open-label extension phase to evaluate the efficacy and safety of oral E5501 versus eltrombopag in adults with chronic immune thrombocytopenia
2014-2017	NIH-NHLBI U34-HL123416	Sub-investigator	Efficacy of Pomalidomide in HHT-related bleeding
2019-2024	NIH-NHLBI 1UG3HL140097	Sub-investigator	1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)

For education: (Note: funding end-dates not available for all activities)

1985-2010	Harvard Medical School	Course Director	Educational funds to support HST 080 Course (honoraria, secretary, course materials)
1998	NIH	Co-PI	Conference grant to support Keystone Symposium: "Molecular Regulation of Platelet Production"
2002	National Anemia Action Council	PI	Educational grant to support CME Course: "Current Advances in Oncology Treatment and Supportive Care at MGH"

For clinical applications: (Note: funding end-dates not available for this activity because activity is ongoing and not limited by time)

1983-	Patient donations	PI	Hematology Development Fund – discretionary funds for conferences, recruitment of new staff, emergency patient care reimbursement
-------	-------------------	----	---

C. Report of Current Research Activities other than those mentioned above:

Bench Research

2000-2009		PI	DNA microarray studies on platelets from essential thrombocythemia (ET) subjects and platelets from normal
-----------	--	----	--

subjects. In collaboration with Millennium Pharmaceuticals we have profiled the expression patterns in platelets from normal individuals and those with ET. Over 400 genetic expression differences have been identified and those that highly differ are currently the focus of study.

2000-2009

PI

The platelet proteome. In collaboration with the Harvard-Partners Center for Genetics and Genomics we have established with 2D gel electrophoresis and MALDI-TOF analysis the platelet proteome in platelets from normal and ET subjects. Over 15 major protein differences have been characterized.

1999-2005

PI

The presence of anti-BSA antibodies in the healthy population. As an off-shoot of our immunoassay development group, a highly sensitive radioimmunoassay for bovine serum albumin (BSA) was developed. This assay demonstrated that all subjects increase their antibody titer after exposure to BSA and that over a third of normal subjects already had pre-formed antibody vs BSA.

Clinical Trials

2003-2008

PI

Standardization of the DDAVP challenge test in patients with von Willebrand's Disease. With Dr. R. Rosovsky, we have measured the VWF response after exposure to DDAVP in over 150 patients and created a benchmark testing procedure.

2004-2008

PI

The incidence of thrombosis in patients diagnosed with isolated heparin-induced thrombocytopenia: an observational study. Over 100 patients with isolated HIT will be studied with Dr. R. Rosovsky to see how many patients have positive non-invasive tests within three days of the diagnosis of HIT.

Outcome Studies

2005-2007

PI

Efficacy of prolonged reduced-dose enzyme replacement therapy in Gaucher's disease. My 55 patients with Gaucher's Disease treated for over 10 years are the subject of this analysis by Dr. A. Moore. It shows that reduced dose therapy is effective and that weight gain is a prominent

feature of therapy.

2002-2008

PI

Therapeutic plateletapheresis for relief of acute neurological symptoms in myeloproliferative disorders. This analysis with Dr. S. Sood has reviewed 20 years of my experience in platelet apheresis in patients with elevated platelet counts and neurological problems. It documents the efficacy of this method.

2008-

Fogerty studies

2006-

Rosovsky studies

D. Report of Teaching

1. Local Contributions:

a. Harvard Medical School

1975-1978

Microbiology and molecular genetics. Section leader. HMS I (25 students). 30 h/year preparation, 30 h/year contact.

1978

Introduction to Clinical Medicine. Tutor. HMS III-IV (12 students). 15 h preparation, 15 h contact.

1985-2009

HST 080 Hematology. Lecturer. HST II (35-45 students). Yearly lecture series on thrombosis and hemostasis, anemia, hematopoiesis, hematopoietic growth factors. 200 h/year preparation, 15 h/year contact.

1985-2009

HST 080 Hematology. Patient-based lecture. HST II (35-45 students). Yearly patient (patient present) presentations on various hematological disorders ranging from Gaucher's Disease to myeloma. 60 h/year preparation, 6 h/year contact.

1985-2009

HST 080 Hematology. Case tutorials. HST II (35-45 students). Yearly patient-based case tutorials. 100 h/year preparation, 21 h/year contact.

1985-2009 HST 080 Hematology. Microscope instruction. HST II (35-45 students). Yearly slide review sessions at the microscope with students. 20 h/year preparation, 4.5 h/year at microscope.

1986 HMS core Hematology Course. Lecturer/Tutor. HMS II (25 students). Lectures on thrombosis and hemostasis. 20 h/year preparation, 4 h/year contact.

b. Harvard Medical School Graduate Medical Courses:

1980-1982 Core Clinical Clerkship in Medicine. Tutor. HMS III/IV (2 students/month). 8h/month preparation, 8h/month contact.

1983 Organized all hospital teaching for medical students doing core medicine clerkship. 20 h/month preparation, 10 h/month contact.

1983 Organized all grand rounds, CPC, Morbidity and Mortality Rounds at Massachusetts General Hospital. 100h/month preparation, 12 h/month contact

1984-2003 Morbidity & Mortality Conference, Residents' Report and House Staff Lecture Series. Lecturer. Staff, Medical House Staff, Fellows, HMS III/IV (20-120). Various topics. 15-20 lectures a year. 200 h/year preparation, 100 h/year contact.

1984- Hematology/Oncology Fellows Course. Lecturer. First year Heme-Onc Fellows (14). 3-4 hours of lecture per year on various hematology topics. 20 h/year preparation, 3-4 h/year contact.

2004- Harvard Pulmonary and Critical Care Medicine Fellows Lecture Series. Pulmonary and Critical Care Fellows (10). 1 hour of lecture per year on heparin-induced thrombocytopenia. 2 h/year preparation, 1.5 h/year contact.

2004-2008 MGH Surgical Residency Lecture Series. All MGH Surgical Residents (55). 1 hour of

lecture per year on thrombosis and anticoagulation. 2 h/year preparation. 1.5 h/year contact.

- c. Local invited presentations: Each of the following lectures was for 1 hour to 50-250 medical staff and students. 10 h of preparation per lecture and 1.25 hour of contact time per lecture.

1987

- | | |
|------------|--|
| January 5 | Pathology Grand Rounds,
Massachusetts General Hospital,
Boston, MA.
"The Structure and Function of
Platelets" |
| May 28 | Seminars in Vascular Biology, Harvard
Medical School, Boston, MA.
"Humoral Regulation of
Megakaryocyte Growth and
Differentiation" |
| November 9 | Hematology Grand Rounds, Brigham and
Woman's Hospital, Boston.
"The Regulation of
Megakaryocyte Ploidy" |

1989

- | | |
|-------------|---|
| November 14 | Pulmonary Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
"The Regulation of Platelet
Production" |
|-------------|---|

1990

- | | |
|---------|---|
| June 7 | Medical Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
"Acute Intermittent Porphyria" |
| July 18 | Hematology/Oncology Grand
Rounds. Massachusetts General
Hospital, Boston, MA.
"Endothelial Cell Biology" |

November 15 Clinicopathological Conference.
Massachusetts General Hospital,
Boston, MA.
"Case of an elderly woman with
thrombocytopenia"

1991

February 14 Medical Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
"Thrombotic Thrombocytopenic
Purpura"

March 21 Medical Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
"The Clinical Use of
Anticoagulants: Heparin,
Warfarin and the Newer Agents"

March 27 Hematology/Oncology Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
"The Clinical Uses of G-CSF"

March 28 Surgical Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
"Immune Thrombocytopenic
Purpura"

April 10 Hematology/Oncology Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
"The Clinical Uses of GM-CSF"

July 18 Surgical Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
"The Treatment of ITP"

September 13 Respiratory Intensive Care Unit Rounds.
Massachusetts General Hospital, Boston,
MA.
"Disorders of Coagulation"

September 20 Respiratory Intensive Care Unit

Rounds. Massachusetts General Hospital, Boston, MA.
"Disorders of Platelets and Endothelium"

December 18 Hematology-Oncology Grand Rounds. Massachusetts General Hospital, Boston, MA.
"Recent Advances in Hematology"

1992

January 16 GYN Grand Rounds. Massachusetts General Hospital, Boston, MA.
"The Clinical Use of Growth Factors"

November 11 Primary Care Unit Rounds. Massachusetts General Hospital, Boston, MA.
"Cases in Hematology"

November 18 Primary Care Unit Rounds. Massachusetts General Hospital, Boston, MA.
"Cases in Hematology"

December 18 Hematology-Oncology Grand Rounds. Massachusetts General Hospital, Boston, MA.
"Recent Advances in Hematology-Report from ASH"

1993

February 25 Medical Grand Rounds. Massachusetts General Hospital, Boston, MA.
"Disseminated Intravascular Coagulation"

1994

January 13 Medical Grand Rounds, Mt Auburn Hosp., Cambridge, MA.
"The Clinical Use of

Anticoagulants”

- July 14 Society of Fellows.
Massachusetts General Hospital,
Boston, MA.
“The Purification of Megapoeitin:
The Physiological Regulator of
Megakaryocyte Growth and
Platelet Production”
- August 30 Hematology Oncology Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
“The Physiology of Platelet
Production”
- October 18 Joint Hematology/Oncology Grand
Rounds, MGH/BWH, Boston, MA
“The Physiology of Platelet
Production”
- October 20 Medical Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
“Thrombopoietin: Some Practical
Lessons on Platelet Physiology”
- 1995**
- January 31 Cardiovascular Grand Rounds, Beth Israel
Hospital, Boston, MA.
“The Regulation of Platelet
Production”
- February 2 Dept of Social Sciences/History of Medicine,
Harvard University, Cambridge, MA.
“To Patent or to Perish: The
Dilemma of Modern Biomedical
Research”
- February 9 Surgical Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
“Surgical Treatment of Hairy Cell
Leukemia”
- June 26 Grand Rounds, Deaconess Hospital,
Boston, MA.

“The Regulation of Platelet
Production”

August 31 Surgical Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
“Chloromas”

1996

February 8 Ob/Gyn Grand Rounds.
Massachusetts General Hospital,
Boston, MA.
“Biology of Platelet Production”

April 18 Transfusion Medicine Grand Rounds,
Brigham & Women’s Hospital, Boston, MA.
“The Impact of Thrombopoietin
on Transfusion Medicine”

May 14 Hematology/Oncology Grand Rounds,
Boston VA Hospital Medical Center, Boston,
MA.
“The Physiology of Platelet
Production”

June 20 Primary Care Grand Rounds, Bunker Hill
Community Health Center, Boston, MA.
“The Clinical Use of Low-
Molecular Weight Heparin”

1997

January 16 Medical Grand Rounds, Massachusetts
General Hospital, Boston, MA.
“Thrombopoietin: Biology and
Emerging Clinical Applications”

March 3 Blood Transfusion Service Grand Rounds,
Massachusetts General Hospital, Boston,
MA.
“Thrombopoietin: Biology and
Applications in Transfusion
Medicine”

June 6 Partners Healthcare Oncology Course,
Boston, MA.
“Thrombopoietin: Biology and

Clinical Uses in Oncology”

1998

- February 10 Hematology Grand Rounds, Brigham and Woman’s Hospital, Boston, MA
“Platelet Growth Factors: From Basic Science to the Bedside”
- Nov 17 Dana Farber/Partners CancerCare Center Grand Rounds, Boston, MA
“Platelet Growth Factors: From Basic Science to the Bedside”

1999

- Feb 16 Dana Farber/Partners CancerCare Center Grand Rounds, Boston, MA
“The Use of Thrombopoietic Growth Factors in Transfusion Medicine”
- June 10 Hematology/Oncology Grand Rounds, St. Elizabeth’s Medical Center, Boston, MA
“Thrombopoietin: The Biology of Platelet Production”
- June 15 Hematology/Oncology Grand Rounds, New England Medical Center, Boston, MA
“Low Molecular Weight Heparins: Evolving Roles in Clinical Practice”
- June 21 Hematology/Oncology Grand Rounds, Jamaica Plain Veterans Administration Hospital, Boston, MA
“Thrombopoietin: Biology and Clinical Applications”

2000

- March 3 Perinatal Grand Rounds, Massachusetts General Hospital, Boston, MA
“Thromboembolic Complications of Pregnancy”

- March 12 Pathology Grand Rounds, BI-Deaconess Medical Center, Boston, MA
"Thrombopoietin: From Molecule to Medicine"
- March 15 Medical Grand Rounds, Massachusetts General Hospital, Boston, MA
"Thrombopoietin: Basic Science and Clinical Biology of Platelet Production"
- March 23 Hematology/Oncology Grand Rounds, Massachusetts General Hospital, Boston, MA
"The Clinical Use of Anticoagulants: New Drugs, New Uses"
- November 17 Medical Grand Rounds, Spaulding Rehabilitation Hospital, Boston, MA
"The Clinical Use of Low Molecular Weight Heparins"

2002

- April 10 Hematology/Oncology Grand Rounds, Beth Israel-Deaconess Medical Center, Boston, MA
"Whatever Happened to Thrombopoietin?"
- May 3 Medical Grand Rounds, Emerson Hospital, Concord, MA
"Clinical Use of Anticoagulants in Internal Medicine"
- June 22 Medical Grand Rounds, Massachusetts General Hospital, Boston, MA
"Anticoagulation for Internists"
- July 12 Medical Rounds, Genzyme Corporation, Cambridge, MA
"Thrombopoietin Biology and Future Uses"
- October 8 Partners/DFCI Cancer Center Grand

Rounds, Massachusetts General
Hospital, Boston, MA
“The Clinical Use of Erythroid
Growth Factors”

November 13 Harvard Radiation Medicine Fellows Course,
Boston, MA
“The Effective Use of
Hematopoietic Growth Factors”

2003

January 22 Medical Grand Rounds, Harvard
University Health Center Grand Rounds,
Cambridge, MA
“The Clinical Use of
Anticoagulants”

February 13 Medical Grand Rounds, Mount Auburn
Hospital, Cambridge, MA
“Anticoagulation for Internists”

July 6 Stroke Service Rounds, Massachusetts
General Hospital, Boston, MA
“Anticoagulation for Neurologists”

August 21 Medical Grand Rounds, Faulkner
Hospital, Boston, MA
“What’s New in Anticoagulation?”

October 16 Anesthesia Grand Rounds,
Massachusetts General Hospital,
Boston, MA
“Anticoagulation”

November 12 Medical Grand Rounds, Jamaica Plain
VA Hospital, Boston, MA.
“The Clinical Use of Erythroid
Growth Factors”

2004

March 10 Palliative Care Grand Rounds,
Massachusetts General Hospital,
Boston, MA
“Hypercoagulability and Its

Management”

- March 17 SICU Grand Rounds, Massachusetts General Hospital, Boston, MA
“Diagnosis and Management of Heparin-induced Thrombocytopenia”
- March 18 Brigham and Womens Hospital Medical Group Rounds, Boston, MA
“Clinical Use of New Antithrombotic Drugs”
- April 13 Hematology Grand Rounds, Brigham and Womens Hospital, Boston, MA
“Whatever Happened to Thrombopoietin?”
- October 12 Hematology Grand Rounds, Brigham and Womens Hospital, Boston, MA
“New Approaches to Treating ITP”
- November 4 Pulmonary Grand Rounds. Massachusetts General Hospital, Boston, MA.
“Heparin: Thrombocytopenia and Thrombosis”
- November 12 Neuro-Oncology Grand Rounds, DFCI/BWH, Boston, MA
“Treating the Hypercoagulability of Malignancy”

2005

- February 15 DFCI/Partners Cancer Center Rounds, Massachusetts General Hospital, Boston, MA.
“Heparin-induced Thrombocytopenia: Pathophysiology and Clinical Management”
- March 8 Joint Medical and Surgical Grand Rounds, Mt. Auburn Hospital, Cambridge, MA
“Anticoagulation of the Medical

and Surgical Patient”

- March 10 Medical Grand Rounds, Massachusetts General Hospital, Boston, MA
 “Heparin-induced Thrombocytopenia: Pathophysiology and Clinical Management”
- March 16 Pulmonary and Critical Care Grand Rounds, Massachusetts General Hospital, Boston, MA
 “Heparin-induced Thrombocytopenia: Pathophysiology and Clinical Management”
- May 9 Partners Clinical Cardiovascular Conference, Boston, MA.
 “HIT as Viewed by the CHEST Guidelines”
- August 25 General Surgical Rounds, Massachusetts General Hospital, Boston, MA
 “Coagulation Issues in the Surgical Patient”
- August 31 Medical/Surgical Grand Rounds, Northeast Rehabilitation Health Network, Salem, NH
 “Clinical Use of Anticoagulation”
- October 26 MGH/BWH Orthopedic Grand Rounds, Massachusetts General Hospital, Boston, MA
 “Clinical Use of Anticoagulants: From Warfarin to the Direct Thrombin Inhibitors”
- December 1 MGH Cancer Center Grand Rounds, Massachusetts General Hospital, Boston, MA
 “Thrombopoietin: Basic Biology and Clinical Applications”

2006

March 16 MIT Medical Grand Rounds,
Massachusetts Institute of Technology,
Cambridge, MA
“Anticoagulation for Internists”

2007

January 9 Harvard Blood Scholars Inaugural
Lecture, Harvard Medical School,
Boston, MA
“Thrombopoietin Receptor
Agonists – From Molecule to
Medicine”

January 11 Medical House Staff Lecture,
Massachusetts General Hospital,
Boston, MA
“Clinical Advances, Treatment,
and Medical Needs in the
Management of ITP”

January 29 MGH/BWH Gyn Oncology Rounds,
Massachusetts General Hospital.
Boston, MA
“Thrombosis and Anticoagulation
in Cancer (Clotting for Medical
and Surgical Oncologists)”

March 20 BWH Hematology Seminar Series.
Brigham and Womens Hospital, Boston,
MA
“New Therapies for
Thrombocytopenia”

September 6 Hematology/Oncology Grand Rounds,
BU Medical Center, Boston, MA
“ITP-Pathophysiology and New
Treatment Approaches”

December 18 MGH Pulmonary Vascular Conference
Grand Rounds, Boston, MA
“Clotting”

2008

January 3 Harvard Medical School Bone Marrow
Transplant Conference, Boston, MA
“New Thrombopoietic Growth

Factors: Biology and Clinical
Uses”

- March 20 MGH Cancer Center Grand Rounds,
Massachusetts General Hospital,
Boston, MA
“Thrombopoietin: From Molecule
to Medicine”
- August 1 MGH Medical House Staff Conference,
Massachusetts General Hospital,
Boston, MA
“Thrombocytopenia: Diagnosis
and Management”
- August 14 MGH Medical House Staff Conference,
Massachusetts General Hospital,
Boston, MA
“Anticoagulation for Internists”
- November 26 MGH Dept of Neurology, Academic
General Neurology Fellowship
Conference, Massachusetts General
Hospital, Boston, MA
“Thrombotic Mechanisms and
Antithrombotic Therapy”

2009

- January 29 Cancer Center Grand Rounds,
Massachusetts General Hospital,
Boston, MA
“New Concepts in Hematology –
A Report from the Recent
American Society of Hematology
Meeting”
- October 30 Hematology/Oncology Grand Rounds,
Tufts New England Medical Center,
Boston, MA
“Assessing Recent
Advancements in the
Management of ITP and
Thrombocytopenia Secondary to
Other Disorders”

2010

- March 11 MGH Cancer Center Grand Rounds, Massachusetts General Hospital, Boston, MA
“Highlights from the 2009 American Society of Hematology Annual Meeting”
- April 6 6th Annual Herbert Cooper MD Visiting Professorship, North Shore Medical Center, Salem, MA
“Thrombocytopenia: Historical Perspective and Clinical Approach”
- April 7 Grand Rounds, North Shore Medical Center, Salem, MA
“Thrombopoietin: From Molecule to Medicine”
- April 7 Resident Lecture Series, North Shore Medical Center, Salem, MA
“Clinical Use of Anticoagulant Drugs: Old and New”
- May 27 Department of Pediatric Hematology Oncology Seminar, Children’s Hospital of Boston, Boston, MA
“Thrombopoietin: From Molecule to Medicine”
- June 1 DFPCC Hematology/Oncology Grand Rounds, Massachusetts General Hospital, Boston, MA
“Thrombopoietin: From Molecule to Medicine”
- December 14 Medical Services Noontime Lecture Series. Massachusetts General Hospital, Boston, MA.
“Antiphospholipid Antibody Syndrome”

2011

- January 3 Medical Services Noontime Lecture Series, Massachusetts General Hospital, Boston, MA
“Anticoagulant Drugs: Old and

New”

- February 6 Medical Services Noontime Lecture Series, Massachusetts General Hospital, Boston, MA
“Immune Thrombocytopenia”
- March 29 Michael Binari Lecture on Anticoagulation, Mt Auburn Hospital, Cambridge, MA
“Thrombotic Mechanisms and Antithrombotic Agents”
- June 20 Medical Services Noontime Lecture Series, Massachusetts General Hospital, Boston, MA
“Anticoagulation”
- October 3 Medical Services Noontime Lecture Series, Massachusetts General Hospital, Boston, MA
“Heparin-induced Thrombocytopenia- Pathophysiology and Treatment”
- November 1 Rheumatology Grand Rounds, Massachusetts General Hospital, Boston, MA
“Clinical Use of Anticoagulants: Old and New”
- December 21 Medical Services Noontime Lecture Series, Massachusetts General Hospital, Boston, MA
“Immune Thrombocytopenia”

2012

- May 15 Department of Medicine Conference, Massachusetts General Hospital, Boston, MA
“Dabigatran Reversal”
- July 20 Medical Services Noontime Lecture Series, Massachusetts General Hospital, Boston, MA
“Anticoagulation in Practice- 2012”

- October 2 Bulfinch Medical Group Noontime
Lecture Series, Massachusetts General
Hospital, Boston, MA
 "Heparin-induced
Thrombocytopenia: Diagnosis
and Treatment"
- October 5 Hematology Grand Rounds,
Massachusetts General Hospital,
Boston, MA
 "Autoimmune Hemolytic Anemia
(AIHA)"

2013

- February 15 Hematology Grand Rounds,
Massachusetts General Hospital,
Boston, MA
 "Gaucher Disease 2013"
- July 11 Medical Services Noontime Lecture
Series, Massachusetts General
Hospital, Boston, MA
 "Anticoagulation in Practice-
2013"
- July 15 Lunder Clinical Conference,
Massachusetts General Hospital,
Boston, MA
 "The Biology of
Thrombocytopenia"
- July 29 Lunder Clinical Conference,
Massachusetts General Hospital,
Boston, MA
 "Diagnosis and Treatment of ITP"
- August 12 Lunder Clinical Conference,
Massachusetts General Hospital,
Boston, MA
 "How to Assess the Patient with
Pancytopenia"

2014

- January 13 Lunder Clinical Conference,

- Massachusetts General Hospital,
Boston, MA
“How to Evaluate the Patient with
an Elevated Hematocrit”
- January 17 Hematology Grand Rounds,
Massachusetts General Hospital,
Boston, MA
“How I Treat ITP”
- February 7 Grand Rounds, Emerson Hospital,
Concord, MA
“What You Should Know About
the Old and New Anticoagulants”
- May 1 Surgical Grand Rounds, Massachusetts
General Hospital, Boston, MA
“Plavix-2014”
- August 14 MGH Medical House Staff Conference,
Massachusetts General Hospital,
Boston, MA
“Anticoagulation for Internists”
- October 6 Partners/DFCI Lecture Series for 1st Year
Fellows, Massachusetts General Hospital,
Boston, MA
“Anticoagulation for Oncologists”

2015

- January 5 MGH Medical House Staff Conference,
Massachusetts General Hospital, Boston,
MA
“Immune Thrombocytopenia:
Pathophysiology and Treatment”
- February 6 Hematology Grand Rounds,
Massachusetts General Hospital, Boston,
MA
“Thrombopoietin Receptor
Agonists: Biology and Uses Other
than ITP”
- June 9 Hematology Grand Rounds, Brigham &
Woman’s Hospital, Boston, MA
“New (and Old) Insights into the

Diagnosis and Management of
ITP”

- September 28 MGH Medical House Staff Conference,
Massachusetts General Hospital,
Boston, MA
“Anticoagulation for Internists-
2015”
- October 6 Partners/DFCI Lecture Series for 1st Year
Fellows, Massachusetts General Hospital,
Boston, MA
“Anticoagulation for Oncologists-
2015”

2016

- January 12 Harvard Blood Scholars Monthly
Colloquium Series, Harvard Medical
School, Boston, MA
“Thrombopoietin: Translating a
Discovery into a Clinical Therapy”
- February 24 Hematology-Oncology Grand Rounds,
Lahey Clinic, Burlington, MA
“Thrombopoietin: Biology and
Clinical Applications”
- April 16 Hematology Grand Rounds,
Massachusetts General Hospital, Boston,
MA
“What is the Role of Novel
Thrombopoietic Agents in the
Management of Acute Leukemia
and MDS?”
- December 12 Internal Medicine Residents Report,
Massachusetts General Hospital, Boston,
MA
“Eosinophilia”

2017

- January 6 Hematology Grand Rounds,
Massachusetts General Hospital, Boston,
MA

“ATIII Inhibition as Treatment for Hemophilia B”

- June 8 Surgical Grand Rounds, Massachusetts General Hospital, Boston, MA
 “Thrombosis and Hemostasis for Surgeons”
- July 24 Medical Residents Noon Conference, Massachusetts General Hospital, Boston, MA
 “Thrombosis and Hemostasis for the Internist”
- Sept 16 Partners Clinicians Day, Partners Healthcare, Boston, MA
 “How to Use the New Oral Anticoagulants”

2018

- January 3 Pulmonary Grand Rounds, Massachusetts General Hospital, Boston, MA
 “Thrombotic Mechanisms and Antithrombotic Agents 2018: How Do the New Oral Agents Fit In?”
- July 2 MGH Internal Medicine Residents Core Course, Massachusetts General Hospital, Boston, MA
 “Thrombotic Mechanisms and Antithrombotic Agents for MGH House Staff 2018”

2019

- November 12 MGH Cancer Center Network Meeting, Boston, MA
 “A Brief Update on ITP”

2020

- April 21 MGH Critical Care Grand Rounds, Boston, MA.
 “COVID-19 Coagulopathy”
- April 23 MGH Surgical Grand Rounds, Boston, MA

“COVID-19 Coagulopathy”

May 27 Case Records of the Massachusetts General Hospital, Clinicopathological Conference, Boston, MA
 “A 55-year-old man with back pain, hypercalemia, and acute hypoxemia”

d. Continuing Medical Education Courses – HMS

1984	MGH Internal Medicine Board Review Course. Taught Hematology/Oncology sections. (40 h preparation, 9 h contact)
1990-Present	HMS-MGH Internal Medicine Course. Annual lecture Coagulation I (20 h/year preparation, 1.0 h/year contact) on how coagulation factors and anticoagulants work.
1990-Present	HMS-MGH Internal Medicine Course. Annual lecture Coagulation II (20 h/year preparation, 1.0 h/year contact) on how platelets and anti-platelet drugs work.
1990-Present	HMS-MGH Internal Medicine Course. Annual two hours of teaching cases per year (20 h/year preparation, 2.0 h/year contact)
1991-1995	HMS-MGH Primary Care Internal Medicine Course. Two annual major lectures on anticoagulation and thrombosis per year (40 h/year preparation, 3 h/year contact)
1995	HMS/UCLA Pri-Med Course on Current Clinical Issues in Primary Care, Long Beach, CA. Lecture on “Common Coagulation Disorders in Primary Care.” (20 h preparation, 1.5 h contact)
1995	HMS/UCLA Pri-Med Course on Current Clinical Issues in Primary Care, Long Beach, CA. Lecture on “Anticoagulation in Primary Care.” (20 h preparation, 1 h contact)

1995-1998	HMS-MGH Postgraduate Infectious Diseases of Adults Course. Annual lecture on use of hematopoietic growth factors. (20 h preparation, 1.5 h contact)
1996	HMS-Brigham and Woman's Hospital Intensive Review in Hematology Course. Lecture on "Thrombopoietic Growth Factors." (20 h preparation, 1 h Contact)
1996	HMS/U. Chicago Pri-Med Course on Current Clinical Issues in Primary Care, Chicago, IL (June 22). Lecture on "Common Coagulation Disorders in Primary Care." (20 h preparation, 1 h contact)
1996	HMS/U. Chicago Pri-Med Course on Current Clinical Issues in Primary Care, Chicago, IL (June 22). Lecture on "Anticoagulation in Primary Care." (20 h preparation, 1 h contact)
1996	HMS Pri-Med Course on Current Clinical Issues in Primary Care, Boston, MA (September 19). Lecture on "The Clinical Use of Anticoagulants in Primary Care." (20 h preparation, 1 h contact)
1997	HMS-Partners Healthcare System Cancer Medicine and Hematology Course. Lecture on "The Use and Abuse of Hematopoietic Cytokines." (30 h preparation, 1 h contact)
1998	HMS/U. Miami Pri-Med Course on Current Clinical Issues in Primary Care, Ft. Lauderdale, FLA (January 23). Lecture on "Common Coagulation Disorders in Primary Care." (20 h preparation, 1 h contact)
1998	HMS/U. Miami Pri-Med Course on Current Clinical Issues in Primary Care Ft. Lauderdale, FLA (January 23). Lecture on "Anticoagulation in Primary Care." (20 h preparation, 1 h contact)

1999	Update in Transfusion Medicine 1999, Harvard Medical School & Yale Medical School. Lecture on "Thrombopoietin and Platelet Donations." (30 h preparation, 1 h contact)
1999	Cancer Medicine and Hematology 1999. Lecture on "The Use and Abuse of Hematopoietic Growth Factors." (30 h preparation, 1 h contact)
2000	The 23 rd Annual Intensive Review Course of Internal Medicine. Brigham and Women's Hospital, Harvard Medical School. Lecture on "Growth Factors: An Internal Medicine Perspective." (30 h preparation, 1 h contact)
2000- present	Cancer Medicine and Hematology, Harvard Medical School. Annual lecture on "Stem Cell Biology and Hematopoietic Growth Factors." (30 h/year preparation, 1 h/year contact)
2000-2013	Primary Care Internal Medicine Principles and Practice. Harvard Medical School. Annual lecture on "Anticoagulation in Practice, Indications and Options." (60 h preparation, 1.75 h contact)
2001-2009	Primary Care for Subspecialists. Harvard Medical School. Annual lecture on "Anticoagulation in Practice." (40 h preparation, 1.25 h contact)
2004	Current Clinical Issues in Primary Care. Harvard Medical School. Lecture on "Anticoagulation." (20 h preparation, 1 h contact)
2006	Thrombosis and Thromboembolism: New Strategies for Improved Patient Care. Harvard Medical School. Lecture on "Direct Thrombin Inhibitors." (40 h preparation, 0.5 h contact)
2007-2015	Cancer Medicine and Hematology, Harvard Medical School. Annual

	Hematology case-based discussion.” (10 h/year preparation, 2 h/year contact)
2008	Partners Physician Day 2008. MGH/Partners/ Harvard Medical School Course. Lecture on “Erythropoietin: How and When to Replace It.” (25 hours preparation, 1.5 h contact)
2007-2008	HMS Pulmonary and Critical Care Medicine Course. Annual lecture on “Thrombotic Mechanisms and Antithrombotic Agents.” (30 h/y preparation, 1 h/year contact)
2008	HMS/MGH Vascular Summit. Annual lecture on “The Best Standard Treatment for DVT?” (20 h/y preparation, 0.5 h/year contact)
2009	HMS Update on Management of Patients with Hematological Malignancies. Boston, MA. Lecture on “New Advances in the Treatment of ITP” (15 h/y preparation, 0.45 h/year contact)
2009	HMS Update on Management of Patients with Hematological Malignancies. Boston, MA. Debate Lecture on “Best Use of Erythroid Stimulating Agents” (6 h/y preparation, 0.5 h/year contact)
2010	Partners Physician Day 2010. MGH/Partners/ Harvard Medical School Course. Lecture on “Heparin-induced Thrombocytopenia: Diagnosis and Treatment.” (15 hours preparation, 1.25 h contact)
2010	HMS Update on Management of Patients with Hematological Malignancies. Boston, MA. Lecture on “Heparin-induced Thrombocytopenia: Pathophysiology and Treatment” (6 h/y preparation, 0.5 h/year contact)
2010-present	HMS Pulmonary and Critical Care

	Medicine Course. Annual lecture on "Thrombotic Mechanisms and Antithrombotic Agents." (30 h/y preparation, 1 h/year contact)
2011	Hematological Malignancies and Hematology Update 2011, Boston, Ma. Lecture on "New Treatments for Thrombocytopenia" (6 h/y preparation, 0.5 h/year contact)
2011-12	Update on General Internal Medicine for Subspecialists. Harvard Medical School. Annual lecture on "Anticoagulation in Practice." (40 h preparation, 1.25 h contact)
2012	Hematological Malignancies and Hematology Update 2012, Boston, MA. Lecture on "American Society of Hematology ITP Guidelines: Data Behind the Guidelines and Clinical Application: Diagnosis and Management of Adult ITP" (6 h/y preparation, 1.0 h/year contact)
2013	Hematological Malignancies and Hematology Update 2013, Boston, MA. Lecture on "What about treating chemotherapy-induced thrombocytopenia (CIT) with TPO receptor agonists?" (20 h/y preparation, 1.0 h/year contact)
2013	Pri-Med East: Current Clinical Issues in Primary Care. Boston, MA. Lecture on "Anticoagulation: New Strategies for Treatment." (10 h preparation, 1.0 h contact)
2014	Controversial Cases in Hematological Malignancies and Hematology, 2014, Boston, MA. Lecture on "What about treating chemotherapy-induced thrombocytopenia (CIT) with TPO receptor agonists?" (40 h/y preparation, 1.0 h/year contact)

- | | |
|------|---|
| 2015 | Controversial Cases in Hematological Malignancies and Hematology, 2015, Boston, MA. Lecture on "Thrombocytopenia: All you need to know" (40 h/y preparation, 1.0 h/year contact). |
| 2015 | Controversial Cases in Hematological Malignancies and Hematology, 2015, Boston, MA. Case Discussion. (40 h/y preparation, 1.0 h/year contact). |
| 2016 | Controversial Cases in Hematological Malignancies and Hematology, 2016, Boston, MA. Lecture on "Red and White Blood Cell Disorders" (60 h/y preparation, 1.0 h/year contact). |
| 2017 | Controversial Cases in Hematological Malignancies and Hematology, 2016, Boston, MA. Case Discussion. (40 h/y preparation, 1.0 h/year contact). |

e. Advisory/supervisory responsibilities (clinical/laboratory)

- | | |
|--------------|---|
| 1983-present | Advisor/mentor to Medical Housestaff. 1 intern, 1 junior resident, 1 senior resident per year. 50 h/year. |
| 1984-present | Advisor/mentor to Clinical Fellows. 2 first year, 2 second year fellows. 50 h/year. |
| 1984-present | Attending Physician on Hematology Service. 250 h/year. |
| 1984-1990 | Attending Physician on General Medical Service. 240 h/year. |
| 1984-1990 | Attending Physician on Primary Care Service. 4 h/year. |
| 1990-1995 | Attending Physician on James Jackson Firm. 40 h/year. |
| 1990-2000 | Senior Physician of the Month. Supervise daily report of House Staff PGY2. 30 h/year. |

- | | |
|--------------|---|
| 1994-2008 | Laboratory supervisor of Post-doctoral fellows (2/year). 500 h/year. |
| 1996-present | Clinical research supervisor for PGY2-3 resident (1/year). 60 h/year. |
| 1999-2003 | Laboratory supervisor of Ph.D. student (1/year). 100 h/year. |
- f. Teaching leadership roles
- | | |
|-----------|--|
| 1984 | Chief resident. Organized all teaching functions of MGH Medical Service. Organized and ran weekly Morbidity and Mortality Rounds, Medical Grand Rounds, CPC Conference. Organized and ran MGH Internal Medicine Board Review Course. |
| 1984-1996 | Director, MGH Society of Fellows. Created and ran this "support group" for physicians doing research. Through quarterly meetings to discuss research and informal one-on-one sessions guided 15-20 physicians per year. Over 90% remain currently in research, many in national leadership positions. |
| 1990-1996 | Director Hematology Fellows Course. Organized lecture series (25 lecturers) for all Hematology/Oncology Fellows at MGH. |
| 1991-1999 | Director of Weekly "Slide Rounds" with the House Staff. Organized and conducted weekly review blood and bone marrow slides with House Staff for one hour every week. |
| 1991- | Director of Weekly Hematology Clinic Conference with 1st year Hematology/Oncology fellows. Organized and direct review of all Hematology Clinic cases, blood and bone marrow smears at the microscope with Hematology-Oncology fellows for 2 hours each week. Recognized by fellows as a major learning mechanism in hematology during their fellowship. |

- 1993 Associate Director, HST Core Hematology Course. Ran course with Dr. Beck. Responsible for all case discussions and thrombosis and hemostasis section.
- 1994-2009 Director, HST Core Hematology Course (HST 080). Completely reorganized HST Hematology Course for second year students in HST, MEMP programs (40-45 students). Organize, select lecturers, lecture and run this course yearly. Ranked as one of the top courses in Harvard Medical School. Has been voted the top HST course for most of the past 10 years.

g. Advisees or trainees.

By 2008 I have advised and/or trained approximately 210 Hematology/Oncology fellows, 14 laboratory fellows, 63 members of the MGH Society of Fellows, 700 HST students, and 675 MGH House Officers. Some are still completing their training but many are currently in local, national, or international leadership positions in medicine. What follows is a list of some of those trainees on whose careers I have had a significant impact.

Duration of Training	Impact During Training	Name	Current Position
1981-1984	Oversaw clinical research project and provided career guidance during Medical Residency Training	Oliver Press, MD, Ph.D.	Prof of Medicine, U Washington, Fred Hutchinson Cancer Center
1982-1984	Oversaw clinical research project and provided career guidance during Medical Residency Training	Roger Perlmutter, MD, Ph.D.	Executive VP of Research and Development, AMGEN; formerly Executive VP, Merck; formerly Chairman of Dept Immunology, U Washington
2003-	Oversaw clinical research projects and providing career guidance during Medical Residency Training	Allan Moore, MD	Deceased
2005-	Oversaw clinical	Annemarie Fogarty,	Staff Physician, Hematology

	research projects and providing career guidance during Medical Residency Training	MD	Division, Massachusetts General Hospital
1996-1999	Was my laboratory Post-doc Fellow; I oversaw research projects and provided mentorship	Chun Yang, Ph.D, MD	Biotech consultant
1996-1999	Was my laboratory Post-doc Fellow; I oversaw research projects and provided mentorship	Junzhi Li, Ph.D.	Director of Cell Biology, Baxter, Inc.
1996-2001	Was my laboratory Post-doc Fellow; I oversaw research projects and provided mentorship	Yuping Xia, MD	Medical practice and pharmacology consultant
1999-2002	Was my laboratory Post-doc Fellow; I oversaw research projects and provided mentorship	Amy Bertino, Ph.D.	Director of MGH Platelet Biology Lab
2002-2004	Was my laboratory Post-doc Fellow; I oversaw research projects and provided mentorship	Tirsit Mogues, Ph.D	Asst Director of MGH Platelet Biology Lab
2008-2010	Transfusion Medicine fellow who rotated with my in Hematology Clinic and did project in my lab.	Amanda Davis, MD	Staff Hematologist, Director of Blood Bank, The Alfred Hospital, Melbourne, Australia
1993-1996	Recruited him to MGH, supervised clinical training and provided career guidance as Heme/Onc Fellow	Panos Fidas, MD	Clinical Director, Center for Thoracic Cancers, MGH; Assistant Professor in Medicine, HMS
1993-1996	Recruited him to MGH, supervised clinical training and	Bimel Dey, MD	Asst Physician, Bone Marrow Transplantation Unit, MGH; Asst Professor of Medicine, HMS

	provided career guidance as Heme/Onc Fellow		
1995-1998	Recruited him to MGH, supervised clinical training and provided career guidance as Heme/Onc Fellow. Also guided his clinical research project	Renato Martins, MD	Asst Prof of Medicine, U Washington, Seattle Cancer Care Network; formerly Chief of Medical Oncology, National Cancer Institute of Brazil
1995-1998	Guided his clinical research project and provided mentoring when he was Heme/Onc Fellow	Alan Colowick, MD, MBA	Chief Medical Officer, Threshold Pharmaceuticals; formerly VP Medical Affairs at AMGEN
1996-1999	Guided her clinical training in Hematology and provided mentoring when she was Heme/Onc Fellow	Paula O'Connor, MD	Director of Medical Affairs, Genentech
1996-1999	Guided his clinical training in Hematology, oversaw his clinical research project and provided mentoring when he was Heme/Onc Fellow	Robert Vonderheide, MD, D.Phil	Assoc Prof of Medicine, Univ Pennsylvania
1999-2002	Guided her clinical training in Hematology, oversaw her clinical research project and provided mentoring when she was Heme/Onc Fellow	Jennifer Brown, MD, Ph.D.	Asst. Prof, HMS; Bone Marrow Transplantation Unit, Dana Farber Cancer Institute
2000-2003	Guided his clinical training in Hematology and provided extensive career guidance when he was a Heme/Onc Fellow	M. Hurwitz, MD, Ph.D.	Post-doctoral fellow, HMS
2000-2003	Guided her clinical training in	Dipti Patel, MD	Private practice, Fairfax, VI

	Hematology and provided extensive career guidance when she was a Heme/Onc Fellow		
2000-2003	Guided his clinical training in Hematology and provided extensive career guidance when he was a Heme/Onc Fellow; supervised his clinical research project.	W. Goessling, MD	Post-doctoral fellow, HMS
2001-2004	Guided his clinical training in Hematology and provided extensive career guidance when he was a Heme/Onc Fellow	Ben Ebert, MD, D. Phil.	Instructor in Medicine, DFCI, HMS
2002-2005	Guided her clinical training in Hematology and provided extensive career guidance when she was a Heme/Onc Fellow	S. Sarantopoulos, MD, Ph.D.	Post-doctoral fellow, HMS
2002-2005	Guided his clinical training in Hematology and provided extensive career guidance when he was a Heme/Onc Fellow; supervised his clinical research project and have helped him become national expert in HIT	Jay Bradner, MD	Instructor in Medicine, DFCI, HMS
2003-	Oversaw her clinical training in Hematology and providing extensive career guidance as a Heme/Onc Fellow;	Rachel Rosovsky, MD	MGH Hematology/Oncology Staff Member

	am supervising her clinical research projects		
2003-	Oversaw his clinical training in Hematology and providing extensive career guidance as a Heme/Onc Fellow; supervised his clinical research project.	Goyo Abel, MD	DFCI Staff member
2004-	Oversaw his clinical training in Hematology and providing extensive career guidance as a Heme/Onc Fellow; supervised his clinical research project.	Andrew Yee, MD	In training
1985-1993	As MGH House Officer and Member of MGH Society of Fellows I provided career guidance and research supervision	Margaret Baron, MD, PhD	Prof of Med, Mt. Sinai School of Med, Ruttenberg Cancer Center and Inst for Gene Therapy and Molecular Medicine
1986-1990	As MGH House Officer and Member of MGH Society of Fellows I provided career guidance and research supervision	James Wilson, MD, Ph.D.	Professor of Medical Genetics; Director, Institute for Human Gene Therapy, Univ of Pennsylvania
1987-1992	As MGH House Officer and Member of MGH Society of Fellows I provided career guidance and research supervision	Paul Kamitsuka, MD	Physician and Consultant, Wilmington Health Associates, Wilmington, NC
1988-1992	As MGH House Officer and Member of MGH Society of Fellows I provided career guidance and	Roger Pomerantz, MD	Chief, Infectious Diseases, Ctr for Human Virology, Prof of Medicine, Thomas Jefferson University

	research supervision		
1993-1996	As MGH House Officer and Member of MGH Society of Fellows I provided career guidance and research supervision	Dennis Willerford, MD, Ph.D	Private Practice, Assoc Clinical Prof of Medicine, U Washington
1993-1996	As MGH House Officer and Member of MGH Society of Fellows I provided career guidance and research supervision	Richard Peters, MD, Ph.D.	Medical Affairs, AMGEN; formerly President and CEO, Mednav Inc.
1996	As MGH House Officer and Member of MGH Society of Fellows I provided career guidance and research supervision	Tom Scheutz, MD, Ph.D.	Vice-President Clinical Affairs, Transkaryotic Therapies, Inc

2. Regional, National and International Contributions:

a. Invited Presentations

1987

June 15

Gordon Research Conference on Hemostasis, Proctor Academy, N.H.
"Plasma Factors Which Regulate Megakaryocyte Maturation"

1989

July 24

Third International Conference on Megakaryocytes: Cellular and Molecular Biology, Conseil Regional de Bourgogne, Dijon, France.
"Platelets Contain Several Inhibitors of Megakaryocyte Growth and Ploidization"

November 20

Genzyme Corp Research Lecture

Series, Framingham, MA.
"The Regulation of Platelet
Production"

1990

July 2 Second Biennial Meeting on Blood
Coagulation and Platelet Biology,
Talloires, France.
"The Regulation of Platelet
Quantity and Quality: Physiology
and Molecular Biology"

September 10 Merck Research Conference Series,
West Point, PA.
"The Regulation of Platelet
Production"

1991

April 18 Medical Grand Rounds, Mercy Hospital,
Rockville, NY.
"Disseminated Intravascular
Coagulation"

1992

April 15 Medical Grand Rounds, Mercy Hospital
Medical Center, Rockville, NY.
" The Harvard Lecture - The
Clinical Use of Anticoagulants"

1994

August 1 Research Conference, Genentech Inc, San
Francisco, CA.
"The Purification of
Thrombopoietin: The
Physiological Regulator of
Megakaryocyte Growth and
Platelet Production"

August 18 NIH Symposium on Thrombopoietin,
Bethesda, MD.
"The Purification and Biology of
Thrombopoietin"

December 5 American Society of Hematology,

Nashville, TN.

“The Purification of Ovine
Thrombopoietin”

1995

January 13

Research Conference, Amgen Inc,
Thousand Oaks, CA.

“The Regulation of Platelet
Production by Thrombopoietin”

May 19

American Society of Clinical Oncology
Thrombopoietin Symposium, Los
Angeles, CA.

“The Regulation of
Thrombopoietin”

1996

February 18

Keystone Symposium on Molecular
Regulation of Platelet Production, Taos,
NM.

“The Physiology of Platelet
Production”

March 13

9th NCI-EORTC Symposium on New
Drugs in Cancer Therapy, Amsterdam,
Netherlands.

“Thrombopoietin: Biological and
Clinical Studies”

March 22

American Society for Apheresis Annual
Meeting, Sante Fe, NM.

“Thrombopoietins: Mechanisms
of Action, Clinical Applications
and Role in the Donor Setting”

May 24

Canadian Red Cross Annual Scientific
Meeting, Toronto, Canada.

“The Clinical Use of
Thrombopoietin in Transfusion
Medicine”

August 23

International Society of Experimental
Hematology (ISEH) Annual Meeting, New
York, NY.

“The Physiology of
Thrombopoietin: Application to

	Clinical Problems of Platelet Production”
August 27	International Society of Experimental Hematology (ISEH) Annual Meeting, New York, NY. “The Regulation of Platelet Production”
September 18	Working Group on Thrombopoietin, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD. “The Impact of Thrombopoietin on Transfusion Medicine”
September 30	American College of Physicians Course on Key Advances in Internal Medicine, Boston, MA. “Hematology” (3 h session)
October 20	American College of Physicians Annual Meeting, Massachusetts Chapter, Brewster, MA. “The Clinical Use of Heparin, Warfarin and the Antiplatelet Agents”
November 3	The American Society for Reproductive Medicine Annual Meeting, Boston, MA. “Hematology for the Obstetrician”
December 6	The American Society for Hematology Annual Meeting, Orlando, FL. A Decade of Hematopoietic Growth Factors: Frontiers in Translational Research Symposium. “Thrombopoietin: Biology and Clinical Applications”
December 8	The American Society for Hematology Annual Meeting, Orlando, FL. Scientific Subcommittee Plenary Session. “Overview of Thrombopoietin Biology and Megakaryocyte Development”
December 8	The American Society for Hematology Annual Meeting, Orlando, FL. Scientific Subcommittee Plenary Session.

“Clinical Disorders of
Thrombopoietin Physiology”

1997

- | | |
|--------------|---|
| February 24 | America’s Blood Centers Annual Meeting,
Palm Springs, CA. Plenary Session.
“Thrombopoietin and Its Impact
on Transfusion Medicine” |
| March 22 | American College of Physicians,
Philadelphia, PA. Meet the Professor
Session.
“The Clinical Use of
Hematopoietic Growth Factors” |
| March 23 | American College of Physicians,
Philadelphia, PA. Meet the Professor
Session.
“The Clinical Use of
Hematopoietic Growth Factors” |
| June 30 | UICC First International Meeting on
Advances in the Knowledge of Cancer
Management, Vienna, Austria.
“Thrombopoietin: Biology and
Clinical Uses in Oncology” |
| July 6 | 10th Symposium on Molecular Biology of
Hematopoiesis, Hamburg, Germany.
“Application of the Principles of
Thrombopoietin Physiology to
Disorders of Altered Platelet
Production” |
| August 18 | NHLBI Workshop on Autoimmune
Thrombocytopenic Purpura, Bethesda, MD.
“Thrombopoietin and
Thrombopoiesis in Normal
Subjects” |
| September 19 | Thrombose et Vaisseaux 97, Reunion
conjointe des Societes d’Angiologie et du
G.E.H.T., Biarritz, France.
“The Clinical Uses of
Thrombopoietin” |

- October 15 2nd International Symposium on Cancer
Chemotherapy, Tokyo, Japan
“Thrombopoietin: Biology and
Applications in Oncology”
- October 16 Kirin Research Symposium, Tokyo, Japan
“The Molecular Physiology of
Platelet Production”
- October 21 American Association of Blood Banks
Annual Meeting, Denver, CO
“Biology and Clinical Applications
of Platelet Growth Factors”
- November 28 Royal College of Physicians of
Edinburgh, Consensus Conference on
Platelet Transfusion, Edinburgh, Scotland
“Thrombopoietin: From Theory to
Practice”
- December 5 American Society of Hematology Annual
Meeting, Progress in High-Dose
Chemotherapy Symposium - The Future
Direction in Hematopoietic Cell-Supported
Therapy, San Diego, CA
“Update on Thrombopoietic
Growth Factors”
- December 9 American Society of Hematology Annual
Meeting, San Diego, CA
“Treatment of Platelet Donors
With Pegylated Recombinant
Megakaryocyte Growth and
Development Factor Increases
Circulating Platelet Counts and
Platelet Apheresis Yields and
Increases Platelet Increments in
Recipients of Platelet
Transfusions”

1998

- January 14 Keystone Symposium on Molecular
Regulation of Platelet Production, Incline
Village, Nevada
“The Use of PEG-rHuMGDF in
Platelet Apheresis”

January 16	Transfusion Medicine Symposium, American Red Cross & University of Utah School of Medicine, Salt Lake City, UT "Platelet Growth Factors: Impact on Transfusion Medicine"
March 11	American Association of Blood Banks National Audio Conference on Transfusion Practice "Platelet Growth Factors in Transfusion Medicine"
March 16	Vanderbilt University Grand Rounds, Nashville, TN "Thrombopoietin: Biological and Clinical Applications"
March 18	Fairfax Co. Oncology Seminar, Reston, VA "Thrombopoietic Growth Factors in Bone Marrow Transplantation"
March 25	Seminars in Clinical Research, Rockefeller University, New York, NY "Thrombopoietin: From Theory to Practice"
March 26	American Society for Blood and Marrow Transplantation, Annual Meeting, Miami Beach, FL "The Use of MPL Ligands for Treatment of BMT Patients and Preparation of the Normal Plateletapheresis Donor"
May 15	Nordic Hematology Society, Annual Meeting, Stockholm, Sweden "Thrombopoietic Growth Factors"
June 3	Eurocancer 98, XI th Annual Meeting, Paris, France "Thrombopoietin: From Basic Biology to Clinical Applications"
June 12	1 st Annual Southeast Area Transfusion Medicine Symposium, American Red Cross, Durham, NC "Platelet Growth Factors: Impact on Transfusion Medicine"

- June 30 XXVth Congress International Society of Blood Transfusion, Oslo, Norway, Plenary Address
“Thrombopoietins and Thrombopoiesis: A Clinical Perspective”
- Sept 7 Vienna University Hospital, Vienna, Austria
“Thrombopoietin: Biology and Clinical Applications”
- Sept 8 World Congresses of Gastroenterology, Vienna, Austria
“Thrombopoietin - Regulation of Platelet Production”
- Oct 31 American Assn of Blood Banks Annual Meeting, Philadelphia, PA, Plenary Symposium
“The Use of Platelet Growth Factors to Increase Platelet and Stem Cell Yields”
- Nov 3 American Assn of Blood Banks Annual Meeting, Philadelphia, PA, Satellite Symposium
“The Potential Effects of Platelet Growth Factors on Platelet Transfusion”

1999

- April 7 Healthsource Maine 4th Annual CME Conference, Augusta, ME
“The Clinical Use of Anticoagulants”
- May 27 Continuing Medical Education Course, Freeport, ME
“Low Molecular Weight Heparins: Evolving Roles in Clinical Practice”
- June 18 Medical Grand Rounds, Albany Medical Center, Albany, N.Y.
“The Clinical Use of Anticoagulants: Role of Low

Molecular Weight Heparin"

- July 2 Grand Rounds, University of South Florida
College of Medicine, Bay Pines Veterans
Administration Medical Center, Tampa, FL
"Low Molecular Weight Heparin –
Role in Clinical Practice"
- July 15 Grand Rounds, Euclid Meridia Hospital,
Cleveland, OH
"Low Molecular Weight Heparin –
Role in Clinical Practice"
- Nov 17 Grand Rounds, Good Samaritan Hospital,
Brockton, MA
"Low Molecular Weight Heparin –
Role in Clinical Practice"
- Dec 3 American Society of Hematology Annual
Meeting, Symposium on Platelet
Transfusion, New Orleans, LA
"Future Directions with Platelet
Growth Factors"
- Dec 5 American Society of Hematology Annual
Meeting, Transfusion Medicine
Subcommittee: Support of the
Thrombocytopenic Patient, New Orleans, LA
"Stimulation of Platelet Production –
Clinical Experience"

2000

- Jan 11 Grand Rounds, Charlton Hospital, Charlton,
MA
"Low Molecular Weight Heparin –
Role in Clinical Practice"
- Feb 16 Medical Grand Rounds, Blood Center of
Southeastern Wisconsin, Medical
College of Wisconsin, Milwaukee, WI
"Thrombopoietin: From Molecule to
Medicine"
- Mar 14 Medical Grand Rounds, Norwood
Hospital, Norwood, MA
"Low Molecular Weight Heparin –
Role in Clinical Practice"

Mar 21	Joseph R. Bove Transfusion Medicine Visiting Lectureship, Yale University School of Medicine, New Haven, CT “Thrombopoietin: Basic Biology and Clinical Applications”
Mar 31	Clinical and Molecular Basis of Transfusion-induced Immunomodulation Symposium, Washington, D.C. “Apoptosis in Transfusion Medicine”
May 22	New Drugs in Development, American Society of Clinical Oncology Annual Meeting, New Orleans, LA “rhTPO: A Novel Thrombopoietic Growth Factor”
May 26	Update with the National Experts: Fine Tuning Anticoagulation Therapy, Salt Lake Valley Hospitals, Salt Lake City “The Clinical Use of Low Molecular Weight Heparins”
June 28	New Approaches to Improve the Viability and Function of Transfused Platelets, National Institutes of Health, Heart, Lung and Blood Institute, Bethesda, MD “Molecular and Cellular Mechanisms of Platelet Viability”
August 12	The Antithrombotic Edge: A Consultant’s Forum of Evolving Concepts. Austin, TX. “Venous Thromboembolism”
August 12	The Antithrombotic Edge: A Consultant’s Forum of Evolving Concepts. Austin, TX. “Outpatient Treatment of DVT”
August 13	The Antithrombotic Edge: A Consultant’s Forum of Evolving Concepts. Austin, TX. “Treatment of Thrombosis”

September 12	Medical Grand Rounds, New York Hospital, New York, NY. “Thrombopoietin: Basic Biology and Clinical Applications”
September 19	Medical Grand Rounds, St. Francis Medical Center, New York, NY. “The Use of Low Molecular Weight Heparins”
September 23	The Antithrombotic Edge: A Consultant’s Forum of Evolving Concepts. Hamilton, Bermuda. “Venous Thromboembolism”
September 23	The Antithrombotic Edge: A Consultant’s Forum of Evolving Concepts. Hamilton, Bermuda. “Outpatient Treatment of DVT”
September 24	The Antithrombotic Edge: A Consultant’s Forum of Evolving Concepts. Hamilton, Bermuda. “Treatment of Thrombosis”
October 2	Meet the Professor Session, Providence St. Joseph Medical Center, Burbank, CA. “Advances in Anti-coagulation Therapy”
October 3	Medical Grand Rounds, Northridge Hospital, Northridge, CA. “The Clinical Use of Anticoagulants”
October 3	Medical Grand Rounds, Providence St. Joseph Medical Center, Burbank CA. “The Clinical Uses of Low Molecular Weight Heparin”
October 10	Medical Grand Rounds, Hackensack University Medical Center, Hackensack, NJ. “Advances in Anti-coagulation Therapy”
October 26	Medical Grand Rounds, Peninsula Hospital, Far Rockaway, NY.

“Use of Low Molecular Weight
Heparins”

November 5 American Association of Blood Banks
Annual Meeting, Washington, D.C.
“The Role of Apoptosis in Transfusion
Medicine and the Development of the
Platelet Storage Lesion”

2001

January 15 Grand Rounds, Cardeza Research
Foundation, Thomas Jefferson Medical
College, Philadelphia, PA
“Heparin: Structure, Function and
Clinical Uses”

February 7 Medical Grand Rounds, Mercy Medical
Center, Rockville Center, NY
“The Clinical Use of Low
Molecular Weight Heparins”

March 21 Hematology Conference, National Heart,
Lung and Blood Institute, Hematology
Branch, NIH, Bethesda, MD
“Thrombopoietin: Basic Science
and Clinical Biology”

April 28 Thromboembolism in Orthopedic Surgery
Conference, Montreal, Canada
“Coagulation for Orthopedists”

May 5 Thromboembolism in Orthopedic Surgery
Conference, Scottsdale, AZ
“Coagulation for Orthopedists”

June 7 Medical Grand Rounds, Hersey Medical
Center, Hersey, PA
“Anticoagulation in Cancer
Patients”

July 11 XVIII Congress, The International Society on
Thrombosis and Haemostasis, Plenary
Session, Paris, France
“Cytokines and Thrombopoiesis:
Clinical Trials”

Sept 25	Geller Memorial Lecture, Department of Medicine, South Nassau Communities Hospital, Oceanside, NY "Thrombosis and Antithrombosis in Primary Care"
Sept 25	Infectious Diseases Grand Rounds, Winthrop University Hospital, New York, NY "Hematological Complications of Antibiotics"
Sept 25	Infectious Diseases CME Lecture, Oceanside, NY "Hematological Complications of Linezolid"
Sept 26	Medical Grand Rounds, North Shore University Hospital, Forest Hills, NY "Current Concepts in Thrombosis"
Oct 5	Symposium on Management of Cancer-related Anemia, Boston, MA "Anemia Management in Oncology"
Oct 6	Symposium on Management of Cancer-related Anemia, Boston, MA "Platelet Growth Factors"
Oct 6	Symposium on Management of Cancer-related Anemia, Boston, MA "Darbepoietin alpha"
Oct 17	New Developments in Cancer Management Symposium, Chicago, IL "Expanding the Options for Cancer-related Anemia. The Evolving Clinical Picture"
Oct 20	Anticoagulation in Cardiology Symposium, Charleston, SC "Antithrombotic Mechanisms of Anticoagulant Drugs; Focus on Low Molecular Weight Heparin"
Nov 28	Anticoagulation Workshop: Outpatient Management of Deep Vein Thrombosis

(DVT), Michigan State University,
Kalamazoo, MI
“Overview: Low Molecular Weight
Heparins”

Dec 7 Building on a Heritage in Thrombosis:
Perspectives in Cancer Care Symposium,
43rd Annual Meeting of the American Society
of Hematology, Orlando, FL
“Catheter-related Complications
(CRC): Preventing CRC in
Patients with Central Venous
Lines”

Dec 8 Critical Issues in Infectious Diseases
Symposium, 43rd Annual Meeting of the
American Society of Hematology, Orlando,
FL
“The Hematological Effects of
Linezolid”

2002

Feb 26 Medical Grand Rounds, St. Luke's Hospital,
Bethlehem, PA
“Mechanisms of Thrombosis and
the Clinical Use of
Anticoagulants”

March 7 Cardiology Grand Rounds, Dartmouth-
Hitchcock Medical Center, Dartmouth
Medical School, Hanover, NH
“Mechanisms of Thrombosis and
the Clinical Use of
Anticoagulants”

March 14 Medical Grand Rounds, New Britain General
Hospital, New Britain, CT
“Mechanisms of Thrombosis and
the Clinical Use of
Anticoagulants”

April 19 The Second Asian-Pacific Congress on
Thrombosis and Hemostasis, Seoul, Korea
“Clinical Studies with
Recombinant Thrombopoietins”

April 27	Consultant's Conference on Anticoagulation in Acute Coronary Syndromes, Hamilton, Bermuda "Mechanisms of Anti-thrombosis"
May 27	Plenary Session, 25 th Brazilian Congress of Hematology and Hemotherapy, Salvador, Brazil "What is the Platelet Trigger and the Platelet Dose"
May 27	Plenary Session, 25 th Brazilian Congress of Hematology and Hemotherapy, Salvador, Brazil "The Clinical Use of Thrombopoietin"
May 28	Plenary Session, 25 th Brazilian Congress of Hematology and Hemotherapy, Salvador, Brazil "The Use of Thrombopoietin in Transfusion Medicine"
July 9	Medical Grand Rounds, Charlton Hospital, Fall River, MA "Anti-embolic Prophylaxis in Pulmonary Embolisms and DVTs"
July 13	Keynote Address, The Antithrombotic EDGE: A Cardiology Consultants Forum, Dana Point, CA "Anticoagulation: Science and Practice"
August 6	Medical Grand Rounds, Skyline Medical Center, Nashville, TN "Use of Low Molecular Weight Heparin in Cardiology"
August 6	Heart Institute Grand Rounds, Saint Thomas Heart Institute, Nashville, TN "Anticoagulation Update"
August 16	Grand Rounds, Champlain Valley Physicians Hospital Medical Center, Plattsburgh, NY "The Use of Erythroid Growth"

Factors”

August 28	27 th Congress of the International Society of Blood Transfusion, Vancouver, Canada “Apoptosis and Cellular Product Storage”
September 11	Medical Grand Rounds, The Reading Hospital and Medical Center, Reading, PA “Mechanisms of Thrombosis and the Clinical Use of Anticoagulants”
October 11	Hematology/Oncology Grand Rounds, Washington Hospital Center, Washington, DC “Thrombosis and Anticoagulation in Cancer”
October 18	Surgical Grand Rounds, Charlton Hospital, Fall River, MA “VTE Prophylaxis in Surgical Patients”
October 22	Medical Grand Rounds, Memorial Sloan Kettering Hospital, New York, NY “Whatever Happened to Thrombopoietin?”
November 20	Medical Grand Rounds, Lawrence General Hospital, Medford, MA “Clinical Use of Erythroid Growth Factors”
December 6	American Society of Hematology, Symposium on Evolving Strategies for Improved Supportive Care and Patient Outcomes in Cancer Treatment, Philadelphia, PA “Thrombocytopenia: Is there a role for cytokine therapy?”

2003

January 17	Medical Grand Rounds, Berkshire Medical Center, Pittsfield, MA “Thrombosis and Hemostasis for the Internist”
------------	---

February 12	Cancer Center Research Program, Columbia Presbyterian Hospital, New York, NY “The Clinical Use of Erythroid Growth Factors in Oncology”
February 26	Caremark National Pharmacy and Therapeutics Committee Meeting, Chicago, IL “The Clinical Use of Hematopoietic Growth Factors”
February 27	Surgery Grand Rounds, Ohio State Medical Center, Columbus, OH “Clinical Anticoagulation: Low Molecular Weight Heparin”
March 26	Medical Grand Rounds, Hahnemann University Hospital, Philadelphia, PA “Hematopoietic Support in Oncologic Therapy: RBC Maintenance”
March 26	Grand Rounds, Medical College of Pennsylvania Hospital, Philadelphia, PA “Hematopoietic Support in Oncologic Therapy: RBC Maintenance”
March 27	Grand Rounds, The Western Pennsylvania Hospital, Pittsburgh, PA “The Clinical Use of Anticoagulant Drugs”
March 27	Grand Rounds, UPMC Shadyside Hospital, Pittsburgh, PA “Thrombosis and Antithrombotic Therapies”
May 9	Advances in the Treatment of Hematological Malignancies, Hackensack University Medical Center, Hackensack, NJ “Treating the Anemia of Cancer with Erythroid Growth Factors”
May 16	Medical Grand Rounds, Tobey Hospital, Wareham, MA

“Prevention and Treatment of
DVT”

- July 15 Medical Grand Rounds, University of
Tennessee, Erlanger Health System,
Chattanooga, TN
 “The Clinical Use of Low
 Molecular Weight Heparins”
- July 15 Medical Grand Rounds, Bradley Memorial
Hospital, Bradley, TN
 “Thrombosis and Antithrombotic
 Therapies”
- November 4 Medical Grand Rounds, Charlton Hospital,
Fall River, MA
 “The Management of Venous
 Thromboembolism: New
 Anticoagulants, New
 Approaches”
- November 21 Medical Education Program, King
Edward VII Memorial Hospital, Hamilton,
Bermuda
 “Immune Thrombocytopenic
 Purpura”

2004

- January 29 Hematology/Oncology Grand Rounds,
Lahey Clinic, Burlington, MA
 “New Antithrombotic Drugs for
 Oncologists”
- March 16 Hematology/Oncology Grand Rounds,
Exeter Hospital, Exeter, NH
 “New Antithrombotic Drugs”
- March 16 New England Research Institute,
Watertown, MA
 “Diagnosis and Treatment of
 Idiopathic Thrombocytopenic
 Purpura”
- June 1 Hematology Grand Rounds, Thomas
Jefferson University Hospital, Philadelphia,
PA

	<p>“Whatever Happened to Thrombopoietin?”</p>
August 1	<p>International Conference on Erythroid Growth Factors, Mauritius “Treating the Anemia of Cancer with Erythropoietin 40,000 IU Weekly”</p>
September 2	<p>Hematology/Oncology Grand Rounds, Montefiore Medical Center, New York, NY “Platelet Growth Factors: Past, Present and Future”</p>
October 26	<p>American College of Chest Physicians Annual Meeting, Seattle, WA Plenary Session Lecture “Heparin-induced Thrombocytopenia (HIT): Diagnosis and Treatment Options”</p>
November 5	<p>Development of Therapeutic Biologics and Immunogenicity. Abbott Pharmaceuticals Symposium, Chicago, IL “Development of Therapeutic Biologics and Immunogenicity: Practical Considerations”</p>
November 8	<p>Gaucher’s Disease Consultants Conference, Windsor, UK “Approach to Treatment of Gauchers Disease – USA”</p>
November 10	<p>Medical Grand Rounds, St. Anne’s Hospital, Fall River, MA “Heparin: Thrombocytopenia and Thrombosis”</p>
December 3	<p>American Society of Hematology Symposium on “The Expanding Role of Cytokines in Supportive Care in Oncology: Emerging Data and Treatment Trends,” San Diego, CA “Preclinical and Early Clinical Development of a Novel Thrombopoietin”</p>

- December 4 American Society of Hematology Annual Meeting, Scientific Subcommittee on Hematopoietic Growth Factors Symposium, "The Role of Chemokines and Their Receptors in Hematopoiesis," San Diego, CA.
"Introduction to Chemokines"
- December 5 American Society of Hematology Annual Meeting, Scientific Subcommittee on Hematopoietic Growth Factors Symposium, "The Role of Chemokines and Their Receptors in Hematopoiesis," San Diego, CA.
"Introduction to Chemokines"
- December 6 American Society of Hematology Annual Meeting, San Diego, CA.
"A Phase 2 Placebo-controlled Study Evaluating the Platelet Response and Safety of a Novel Thrombopoietic Protein (AMG 531) in Thrombocytopenic Adult Patients with Immune Thrombocytopenic Purpura (ITP)"

2005

- April 22 Glaxo Smith Kline Lecture Series in Medicine, Collegeville, PA
"Immune Thrombocytopenic Purpura: Pathophysiology and Novel Therapeutic Approaches"
- May 5 Hartford Vascular Society Spring Meeting, Hartford, CT
"Clinical Uses of Anticoagulants: New Drugs, New Indications"
- May 23 Genomics Institute of the Novartis Research Foundation, San Diego, CA
"Immune Thrombocytopenic Purpura: Pathophysiology and Novel Therapeutic Approaches"
- May 25 Pfizer Global Research Symposium, Groton, CT
"Immune Thrombocytopenic

Purpura: Pathophysiology and
Novel Therapeutic Approaches”

- | | |
|-------------|--|
| August 10 | XX Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia
“The Treatment of ITP with AMG-531” |
| November 11 | Medical Grand Rounds, Albany Medical Center, Albany, NY
“The Clinical Use of Anticoagulants: New Drugs, New Indications” |
| November 15 | Medical Grand Rounds, Maine Medical Center, Portland, ME
“Chronic ITP: Pathophysiology and New Therapies” |
| November 22 | Grand Rounds, Charlton Hospital, Fall River, MA
“The Clinical Use of Anticoagulants: New Drugs, New Indications” |
| December 9 | American Society of Hematology Annual Meeting, Symposium on “Cytokines and Their Role in Improving Health Care,” Atlanta, GA
“New Therapies for Chronic Thrombocytopenic Purpura” |

2006

- | | |
|------------|--|
| January 10 | Coagulation Deficiencies: A Look to the Future. London 2006 Workshop, London, UK
“Thrombopoietin” |
| March 3 | Grand Rounds, Lankenau Hospital, Philadelphia, PA
“ITP and Related Diseases” |
| May 10 | Medical Grand Rounds, Drexel University College of Medicine, Philadelphia, PA
“Immune Thrombocytopenic Purpura – New Concepts and |

New Theories”

May 26	Closing Symposium: Emerging Diagnostic and Therapeutic Developments in Hemapheresis Patient and Donor Management, 27 th Annual Meeting of the American Society for Apheresis, Las Vegas, NV “The Use of Thrombopoietic Growth Factors in Transfusion Medicine”
June 1	University of California, Irving School of Medicine and CME Enterprise ITP CME Series, Atlanta, GA. “Immune Thrombocytopenic Purpura: New Concepts and Approaches”
June 8	University of California, Irving School of Medicine and CME Enterprise ITP CME Series, New York, NY. “Immune Thrombocytopenic Purpura: New Concepts and Approaches”
June 14	University of California, Irving School of Medicine and CME Enterprise ITP CME Series, Boston, MA. “Immune Thrombocytopenic Purpura: New Concepts and Approaches”
June 15	University of California, Irving School of Medicine and CME Enterprise ITP CME Series, New Brunswick, NJ. “Immune Thrombocytopenic Purpura: New Concepts and Approaches”
June 20	2006 National Biotechnology Conference, Boston, MA “Immunogenicity of Therapeutic Proteins: Clinical Implications”

September 21	2 ^{ème} Journee Francaise de la Maladie de Gaucher, Paris, France “Clinical Aspects of Gaucher’s Disease : North American Perspective”
November 9	National Institutes of Health Meeting on MPD and MDS, Bethesda, MD “A Proteogenomic Analysis of the Platelets in Essential Thrombocythemia”
November 14	Hematology and Medical Oncology Grand Rounds, Memorial Sloan-Kettering Cancer Center, New York, NY “New Thrombopoietic Growth Factors: Structure, Function, and Clinical Studies”
December 8	American Society of Hematology Symposium: Thrombocytopenia in the Practice of Hematology and Oncology - Focus on Increasing Platelet Production, Orlando, FL “Emerging Therapies for Thrombocytopenia”
December 8	American Society of Hematology Symposium: ITP Study Group Meeting, Orlando, FL “Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura (ITP)”
December 8	American Society of Hematology Symposium: ITP Study Group Meeting, Orlando, FL “Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: ≥ 48-Week Update”
December 11	American Society of Hematology Symposium, Orlando, FL “Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: ≥ 48-Week Update”

2007

- February 17 Future Directions in Gaucher Disease:
Charting New Territories Symposium,
Lisbon, Portugal
 “Oncological Complications of
Gaucher Disease: Fact or Fiction”
- February 18 Future Directions in Gaucher Disease:
Charting New Territories Symposium,
Lisbon, Portugal
 “Gaucher Disease is Best
Monitored by Biochemical
Parameters”
- March 15 Hematopoietic Growth Factors - Use in
Normal Blood and Stem Cell Donors:
Clinical and Ethical Issues, Bethesda,
MD
 “Emerging Therapies for
Thrombocytopenia”
- April 13 Hemophilia and Thrombosis Research
Society Annual Scientific Symposium,
Chicago, IL
 “What’s New in HIT”
- May 15 Caremark National Pharmacy and
Therapeutics Committee Meeting, Chicago,
IL
 “Hematopoietic Growth Factors”
- June 7 European Hematology Association 12th
Congress, Symposium: Meeting the
Treatment Challenges of Chronic Immune
Thrombocytopenic Purpura: An Interactive
Clinical Discussion, Vienna, Austria
 “New Drugs for Familiar
Therapeutic Targets:
Thrombopoietin Receptor
Agonists and ITP”
- June 7 European Hematology Association 12th
Congress, Symposium: Meeting the
Treatment Challenges of Chronic Immune
Thrombocytopenic Purpura: An Interactive
Clinical Discussion, Vienna, Austria

“Clinical Case Interlude 1”

- June 7 European Hematology Association 12th Congress, Symposium: Meeting the Treatment Challenges of Chronic Immune Thrombocytopenic Purpura: An Interactive Clinical Discussion, Vienna, Austria
“Clinical Case Interlude 2”
- June 7 European Hematology Association 12th Congress, Symposium: Meeting the Treatment Challenges of Chronic Immune Thrombocytopenic Purpura: An Interactive Clinical Discussion, Vienna, Austria
“New Agents and Evolving Management Paradigms”
- September 5 Hematology Grand Rounds, National Institutes of Health, Bethesda, MD
“New Thrombopoietic Growth Factors”
- September 11 American College of Clinical Pharmacology, 36th Annual Meeting, Plenary Symposium on “Drug Development and Biotechnology: Update 2007”, San Francisco, CA
“Biology and Clinical Applications of AMG-531, a New Thrombopoietic Growth Factor”
- September 21 40th Annual Meeting of the German Society for Transfusion Medicine and Immunohematology (DGTI), Plenary Symposium, Friedrichshafen, Germany
“New Thrombopoietic Growth Factors”
- September 29 American School of Oncology, Great Debates in Hematology Symposium, Chicago, IL
“Advances in the Management of Thrombocytopenia”
- October 5 Cytopenias in 2007: Emphasis on ITP Symposium, Weill Medical College of Cornell University, San Diego, CA
“New Thrombopoietic Growth Factors”

October 29	Hematology Grand Rounds, Royal Victoria Hospital-McGill University Health Centre, Montreal, CA “New Insights into the Pathophysiology and Treatment of ITP”
October 29	Hematology Grand Rounds, Jewish Hospital, Montreal, CA “New Insights into the Pathophysiology and Treatment of ITP”
October 29	Ottawa Blood Club, Ottawa, CA “New Insights into the Pathophysiology and Treatment of ITP”
October 30	Medical Grand Rounds, Hotel-Dieu de Quebec Hospital, Quebec, CA “New Insights into the Pathophysiology and Treatment of ITP”
October 30	Hematology Grand Rounds, Hopital de l’Enfant-Jesus, Quebec, CA “Clinical Management of Thrombocytopenia”
November 27	Hematology/Oncology Grand Rounds, Yale University Cancer Center, New Haven, CT “New Thrombopoietic Growth Factors – Biochemistry and Clinical Uses”
December 7	49 th Annual Meeting American Society of Hematology Symposium, Thrombocytopenia Treatment Exposed: Challenging Cases Brought to Life, Atlanta GA “Heparin-induced Thrombocytopenia”
December 7	49 th Annual Meeting American Society of Hematology Symposium, Thrombocytopenia Treatment Exposed: Challenging Cases Brought to Life, Atlanta GA “Chemotherapy-induced

Thrombocytopenia”

- December 7 49th Annual Meeting American Society of Hematology Symposium, ITP Study Group Meeting, Atlanta GA
“Evaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic Immune Thrombocytopenia Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study”
- December 10 49th Annual Meeting American Society of Hematology Symposium, Atlanta GA
“Evaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic Immune Thrombocytopenia Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study”

2008

- January 27 International Oncology Network Hematology Review, Orlando, FL
“New Thrombopoietic Agents in Managing Thrombocytopenia in ITP, MDS and Chemotherapy”
- January 29 Society for the Study of Blood, New York, NY
“New Thrombopoietic Agents”
- January 30 Hematology/Oncology Grand Rounds, Weill Cornell Medical College, New York, NY
“New Thrombopoietic Drugs: Biology and Clinical Uses”
- February 27 Hematology Grand Rounds, University of Texas M.D. Anderson Cancer Center, Houston, TX
“Thrombopoietic Growth Factors: Pathophysiology and New Clinical Applications”
- February 27 Hematology Grand Rounds, Methodist Hospital Medical Center, Houston, TX

	"News About Erythropoiesis Stimulating Agents"
February 27	Gulf Coast Hematology Society, Houston, TX "New Thrombopoietic Growth Factors: Pathophysiology and Clinical Uses"
February 28	Robert Hettig Lectureship in Hematology, Medicine Grand Rounds, Baylor College of Medicine, Houston, TX "New Insights into the Pathophysiology and Treatment of ITP"
March 12	Oncology Drugs Advisory Committee, Food and Drug Administration, Gaithersburg, MD "Romiplostim"
May 7	AABB Audioconference: The Impact of Thrombopoietin (TPO) Agonists on Platelet Transfusion. "Thrombopoietic Growth Factors: Pathophysiology and New Clinical Applications"
May 17	The Architecture of Bone Manifestations in Gaucher Disease: Classical Themes Applied to Innovative Concepts, Athens, Greece "Rethinking foundations for assessing response to treatment in Gaucher-related bone disease"
June 12	Nplate ELEVATE Launch, Las Vegas, NV "Thrombopoietin: from idea to molecule to medicine. A personal perspective"
June 20	Targeted Approaches for the Management of ITP, PDSA Annual ITP Conference 2008, Chicago, IL "Pathophysiology of ITP with an emphasis on suboptimal platelet production and the role of thrombopoietic agents"

June 21	PDSA Annual ITP Conference 2008, Chicago, IL “New treatments for ITP”
June 21	PDSA Annual ITP Conference 2008, Chicago, IL “Ask the experts: Adults with ITP”
July 25	Joseph E. Sokal Memorial Lecture, Duke University Medical Center, Durham, NC “Thrombopoietin: From molecule to medicine”
September 15	WebCast-p4Healthcare. Boston, MA. “Romiplostim for Chronic Immune Thrombocytopenic Purpura”
September 17	WebCast-p4Healthcare. Boston, MA. “Romiplostim for Chronic Immune Thrombocytopenic Purpura”
September 27	Leukemia 2008, MD Anderson Cancer Center, Houston, TX. “New Thrombopoietic Growth Factors”
September 29	ReachMD Radio Lecture. Boston, MA. “New Thrombopoietic Growth Factors”
September 29	ReachMD Radio Lecture. Boston, MA. “New Treatments for ITP”
October 3	Plenary Lecture, Pediatric Hemostasis and Thrombosis Update 2008. Toronto, Canada. “Thrombopoiesis: New Insights and Therapeutic Products”
October 4	Joint AABB/ASH Symposium, American Association of Blood Banks Annual Meeting, Montreal, Canada. “Growth Factors as Drugs: Thrombopoietin”
October 18	Platelets 2008. 5 th International Platelet Symposium. Woods Hole, MA. “Novel Thrombopoietic Agents”

October 28	Webcast-p4Healthcare, Boston, MA. “Practical Aspects of Using Thrombopoietic Agents”
November 1	Management of ITP: Current Perspectives on Diagnosis and Therapeutic Approaches. Platelet Disorders Support Association Meeting. Washington, DC. “Current and Emerging Therapies for ITP”
November 14	Plenary Lecture. The Science and Treatment of ITP Symposium. The Royal College of Pathologists. London, UK. “Emerging Therapies for the Management of ITP”
November 15	The ITP Support Association 10 th Annual Patient Convention. The Royal College of Pathologists. London, UK. “Emerging Therapies for the Management of ITP”
November 15	The ITP Support Association 10 th Annual Patient Convention. The Royal College of Pathologists. London, UK. “ITP Case Management”
November 20	Medical Grand Rounds, Dept of Medicine, St Vincent Hospital, Worcester, MA “Thrombopoietin: From Molecule to Medicine”
December 5	ITP Study Group Meeting, American Society of Hematology 50 th Annual Meeting, San Francisco, CA “Long-term treatment with romiplostim in patients with chronic immune thrombocytopenic purpura (ITP: 3-year update from an open-label extension study”
December 5	ITP Study Group Meeting, American

- Society of Hematology 50th Annual Meeting, San Francisco, CA
“Evaluation of bone marrow reticulin formation in romiplostim-treated adult patients with chronic immune thrombocytopenic purpura (ITP)”
- December 7 Intercontinental Childhood ITP Study Group, American Society of Hematology 50th Annual Meeting, San Francisco, CA
“Update on Thrombopoietin Mimetics”
- December 8 American Society of Hematology 50th Annual Meeting, San Francisco, CA
“Long-term treatment with romiplostim in patients with chronic immune thrombocytopenic purpura (ITP: 3-year update from an open-label extension study”
- December 8 AMGEN Press Briefing, American Society of Hematology 50th Annual Meeting, San Francisco, CA
“Update on long-term use of romiplostim”
- December 16 Webcast-p4Healthcare, Boston, MA.
“Romiplostim for chronic ITP”

2009

- January 6 Webcast-p4Healthcare, Boston, MA.
“Romiplostim for chronic ITP”
- February 4 Nplate Symposium, Birmingham, UK.
“The role of romiplostim in patients with chronic ITP”
- February 6 Einfuhrungssymposium eines innovativen Arzneimittels: Thrombopoese-Stimulation als neuer Therapiensatz in der Behandlung der chronischen Immunthrombozytopenie (ITP), Berlin, Germany.

- “Thrombopoiesis stimulation in ITP: Paradigm shift and new treatment option for chronic ITP – Results of clinical studies”
- March 13 Romiplostim in ITP Meeting. New York, NY.
“What’s new in ITP?”
- March 17 Gordon Research Conference: The Cell Biology of Megakaryocytes and Platelets, Galveston, TX
“Clinical rationale for TPO mimetics in ITP”
- March 27 Combined Grand Rounds-Cape Cod Hospital, Hyannis, MA
“Anticoagulation for internists”
- April 17 Annual Hemophilia and Thrombosis Research Society Scientific Symposium, Chicago, IL
“New Thrombopoietic Growth Agents”
- April 18 Annual Hemophilia and Thrombosis Research Society Scientific Symposium, Chicago, IL
“Treatment of HIT: Use of Fondaparinux”
- April 27 British Society of Haematology Annual Meeting. Improving Outcomes in the Haematology Patient – Focus on ITP. Brighton, UK
“ ‘A Case for Romiplostim’ – Experience in the Clinic”
- June 6 14th Congress of the European Hematology Association, Hematology-in-Focus Session: New Thrombopoietic Growth Factors. Berlin, Germany
“Regulation of Thrombopoiesis and the Clinical Use of Second Generation Mpl Ligands”
- June 6 14th Congress of the European Hematology Association, Treatment Advances in ITP.
“The Complexity of ITP and

Current Treatment Options"

June 16	Hematology/Oncology Grand Rounds, Neag Comprehensive Cancer Center University of Connecticut Health Center Farmington, CT "Thrombopoietin: From Molecule to Medicine"
July 14	CVS/Caremark National Pharmacy and Therapeutics Committee Meeting. Chicago, IL "Hematopoietic Growth Factors"
July 23	S2PrePro Meeting. Orlando, FL. "Clinical Use of Nplate"
July 31	Australia & Asia Pacific Gaucher Disease Meeting, Sydney, Australia "Overview of Efficacy and Safety of Miglustat in GD1"
July 31	Australia & Asia Pacific Gaucher Disease Meeting, Sydney, Australia "Clinical Experience with GD1 in Boston"
August 11	University of Pittsburgh Medical Center, Hematology/Oncology Lecture, Pittsburgh, PA. "Thrombopoietin: From Molecule to Medicine"
September 9	Hematology/Oncology Grand Rounds, Montreal General Hospital, Montreal, Quebec, Canada "New Insights into the Pathophysiology and Treatment of ITP"
September 9	Hematology/Oncology Grand Rounds, Jewish General Hospital, Montreal, Quebec, Canada "New Insights into the Pathophysiology and Treatment of ITP"
September 9	Hematology/Oncology Grand Rounds,

- CHUM-Hopital Notre-Dame, Montreal,
Quebec, Canada
“New Insights into the
Pathophysiology and Treatment
of ITP”
- September 10 Hematology/Oncology Grand Rounds,
Princess Margaret Hospital, Toronto,
Ontario, Canada
“New Insights into the
Pathophysiology and Treatment
of ITP”
- September 10 Hematology/Oncology Grand Rounds,
McMaster Hospital, Hamilton, Ontario,
Canada
“New Insights into the
Pathophysiology and Treatment
of ITP”
- September 12 NCCN 4th Annual Congress:
Hematologic Malignancies, New York,
NY
“Platelet Support in the
Management of Hematologic
Malignancies”
- September 17 Immunoematology and Blood
Transfusion, 28th Annual Symposium.
National Institutes of Health/American
Red Cross, Bethesda, MD.
“Stimulation of Platelet
Production with Thrombopoietin
Mimeics: Pathophysiology and
Clinical Applications”
- September 24 Cytopenias and Hemostasis in 2009.
Orlando, FL
“Platelet Production in ITP”
- October 3 Canadian Convergence on ITP: New and
Old Targets, Vancouver, CA
“The Pathophysiology of ITP”
- October 3 Canadian Conference on ITP: New and
Old Targets, Vancouver, CA
“Case Studies in ITP”

- October 7 Hematology Grand Rounds, Yale-New Haven Medical Center, New Haven, CT
 "Thrombopoietin: From Molecule to Medicine"
- October 10 Assessing Recent Advancements in the Management of ITP and Thrombocytopenia Secondary to Other Disorders, New York, NY.
 "Recent Clinical Findings with Thrombopoietic Agents and Emerging Therapies"
- October 21 American Society of Human Genetics Annual Meeting. Facing Up to Today's Clinical Challenges of Treating Lysosomal Storage Disorders Symposium. Honolulu, HI.
 "Treatment of Unmet Gaucher Disease Manifestations"
- October 24 Congres Lymphome et Myelome. Symposium de lancement Nplate. New York, NY.
 "Nplate: Donnees d'efficacite des etudes cliniques"
- November 6 Novel Agents, New Guidance: Standardising the Treatment for ITP, International Symposium, Lisbon, Portugal
 "Guidance for a new era: Management of adult ITP"
- November 6 Novel Agents, New Guidance: Standardising the Treatment for ITP, International Symposium, Lisbon, Portugal
 "Clinical perspective: working from guidance in daily practice"
- November 7 Novel Agents, New Guidance: Standardising the Treatment for ITP, International Symposium, Lisbon, Portugal
 "Adhering to guidance: case studies"

November 7	Novel Agents, New Guidance: Standardising the Treatment for ITP, International Symposium, Lisbon, Portugal “Future developments in novel agents”
November 17	Nplate: A New Development in the Treatment of ITP, International Symposium, Glasgow, Scotland “Nplate clinical data”
November 17	Nplate: A New Development in the Treatment of ITP, International Symposium, Glasgow, Scotland “International ITP Management Consensus”
December 4	International ITP Breakfast Meeting, 51 st Annual Meeting of American Society of Hematology, New Orleans, LA “Comparison of splenectomy and treatment failure incidence in nonsplenectomized patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care: 1-year treatment and 6-month follow-up”
December 7	51 st Annual Meeting of American Society of Hematology, New Orleans, LA “Comparison of splenectomy and treatment failure incidence in nonsplenectomized patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care: 1-year treatment and 6-month follow-up”
December 7	Advances in Chronic ITP Research and Management, 51 st Annual Meeting of American Society of Hematology, New Orleans, LA “The complexity of ITP and recent recommendations for

diagnosis and treatment: new
consensus report on ITP”

2010

- | | |
|-------------|---|
| January 20 | Novel Therapeutics in Chronic ITP
Treatment Symposium, Galway, Ireland
“Romiplostim in adult ITP:
efficacy and safety” |
| January 20 | Novel Therapeutics in Chronic ITP
Treatment Symposium, Galway, Ireland
“Diagnosis and treatment of
adult ITP – guidelines” |
| January 21 | Novel Therapeutics in Chronic ITP
Treatment Symposium, Royal College
of Physicians Ireland, Dublin, Ireland
“Romiplostim in adult ITP:
efficacy and safety” |
| January 21 | Novel Therapeutics in Chronic ITP
Treatment Symposium, Royal College
of Physicians Ireland, Dublin, Ireland
“Diagnosis and treatment of
adult ITP – guidelines” |
| January 22 | Novel Therapeutics in Chronic ITP
Treatment Symposium, Cork, Ireland
“Romiplostim in adult ITP:
efficacy and safety” |
| January 22 | Novel Therapeutics in Chronic ITP
Treatment Symposium, Cork, Ireland
“Diagnosis and treatment of
adult ITP – guidelines” |
| February 13 | Current Trends in Leukemia,
Lymphoma, and Myeloma. Boston, MA.
“Update on therapies for ITP and
other benign hematology
disorders” |
| February 17 | Nichols Institute Seminar Series,
Nichols Institute, San Juan Capistrano,
CA.
“Thrombopoietin: Biology and
Clinical Applications” |

March 18	Texas Children's Cancer Center Research Seminar, Texas Children's Hospital, Baylor College of Medicine, Houston, TX. "Thrombopoietin: From Molecule to Medicine"
April 15	2 nd Amgen Middle East and Africa Oncology-Haematology Summit, Istanbul, Turkey "Romiplostim: A Second- Generation Thrombopoietin Agonist"
April 16	2 nd Amgen Middle East and Africa Oncology-Haematology Summit, Istanbul, Turkey "Real-life With Romiplostim: The French Experience"
April 28	Focus on Chronic Immune Thrombocytopenia (ITP): New Treatments and Consensus on Management, Southampton, UK "Romiplostim in Adult ITP: Efficacy and Safety"
April 28	Southampton Regional Hematology Meeting, Southampton, UK "New Consensus on ITP Management"
April 30	European School of Haematology, International Conference on Immune Thrombocytopenia, Lisbon, Portugal "New International Consensus Guidelines in ITP"
May 1	European School of Haematology, International Conference on Immune Thrombocytopenia, Lisbon, Portugal "Thrombopoietin Mimetics: Old and New"
May 1	European School of Haematology International Conference on Immune Thrombocytopenia, Lisbon, Portugal

“Clinical Studies with TPO
Mimetics”

May 12	Focus on Chronic Immune Thrombocytopenia (ITP): New Treatments and Consensus on Management, London, UK “Romiplosim in Adult ITP: Efficacy and Safety”
June 10	What is the future for ITP? Satellite Symposium, 15 th Congress, European Hematology Association, Barcelona, Spain “What Is the Future for ITP?”
June 15	Hematology/Oncology Grand Rounds, Memorial Sloan-Kettering Cancer Center, New York , NY “Thrombopoietin: From Molecule to Medicine”
July 20	Hematology and Transfusion Medicine Symposium, Blood Center of Wisconsin, Milwaukee, WI “Thrombopoietin: From Molecule to Medicine”
August 20	Yamagata Medical Society, Yamagata University Medical School, Yamagata, Japan “Thrombopoietin and Chronic Immune Thrombocytopenia”
August 21	8 th ORBIS Meeting, Tokyo, Japan “Thrombopoietin: From Molecule to Medicine”
September 8	European Medicines Evaluation Agency (EMA) – Scientific Advisory Board-Oncology (SAG-O) Meeting, Canary Wharf, London, UK “Clinical Evaluation of Romiplostim”
September 9	Hematology Rounds, Queen Elizabeth II Health Sciences Center, Halifax, Canada

	"New Insights Into the Pathophysiology of ITP"
September 10	Hematology Rounds, Moncton Regional Cancer Center, Moncton, Canada "New Insights Into the Pathophysiology of ITP"
September 22	Hematology/Oncology Case Conference, Tom Baker Cancer Center, University of Alberta, Calgary, Canada "How I Treat ITP"
September 23	Hematology-Oncology Grand Rounds, Tom Baker Cancer, University of Alberta, Calgary, Canada "New Insights Into the Pathophysiology of ITP"
September 23	Hematology Fellows Conference, Tom Baker Cancer Center, University of Alberta, Canada "ITP Rounds"
September 24	Hematology/Oncology Rounds, University of Alberta Medical School and Hospital, Edmonton, Canada "How I Use Romiplostim"
September 24	Medical Grand Rounds, University of Alberta Medical School and Hospital, Edmonton, Canada "New Insights Into the Pathophysiology of ITP"
October 12	Australia and Asia Pacific Gaucher Disease Symposium, Melbourne, Australia "Clinical Experience with GD1 in Boston"
October 12	Australia and Asia Pacific Gaucher Disease Symposium, Melbourne, Australia "Emerging Miglustat Data"
October 13	Type 1 Gaucher Disease: Challenges and Opportunities in Patient

- Management, Melbourne, Australia
“A Review of Type 1 Gaucher Disease: Successes and Challenges in Current Practice”
- October 13 Type 1 Gaucher Disease: Challenges and Opportunities in Patient Management, Melbourne, Australia
“Future Directions for Treating Type 1 Gaucher Disease: Emerging Treatments and Advances in Clinical Knowledge”
- November 12 International ITP Symposium 2010, Prague, Czechslovakia.
“Welcome to Prague”
- November 12 International ITP Symposium 2010, Prague, Czechslovakia.
“Practical Patient Care Workshop”
- November 12 International ITP Symposium 2010, Prague, Czechslovakia.
“The Management of ITP: Applying the New International Consensus Guidelines”
- November 12 International ITP Symposium 2010, Prague, Czechslovakia.
“Meet-the-Professor-ITP”
- November 13 International ITP Symposium 2010, Prague, Czechslovakia.
“Controversies and Conundrums: Unanswered Questions in ITP”
- November 13 International ITP Symposium 2010, Prague, Czechslovakia.
“Clinical Experience with TPO Mimetics”
- November 13 International ITP Symposium 2010, Prague, Czechslovakia.
“Development of Novel Agents in ITP”
- November 13 International ITP Symposium 2010,

Prague, Czech Republic.
“Using TPO-receptor Agonists:
When Where, and How”

- December 3 ITP Breakfast Meeting, 52nd Annual Meeting American Society of Hematology, Orlando, FL
“Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study”
- December 3 The Many Facets of Immune Thrombocytopenia Satellite Symposium, 52nd Annual Meeting American Society of Hematology, Orlando, FL
“Using TPO Agonists: Expectations and Challenges”
- December 4 Amgen Europe Satellite Meeting, 52nd Annual Meeting American Society of Hematology, Orlando, FL
“Caring for the ITP Patient Over Time”
- December 6 52nd Annual Meeting American Society of Hematology, Orlando, FL
“Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study”
- December 16 Hematology-Oncology Grand Rounds, University of Massachusetts Memorial Medical Center, Worcester, MA
“Thrombopoietin: From Molecule to Medicine”

2011

- January 21 Special Hematology Rounds, Kyoto University School of Medicine, Kyoto, Japan

	"The Treatment of Immune Thrombocytopenia with Eltrombopag"
January 22	APJME Congress on ITP, Imperial Hotel, Tokyo, Japan "The Treatment of Immune Thrombocytopenia with Eltrombopag"
February 5	2011 Highlights of ASH in North America, American Society of Hematology, New York, NY "Novel Treatments for Relapsed/Refractory Chronic Idiopathic Thrombocytopenic Purpura"
February 12	Gaucher Disease Expert Summit, Zurich, Switzerland "Review of 001 Study"
February 28	New Innovations in ITP Symposium, Edinburgh, Scotland "TPO Mimetics in the Treatment of Immune Thrombocytopenia"
March 25	Acute Leukemia Forum 2011 – Advances and Controversies in the Biology and Therapy of Acute Leukemia and Myelodysplasia, San Francisco, CA "What is the Potential for Thrombopoietic Agents in Acute Leukemia?"
April 13	ITP-The Clinicians Experience with Nplate. Royal College of Physicians of Ireland, Dublin, Ireland "A New Perspective on Immune Thrombocytopenia: Pathophysiology and Treatment"
April 13	ITP-The Clinicians Experience with Nplate. Royal College of Physicians of Ireland, Dublin, Ireland "New ITP Guidelines: International Consensus and

American Society of Hematology

- April 14 ITP-The Clinicians Experience with Nplate. Cork University Hospital, Cork, Ireland
“A New Perspective on Immune Thrombocytopenia: Pathophysiology and Treatment”
- April 14 ITP-The Clinicians Experience with Nplate. Cork University Hospital, Cork, Ireland
“New ITP Guidelines: International Consensus and American Society of Hematology”
- May 5 “How I treat ITP” Webcast. Hemedicus. Chicago, IL.
Treating Adults with ITP”
- May 6 Cytopenias and Hemostasis in 2011 Symposium. Chicago, IL.
“Autoimmune Hemolytic Anemia”
- May 14 3d Middle East and Africa Oncology-Haematology Summit. Dubai, UAE.
“Introduction to Current Issues in ITP”
- May 14 3d Middle East and Africa Oncology-Haematology Summit. Dubai, UAE.
“Romiplostim in ITP: Optimising Treatment”
- May 14 3d Middle East and Africa Oncology-Haematology Summit. Dubai, UAE.
“Cases in ITP”
- May 20 2011 Australian Haematology and Oncology Symposium. Sydney, Australia.
“Clinical Experience with TPO Receptor Agonists”
- May 21 2011 Australian Haematology and Oncology Symposium. Sydney,

- Australia.
“Immune Thrombocytopenia:
From Bench to Bedside”
- May 22 2011 Australian Haematology and
Oncology Symposium. Sydney,
Australia.
“Clinical Cases of ITP”
- June 9 16th Congress of the European
Hematology Association, From
Paradigm to Practice: Transforming
Treatments in ITP Symposium, London,
UK.
“From Bench to Bedside: The
Evolution of ITP Treatment”
- June 9 16th Congress of the European
Hematology Association, From
Paradigm to Practice: Transforming
Treatments in ITP Symposium, London,
UK.
“Virtual ITP Clinic”
- June 10 16th Congress of the European
Hematology Association, ITP Belgian
Evening EHA Symposium, London, UK.
“The Changing Treatment
Paradigm and New Approaches
in ITP”
- July 9 ITP Conference 2011, Platelet
Disorders Support Association, Boston,
MA
“What the Recent ITP Guidelines
Tell Us”
- July 9 ITP Conference 2011, Platelet
Disorders Support Association, Boston,
MA
“ITP in Adults”
- July 26 22nd Congress of the International
Society on Thrombosis and
Haemostasis, Plenary Symposium on
Immune Thrombocytopenia, Kyoto,
Japan

“TPO Mimetics in ITP”

- July 30 Kyowa-Kirin Memorial Lecture for the Launch of Romiplostim, Tokyo, Japan
“New Treatment Strategy for Immune Thrombocytopenia (ITP)”
- September 17 Canadian Conference on ITP, Toronto, Canada
“Using TPO Mimetics: The Data Behind the Guidelines”
- September 17 Canadian Conference on ITP, Toronto, Canada
“Debate: TPO Mimetics Should Replace Splenectomy as Second Line Treatment of ITP”
- September 17 Canadian Conference on ITP, Toronto, Canada
“Management of ITP: Case Based Approach”
- October 12 Waseda Seminar in Biology, Waseda University, Tokyo, Japan
“Discoveries of Molecules for Platelet Production: From Native Thrombopoietin to Its Mimetics”
- October 13 Seminar in Biology, Kyowa-Kirin Research Institute, Tokyo, Japan
“Thrombopoietin: From Molecule to Medicine: A Personal Voyage”
- October 15 ITP Symposium, 73^d Annual Meeting of the Japanese Society of Hematology, Nagoya, Japan
“Development and Clinical Practice of TPO Receptor Agonists”
- November 11 International ITP Assembly 2011, Brussels, Belgium.
“The Latest Guidance for ITP: International Consensus and American Society of Hematology Guidance”

- November 11 International ITP Assembly 2011, Brussels, Belgium.
"Patient Care in Practice"
- November 12 International ITP Assembly 2011, Brussels, Belgium.
"TPO Receptor Agonists in Clinical Practice"
- November 12 International ITP Assembly 2011, Brussels, Belgium.
"Which Treatment Advances Will Shape the Future of ITP"
- November 12 International ITP Assembly 2011, Brussels, Belgium.
"Using the TPO-receptor Agonists: When, Why, How"
- December 9 American Society of Hematology 2011 Annual Meeting, Symposium on The Care of ITP Patients: Advancing Quality of Life and Improving Treatment Outcomes, San Diego, CA.
"Diagnosis and Treatment of Adult ITP"

2012

- February 10 Medical Grand Rounds, Lankenau Medical Center, Wynnewood, PA.
"Immune Thrombocytopenia: New Pathophysiology and New Treatments"
- February 10 Housestaff Rounds, Lankenau Medical Center, Wynnewood, PA.
"Cases in Hematology"
- February 13 Hematology Rounds, Hadassah Ein Karem Medical Center, Jerusalem, Israel
"Coagulation Cases"
- February 14 Patient Conference, Shaare Zedek Medical Center, Jerusalem, Israel
"A Patient with ITP"

February 14	Translating Clinical Data of Romiplostim Into the Treatment of ITP Patients in Israel, Israel Hematology Society Symposium, Tel Aviv, Israel “Understanding Immune Thrombocytopenia: New Insights And Treatments”
March 20	Hematology Grand Rounds, Department of Clinical Haematology, Royal Melbourne Hospital, Melbourne, AUS “American Society of Hematology ITP Guidelines: Data Behind the Guidelines and Clinical Application”
March 20	Meet the Professor Symposium, Melbourne Hospitals, Melbourne, AUS “How I Use TPO Receptor Agonists”
March 21	Meet the Professor Symposium, Adelaide Hospitals, Adelaide, AUS “How I Use TPO Receptor Agonists”
March 22	Australia ITP Masterclass Symposium, Sydney, AUS “How I Use TPO Receptor Agonists”
March 22	Hematology Association of Australia (HAA) Meeting, Sydney, AUS “Thrombopoietin: From Molecule to Medicine”
April 8	Hematology Grand Rounds, Al Sabah NBK Pediatric Hospital, Kuwait City, Kuwait “Understanding ITP: New Insights and Treatments”
April 8	Hematology Society of Kuwait, Kuwait City, Kuwait “Thrombopoietin: From Molecule to Medicine”

April 9	Hematology Society of Bahrain, Manana, Bahrain “Thrombopoietin: From Molecule to Medicine”
April 10	Hematology Society of Qatar, Doha, Qatar “Thrombopoietin: From Molecule to Medicine”
April 12	Hematology Society of UAE, Abu Dhabi, UAE “Thrombopoietin: From Molecule to Medicine”
April 30	Hematology Grand Rounds, Toronto General Hospital, Toronto, Canada “Implications for Clinical Management of ITP”
April 30	Hematology Grand Rounds, St. Michael's Hospital, Toronto, Canada “Implications for Clinical Management of ITP”
May 1	Amgen Hematology Conference, Mississauga, Canada “Thrombopoietin: From Molecule to Medicine”
May 1	Hematology Meet the Professor, McMaster University, Thornhill, Canada “New Insights into the Pathophysiology and Treatment of ITP”
May 12	GD1 Expert Summit 2012: Optimising Therapeutic Approaches with Miglustat in Patients with GD1, Madrid, Spain “Long-term Experience with Miglustat: Data from a Retrospective Cohort Study”
May 12	GD1 Expert Summit 2012: Optimising Therapeutic Approaches with Miglustat in Patients with GD1, Madrid, Spain “Clinical Experiences with Miglustat”

- May 23 Velaglycerase global conference,
Brussels, Belgium
“Clinical case of bone disease
and elevated ferritin”
- June 11 7th International Platelet Symposium,
Beverly, MA
“Thrombopoietin mimetics:
Biology and clinical applications”
- July 21 ITP Conference 2012, Platelet
Disorders Support Association, Denver,
CO
“TPO agents update: What the
data tells us”
- July 21 ITP Conference 2012, Platelet
Disorders Support Association, Denver,
CO
“Patient care in practice”
- July 21 ITP Conference 2012, Platelet
Disorders Support Association, Denver,
CO
“ITP in adults”
- July 21 ITP Conference 2012, Platelet
Disorders Support Association, Denver,
CO
“What’s on the horizon? Future
developments in novel agents to
treat ITP”
- July 29 The Advanced Clinical Approaches on
ITP Symposium, Beijing, China
“Thrombopoietin: A new
pathophysiology and treatment
for ITP and its potential use in
secondary thrombocytopenia”
- July 30 Visiting Professor Lecture, Institute of
Hematology & Blood Diseases Hospital,
Chinese Academy of Medical
Sciences & Peking Union Medical
College, Tianjin, China
“Thrombopoietin: A new
pathophysiology and treatment

	for ITP and its potential use in secondary thrombocytopenia"
August 2	The Advanced Clinical Approaches on ITP Symposium, Shanghai, China "Thrombopoietin: A new pathophysiology and treatment for ITP and its potential use in secondary thrombocytopenia"
September 21	Taussig Cancer Center Grand Rounds, Cleveland Clinic, Cleveland, Ohio "Autoimmune Hemolytic Anemia (AIHA)"
September 26	Finnish Association for Hematology Annual Meeting, Helsinki, Finland "Treating ITP with TPO Receptor Agonists: Clinical Studies and Clinical Experience"
October 19	74 th Annual Meeting of the Japanese Society of Hematology, Kyoto, Japan. "Thrombopoietin Mimetics for the Treatment of ITP"
November 15	Iberian ITP Association, Berlin, Germany. "Romiplostim for the Individualized Management of ITP: Discussion of Clinical Cases"
November 16	International ITP Symposium 2012, Berlin, Germany. "ITP in Adult Patients Workshop"
November 17	International ITP Symposium 2012, Berlin, Germany. "Practical Aspects of Using TPO-Receptor Agonists"
November 17	International ITP Symposium 2012, Berlin, Germany. "TPO-receptor Agonists: Clinical Use Workshop"
November 17	International ITP Symposium 2012,

- Berlin, Germany.
“Future Developments in Novel Agents in ITP”
- November 17 International ITP Symposium 2012, Berlin, Germany.
“Expanding Our Experience: Use of TPO-receptor Agonists in Thrombocytopenia Beyond ITP”
- December 7 American Society of Hematology, 54th Annual Meeting, Unanswered Questions in ITP Symposium, Atlanta, GA
“What’s the harm? Long-term consequences of using TPO-receptor agonists”
- December 7 American Society of Hematology, 54th Annual Meeting, Unanswered Questions in ITP Symposium, Atlanta, GA
“Future directions in ITP – Soluble FcγRIIb receptors”

2013

- January 4 Hematology/Oncology Grand Rounds, Tufts New England Medical Center, Boston, MA
“Thrombopoietin: From Molecule to Medicine”
- January 18 Nichols Institute Seminar Series, Nichols Institute, San Juan Capistrano, CA.
“Autoimmune Hemolytic Anemia”
- March 7 3^d Emirates Haematology Conference, Dubai, UAE.
“Diagnosis and Management of ITP in 2013: The data behind the guidelines”
- March 7 3^d Emirates Haematology Conference, Dubai, UAE.
“Management of Relapsed/Refractory ITP: The case for TPO mimetics”

March 14	Gordon Research Conference on Cell Biology of Megakaryocytes and Platelets, Galveston, TX “Romiplostim in the treatment of thrombocytopenia: Development, physiology and clinical effects”
April 13	South Africa ITP Meeting, Johannesburg, South Africa “The New Era of ITP: Management with TPO-Receptor Agonists: Romiplostim”
April 13	South Africa ITP Meeting, Johannesburg, South Africa “TPO-Receptor Agonists: Balancing Differing Perspectives”
April 24	Haematology Seminar, Oakville, Canada “TPO-receptor Agonists: Efficacy and Safety in ITP”
April 25	McMaster Haematology Rounds, St. Joseph’s Hospital, Hamilton, Canada “Cases of Autoimmune Hemolytic Anemia and Immune Thrombocytopenia”
April 25	ITP Advisory Board and Steering Committee Meeting, Toronto, Canada “What’s New in ITP”
April 26	Haematology Rounds, Sunnybrook Hospital, Toronto, Canada “Implications for Clinical Management of ITP”
April 26	The Pathogenesis and Clinical Treatment of the Immune Cytopenias Symposium, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Canada “Autoimmune Hemolytic Anemia”
May 12	Qatar Hematology Society, Doha, Qatar

- “Updates in the Management of ITP”
- May 13 Jordanian Hematology Society,
Amman, Jordan
“Updates in the Management of ITP”
- May 14 Hematology Rounds, King Faisal
Specialist Hospital, Riyadh, Saudi Arabia
“Updates in the Management of ITP”
- May 14 Grand Rounds, King Khaled University
Hospital, Riyadh, Saudi Arabia
“Updates in the Management of ITP”
- May 14 Riyadh Hematology Society,
Riyadh, Saudi Arabia
“Updates in the Management of ITP”
- May 15 Hematology Rounds, King Faisal
Specialist Hospital, Jeddah, Saudi
Arabia
“Updates in the Management of
ITP”
- May 15 Jeddah Hematology Society, Jeddah,
Saudi Arabia
“Updates in the Management of ITP”
- May 16 Keynote Address, Egyptian Stem Cell
Transplantation & Hematological Disease
Association Conference,
Cairo, Egypt
“Updates in the Management of ITP”
- May 21 Conflict and Conundrums in the
Management of Acute Pulmonary Embolism
Session, American Thoracic Society,
Philadelphia, PA
“Anticoagulation in PE: What You
Need to Know”
- July 20 ITP Conference 2013, Platelet
Disorders Support Association,
Washington, DC
“What is the optimal
treatment for refractory immune
thrombocytopenia and when to
do what?””

July 20	ITP Conference 2013, Platelet Disorders Support Association, Washington, DC “Patient care in practice”
July 20	ITP Conference 2013, Platelet Disorders Support Association, Washington, DC “ITP in adults”
July 20	ITP Conference 2013, Platelet Disorders Support Association, Washington, DC “Key topics in ITP: Fatigue, bleeding, blood clots”
August 17	Singapore Society of Haematology ITP Conference, Singapore, Singapore “New Aspects of the Pathophysiology and Treatment of ITP: A Focus on TPO Receptor Agonists”
August 17	Malaysia Society of Haematology ITP Conference, Kuala Lumpur, Malaysia “New Aspects of the Pathophysiology and Treatment of ITP: A Focus on TPO Receptor Agonists”
September 24	Venezuelan Hematology Congress, Barquisimeto, Venezuela “TPO Receptor Agonists: Balancing Different Perspectives”
October 18	The Australian ITP Assembly, Gold Coast, Queensland, Australia “How I Treat ITP (and Why)”
December 6	ITP Breakfast Meeting, 55 th Annual Meeting American Society of Hematology, New Orleans, LA “Thrombopoietin: From Molecule to Medicine, A Personal Journey”
December 9	Ernest Beulter Lecture, 55 th Annual

Meeting American Society
of Hematology, New Orleans, LA
“Thrombopoietin: From Molecule
to Medicine”

2014

- | | |
|-------------|--|
| January 25 | 2014 Winter Oncology Symposium,
Holy Cross Hospital, Fort Lauderdale,
FL.
“What You Should Know About
The Old and New Anticoagulants” |
| February 14 | The 3d International Conference of the
Jordanian Society of Hematology,
Amman, Jordan.
“Immune Thrombocytopenia:
New Pathophysiology and New
Treatments” |
| March 7 | Basic Science Rounds, Pfizer,
Cambridge, MA.
“Pathophysiology and Treatment
of Immune Thrombocytopenia” |
| March 20 | TPIAO Symposium for the Treatment of
ITP, Chinese Society of Hematology,
Shanghai, PRC.
“Thrombopoietin: A New
Treatment for ITP and Its
Potential Use in Secondary
Thrombocytopenia” |
| March 21 | TPIAO Symposium for the Treatment of
ITP, Hubei Society of Hematology,
Wuhan, PRC.
“Thrombopoietin: A New
Treatment for ITP and Its
Potential Use in Secondary
Thrombocytopenia” |
| March 22 | TPIAO Symposium for the Treatment of
ITP, Zhejiang Society of Hematology,
Hangzhou, PRC.
“Thrombopoietin: A New
Treatment for ITP and Its
Potential Use in Secondary
Thrombocytopenia” |

- March 24 TPIAO Symposium for the Treatment of ITP, Guangdong Society of Hematology, Guangdong, PRC.
“Thrombopoietin: A New Treatment for ITP and Its Potential Use in Secondary Thrombocytopenia”
- April 3 Gaucher Disease Summit, Geneva, Switzerland.
“Enzyme replacement therapy vs substrate reduction therapy”
- April 12 Thrombosis and Hemostasis Summit 2014, Thrombosis and Hemostasis Societies of North America (THSNA), Plenary Lecture, Chicago IL.
“Managing Patients with ITP: Best Care in 2014”
- June 17 Fuji Film Advanced Research Laboratories Research Symposium, Kanagawa, Japan.
“Thrombopoietin: A New Treatment for ITP and Its Potential Use in Other Thrombocytopenic Disorders
- July 12 Platelet Disorders Support Association ITP Conference 2014, Los Angeles, CA.
“ITP Treatments Update”
- July 12 Platelet Disorders Support Association ITP Conference 2014, Los Angeles, CA.
“Patient Care in Practice”
- July 12 Platelet Disorders Support Association ITP Conference 2014, Los Angeles, CA.
“Is There a Real Thrombotic Risk for ITP Patients?”
- July 12 Platelet Disorders Support Association ITP Conference 2014, Los Angeles, CA.
“ITP in Adults”
- July 12 Platelet Disorders Support Association ITP Conference 2014, Los Angeles, CA.

“New Developments in ITP”

- | | |
|------------|--|
| July 18 | CEMA – Continuing Education in Medical Advances Symposium, Cancun, Mexico
“Evidence-based Approach to Therapeutic Strategies in ITP” |
| July 19 | CEMA – Continuing Education in Medical Advances Symposium, Cancun, Mexico
“Challenging Cases and Practical Considerations in the Management of ITP - 1” |
| July 19 | CEMA – Continuing Education in Medical Advances Symposium, Cancun, Mexico
“Challenging Cases and Practical Considerations in the Management of ITP - 2” |
| October 2 | Granite State Study Club, Bedford, NH.
“Clinical Use of Anticoagulants: Old and New” |
| October 10 | International ITP Update Meeting, School of Oriental and African Studies, London, UK
“TPO-R Agonists: What Have We Learned?” |
| October 10 | International ITP Update Meeting, School of Oriental and African Studies, London, UK
“Clinical use of TPO R drugs” |
| November 6 | HEMO: Congresso Brasileiro de Hematologia, Hemoterapia, e Terapia Celular . Workshop on Nplate: Evidence-based Approach to Novel Therapy, Challenging Cases and Practical Considerations in the Management of ITP. Florianopolis, SC, Brazil
“Evidence-based approach to therapeutic strategies in ITP” |

- November 8 HEMO: Congresso Brasileiro de Hematologia, Hemoterapia, e Terapia Celular. Florianopolis, SC, Brazil
“The pathophysiology of ITP: the new insights and implications in the treatment”
- November 14 56th Fall Scientific Meeting of the Korean Society of Hematology, Gwangju, Korea
“Development and Clinical Use of TPO Receptor Agonists”

2015

- January 11 Hematology Rounds, The Royal Clinic, King Abdulaziz Medical City, Riyadh, Saudi Arabia
“Thrombopoietin: From Molecule to Medicine”
- February 25 2015 Highlights of ASH in Asia, Bangkok, Thailand
“Immune Thrombocytopenia”
- February 25 2015 Highlights of ASH in Asia, Bangkok, Thailand
“Meet the Professor”
- March 13 International ITP Symposium 2015, Berlin, Germany.
“Interactive ITP Cases”
- March 13 International ITP Symposium 2015, Berlin, Germany.
“ITP Clinic Workshop”
- March 14 International ITP Symposium 2015, Berlin, Germany.
“Update from ASH”
- March 14 International ITP Symposium 2015, Berlin, Germany.
“Shaping the Future of ITP Treatment”
- March 31 Hematology Grand Rounds, Mt. Sinai Hospital, Toronto, Canada

“Clinical Experience with GD1 in
Boston-2015”

- April 1 Medical Grand Rounds, Mt. Sinai Hospital,
Toronto, Canada
 “Thrombopoietin: Physiology and
 Clinical Uses”
- May 1 CASCADE 2015 – Advances in
Hemostasis and Thrombosis, University
of Pittsburgh School of Medicine,
Pittsburgh, PA
 “New Insights into the Diagnosis
 and Management of ITP”
- May 2 Simposio Anemia y Trombocitopenia, 56th
National Congress of the Agrupacion
Mexicana para el Estudio de la
Hematologia (AMEH AC), Acapulco, Mexico
 “TIP Desafio de su Manejo en la
 `era de Agents
 Trombopoyeticos/ITP and How
 TPO Agonists Have Changed its
 Treatment”
- May 2 Lecture Magisterio (Plenary Lecture), 56th
National Congress of the Agrupacion
Mexicana para el Estudio de la
Hematologia (AMEH AC), Acapulco, Mexico
 “Thrombopoietin: From Beginning
 to End”
- July 24 Platelet Disorders Support Association
ITP Conference 2015, Nashville, TN.
 “ABCs of ITP – ITP Jeopardy”
- July 25 Platelet Disorders Support Association
ITP Conference 2015, Nashville, TN.
 “The Connection Between ITP and
 Blood Clots”
- July 25 Platelet Disorders Support Association
ITP Conference 2015, Nashville, TN.
 “The Treatment of ITP in Adults”
- July 25 Platelet Disorders Support Association
ITP Conference 2015, Nashville, TN.
 “ITP R & D: From Developing New

Treatments to Participating in
Clinical Trials"

- September 17 International Lymphoma Conference, The 18th Annual Meeting of Chinese Society of Clinical Oncology, Xiamen, China.
"The Science Behind the New Treatments for ITP"
- September 19 The 18th Annual Meeting of Chinese Society of Clinical Oncology, Xiamen, China.
"Diagnosis and Treatment of Thrombocytopenia Associated with Cancer Chemotherapy"
- November 7 2015 Dalhousie University Hematology Symposium, Halifax, Nova Scotia.
"New (and Old) Insights into the Diagnosis and Management of ITP"

2016

- February 5 Prader Willi Syndrome Expert Panel Meeting, Miami, FL
"All You Need to Know About Coagulation and Anticoagulation"
- February 12 4th International Conference of the Jordanian Society of Hematology, Amman, Jordan
"The Biology of Thrombopoietin and Its Clinical Use in Hematology"
- March 18 Acute Leukemia Forum 2016, Newport Beach, CA
"What is the Role of Novel Thrombopoietic Agents in the Management of Acute Leukemia?"
- April 1 6th Emirates Haematology Conference 2016), Dubai, UAE
"How I Treat ITP"
- April 1 6th Emirates Haematology Conference 2016), Dubai, UAE
"The Approach to

Thrombocytopenia in Cancer
Chemotherapy”

- April 1 6th Emirates Haematology Conference
2016), MDS Summit: Improving MDS
Outcomes from Diagnosis to Treatment:
A Multidisciplinary Approach, Dubai, UAE
“Tumor Board”
- April 1 6th Emirates Haematology Conference
2016), MDS Summit: Improving MDS
Outcomes from Diagnosis to Treatment:
A Multidisciplinary Approach, Dubai, UAE
“MDS: High Grade/Low Grade”
- April 9 Cumbre de Excelencia Médica Amgen
(CEMA 2016), Cancun, Mexico
“How I Treat ITP?”
- April 9 Cumbre de Excelencia Médica Amgen
(CEMA 2016), Cancun, Mexico
“Clinical Cases of ITP”
- April 18 XXXVI World Congress of the
International Society of Hematology,
Glasgow, Scotland
“New Treatment Options in ITP”
- April 19 XXXVI World Congress of the
International Society of Hematology,
Glasgow, Scotland
“Meet the Professor: How I Treat
ITP”
- April 22 Argenx Investigators Meeting,
Amsterdam, Netherlands
“ITP: The Patient’s Perspective”
- May 26 57th Spring Meeting of the Korean Society
of Hematology, Seoul, Republic of Korea
“How I Use Romiplostim”
- May 28 57th Spring Meeting of the Korean Society
of Hematology, Special Lecture, Seoul,
Republic of Korea
“The Clinical Impact of
Romiplostim for Patients with
Immune Thrombocytopenia (ITP)”

June 4	Full Potential of TPOr Agonists Symposium, Sao Paolo, Brazil “How I Treat ITP”
June 4	Full Potential of TPOr Agonists Symposium, Sao Paolo, Brazil “Making New Sense Out of Guidelines”
June 4	Full Potential of TPOr Agonists Symposium, Sao Paolo, Brazil “What Is An ITP Remission? Do TPO Receptor Agonists Help?”
July 9	ITP Conference 2016, Platelet Disorders Support Association 16 th Annual Conference, Orlando, FLA “The ABCs of ITP-ITP Jeopardy”
July 9	ITP Conference 2016, Platelet Disorders Support Association 16 th Annual Conference, Orlando, FLA “Vaccinations for Asplenic ITP Patients”
July 9	ITP Conference 2016, Platelet Disorders Support Association 16 th Annual Conference, Orlando, FLA “Patient Cases”
July 9	ITP Conference 2016, Platelet Disorders Support Association 16 th Annual Conference, Orlando, FLA “New Treatment Options for ITP”
September 5	Taliglucerase EOS Meeting, Pfizer Rome, Italy “An Open-label Expanded Access Trial of Plant Cell Expressed Recombinant Human Glucocerebrosidase (taliglucerase alfa) in Patients with Gaucher Disease Who Require Enzyme Replacement Therapy: Protocol # PB-06-004”

September 16	EHA Scientific Conference on Bleeding Disorders, Barcelona, Spain “Thrombopoietin Mimetics: Possible Future directions”
September 30	International ITP Assembly, Amsterdam, The Netherlands “Bone Marrow Fibrosis in ITP Patients”
September 30	International ITP Assembly, Amsterdam, The Netherlands “Meet the Professor Session”
October 1	International ITP Assembly, Amsterdam, The Netherlands “Reacting to Research—Low Level Laser Light”
October 1	International ITP Assembly, Amsterdam, The Netherlands “Chemotherapy-induced Thrombocytopenia - 1”
October 1	International ITP Assembly, Amsterdam, The Netherlands “Chemotherapy-induced Thrombocytopenia - 2”
October 1	International ITP Assembly, Amsterdam, The Netherlands “Future Horizons in ITP”
October 20	The Eighth Annual Arthur Haut, M.D. Lecture, University of Arkansas College of Medicine, Little Rock, Arkansas “Physiology and Use of Hematopoietic Growth factors”
October 22	American Association of Blood Banks Annual Meeting, Orlando “Treating Presurgical Thrombocytopenia with TPO Receptor Agonists”
October 29	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 150 th Anniversary

- Symposium on Cancer Treatment,
Wuhan, China
“Diagnosis and Treatment of
Thrombocytopenia Associated with
Cancer Chemotherapy”
- October 29 Advanced Clinical Studies and
Management of Thrombocytopenia
Symposium, Wuhan, China
“Advances in the Management of
Thrombocytopenia”
- October 30 Advanced Clinical Studies and
Management of Thrombocytopenia
Symposium, Xian, China
“Advances in the Management of
Thrombocytopenia”
- November 9 CVS Health National Pharmacy and
Therapeutics Committee Meeting,
Chicago, IL
“Hematopoietic Growth Factors”
- November 17 Treatment-associated Thrombocytopenia
Meeting, London, UK
“The Pathophysiology and Current
Management of Treatment-
associated Thrombocytopenia”
- December 2 Preamble Investigator Meeting, American
Society of Hematology Meeting, San
Diego, CA
“Unmet Need and Unanswered
Clinical Questions in the
Management of Patients with
Multiple Myeloma”
- December 15 Hematology-Oncology Grand Rounds,
Tufts University School of Medicine,
Boston, MA
“Clinical Uses of TPO Receptor
Agonists: From ITP to
Chemotherapy”

2017

- January 21 5th Annual Hematology Conference, The
Eastern Virginia Medical School, Virginia

Beach, VA
"Autoimmune Hemolytic Anemia"

February 23 21st Annual Congress on Hematologic
Malignancies, Sunny Isles, FL
"ITP: Pathophysiology and
Treatment Approaches"

March 2 Hematology Grand Rounds, National
Guard Hospital, King Abdulaziz Medical
City, Riyadh, Saudi Arabia
"TPO Receptor Agonists: Biology
and Clinical Uses"

March 2 Hematology Grand Rounds, Riyadh
Armed Forces Hospital, Prince Sultan
Military Medical City, Hospital, Riyadh,
Saudi Arabia
"TPO Receptor Agonists: Biology
and Clinical Uses"

March 3 Hematology Grand Rounds, University
Hospitals, Dammam, Saudi Arabia
"TPO Receptor Agonists: Biology
and Clinical Uses"

March 5 Hematology Grand Rounds, The Royal
Hospital, Muscat, Oman
"TPO Receptor Agonists: Biology
and Clinical Uses"

March 5 Hematology Grand Rounds, Sultan
Qaboos University Hospital, Muscat,
Oman
"TPO Receptor Agonists: Biology
and Clinical Uses"

March 6 Medical Grand Rounds, Al Sabah
Hospital, Kuwait City, Kuwait
"Immune Thrombocytopenia:
Biology and Treatment"

March 6 Hematology Grand Rounds, Al Sabah
Hospital, Kuwait City, Kuwait
"Case Studies in ITP"

March 6 Hematology Grand Rounds, Mubarak Al-
Kabeer Hospital, Kuwait University,

	Kuwait City, Kuwait “American Society of Hematology ITP Guidelines: Data Behind the Guidelines and Clinical Application”
March 7	ITP Research Symposium, Abu Dhabi, UAE “Update on TPO Receptor Agonists: Focus on ITP”
March 21	Hemophilia Awareness Day, Genzyme Corporation, Cambridge, MA “Hemophilia Review”
May 18	Hematology Grand Rounds, Rambam Medical Center, Haifa, Israel “TPO Receptor Agonists in ITP”
May 18	Hematology Grand Rounds, Sourasky Medical Center, Tel Aviv, Israel “TPO Receptor Agonists in ITP”
May 18	ITP Working Group Assembly, Tel Aviv, Israel “TPO Receptor Agonists: <i>ITP and Beyond</i> ”
May 19	Hematology Grand Rounds, Wolfson Medical Center, Tel Aviv, Israel “TPO Receptor Agonists in ITP”
May 19	Hematology Grand Rounds, Hadassa Medical Center, Jerusalem, Israel “TPO Receptor Agonists in ITP”
May 25	Hematology Roundtable Meeting, Brisbane, Australia “How I Treat Complex ITP Cases”
May 25	Hematology Roundtable Meeting, Brisbane, Australia “New Approaches to ITP Treatment”
May 25	Hematology Roundtable Meeting, Brisbane, Australia

“ITP Case Discussion”

May 26	Hematology Grand Rounds, Princess Alexandria Hospital, Brisbane, Australia “Autoimmune Hemolytic Anaemia”
May 26	Princess Alexandria Hospital, Brisbane, Australia “Hematology Clinic Cases”
May 29	Westmead Hospital, Sydney, Australia “Hematology Clinic Cases”
May 29	Liverpool Hospital, Sydney, Australia “Hematology Clinic Cases”
May 29	Sydney Clotters Meeting, Sydney, Australia “How I Treat Complex ITP Cases”
May 29	Sydney Clotters Meeting, Brisbane, Australia “New Approaches to ITP Treatment”
May 29	Sydney Clotters Meeting, Brisbane, Australia “ITP Case Discussion”
May 30	Haemostasis and Thrombosis Meeting, Alfred Hospital, Melbourne, Australia “How I Treat Complex ITP Cases”
May 30	Haemostasis and Thrombosis Meeting, Alfred Hospital, Melbourne, Australia “Hematology Clinic Cases”
May 30	Hematology Roundtable Meeting, Melbourne, Australia “How I Treat Complex ITP Cases”
May 30	Hematology Roundtable Meeting, Melbourne, Australia “New Approaches to ITP Treatment”
May 30	Hematology Roundtable Meeting, Melbourne, Australia “ITP Case Discussion”

May 31	Hematology Grand Rounds, Austin Health Hospital, Melbourne, Australia “New Approaches to ITP Treatment”
May 31	Hematology Grand Rounds, Austin Health Hospital, Melbourne, Australia “ITP Case Discussion”
May 31	Perth Hematology Rounds, Web Cast with Perth, Australia “ITP Case Discussion”
May 31	Adelaide Blood Club, Adelaide, Australia “How I Treat Complex ITP Cases”
May 31	Adelaide Blood Club, Adelaide, Australia “New Approaches to ITP Treatment”
May 31	Adelaide Blood Club, Adelaide, Australia “ITP Case Discussion”
June 22	European Hematology Association. Symposium: A new practical tool to help identify Gaucher Disease: Accelerating diagnosis and improving outcome for patients. Madrid, Spain. “Approaching thrombocytopenia: Where does Gaucher Disease fit in?”
June 22	European Hematology Association. Symposium: A new practical tool to help identify Gaucher Disease: Accelerating diagnosis and improving outcome for patients. Madrid, Spain. “Case Discussions”
July 29	ITP Conference 2017, Platelet Disorders Support Association 17 th Annual Conference, Chandler, Arizona “100 Years of ITP – Take the ITP Jeopardy Challenge”
July 29	ITP Conference 2017, Platelet Disorders Support Association 17 th Annual Conference, Chandler, Arizona “Primary vs Secondary ITP: The Similarities, Differences and Significance”

July 29	ITP Conference 2017, Platelet Disorders Support Association 17 th Annual Conference, Chandler, Arizona Conference, Orlando, FLA “Patient Cases with the Professor-I”
July 29	ITP Conference 2017, Platelet Disorders Support Association 17 th Annual Conference, Chandler, Arizona “Communicating With Your Doctor: Asking the Right Questions to Get the Right Answers”
July 29	ITP Conference 2017, Platelet Disorders Support Association 17 th Annual Conference, Chandler, Arizona “Patient Cases with the Professor-II”
July 29	ITP Conference 2017, Platelet Disorders Support Association 17 th Annual Conference, Chandler, Arizona “The Next 100 Years of ITP: The Future of ITP Research and Treatments”
August 3	The 9 th International Summit Forum on Hematology, The 60 th Anniversary of Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Sciences, Tianjin, China “Advances in the Treatment of ITP”
October 21	International ITP Assembly 2017, Geneva, Switzerland “Chemotherapy-induced Thrombocytopenia”
October 21	International ITP Assembly 2017, Geneva, Switzerland “Future of ITP Treatment”
November 3	Medical Grand Rounds, Lankenau Medical Center, Philadelphia, PA “Thrombocytopenia: Biology and New Therapies”
November 16	Autoimmune Hemolytic Anemia Consensus

Meeting, Vienna, Austria
“Future Developments on AIHA”

2018

April 11	Advances in ITP, Hammersmith Hospital, London, UK “What is the Position of Thrombopoietin Receptor Agonists in ITP?”
April 11	Advances in ITP, Hammersmith Hospital, London, UK “Patient Roundtable
July 13	ITP Conference 2018, Platelet Disorders Support Association 18 th Annual Conference, Cleveland, Ohio “20 Years of PDSA – Take the ITP Jeopardy Challenge”
July 14	ITP Conference 2018, Platelet Disorders Support Association 18 th Annual Conference, Cleveland, Ohio “Meet the Professor I”
July 14	ITP Conference 2018, Platelet Disorders Support Association 18 th Annual Conference, Cleveland, Ohio “Meet the Professor II”
July 14	ITP Conference 2018, Platelet Disorders Support Association 18 th Annual Conference, Cleveland, Ohio “Meet the Professor III”
August 4	Human Genetics Society of Australasia, 42 nd Annual Meeting, Sydney, Australia “Management Goals and Normalization Concept for Gaucher Disease: Results From a Survey of Expert Physicians”
September 4	Cardiology Grand Rounds, The Alfred Hospital, Melbourne, Australia “Thrombotic Mechanisms and Antithrombotic Agents: How do the New Oral Agents Fit In?”

September 4	Haemostasis and Thrombosis Clinical Cases and Journal Club, The Alfred Hospital, Melbourne, Australia “Approach to Difficult Haematology Conditions”
September 4	Haematology Inter-Hospital Meeting, Melbourne, Australia “The Diagnosis and Management of ITP”
September 6	Haematology Translational and Educational Meeting, The Alfred Hospital, Melbourne Australia “Thrombopoietin: Biology and Clinical Applications”
September 6	Registrar Microscope Session, The Alfred Hospital, Melbourne, Australia “Various Cases”
September 7	Haematology Grand Rounds, Box Hill Hospital, Melbourne, Australia “Autoimmune Haemolytic Anemias”
September 10	Haematology Journal Club, Oliva Newton John Centre, Austin Hospital, Melbourne, Australia “Thrombocytopenia: Review and Cases”
September 11	Haemostasis and Thrombosis Rounds, The Alfred Hospital, Melbourne, Australia “Consultative Haematology Cases”
September 11	APT Educational Conference, The Alfred Hospital, Melbourne, Australia “Thrombocytopenia: Biology, Clinical Approach and Treatment”
September 12	Haematology Journal Club, Monash Medical Centre, Melbourne, Australia “Future Developments in ITP”
September 12	Clinical Hematology Multidisciplinary Meeting, The Alfred Hospital, Melbourne, Australia

“Autoimmune Haemolytic Anemias”

- September 13 Registrar’s Microscope Session, The Alfred Hospital, Melbourne, Australia
Teaching Cases at the Microscope”
- October 26 International ITP Assembly 2018, Amsterdam, Netherlands
“Evolving Guidelines for ITP - Discussion”
- October 27 International ITP Assembly 2018, Amsterdam, Netherlands
“Meet the Professor”
- October 27 International ITP Assembly 2018, Amsterdam, Netherlands
“Practical Aspects of ITP – Discussion”
- October 27 International ITP Assembly 2018, Amsterdam, Netherlands
“Reacting to Research - Discussion”
- October 27 International ITP Assembly 2018, Amsterdam, Netherlands
“Chemotherapy-induced Thrombocytopenia”
- October 27 International ITP Assembly 2018, Amsterdam, Netherlands
“ITP Treatments on the Horizon”

2019

- January 22 Israel ITP Working Group, Tel Aviv, Israel
“ASH Guidelines 2019”
- January 22 Israel ITP Working Group, Tel Aviv, Israel
“How I Treat ITP - 2019”
- January 22 Israel ITP Working Group, Tel Aviv, Israel
“Future Developments in ITP Treatment”

January 23	Hematology Grand Rounds, Soroka Medical Center, Beersheba, Israel “Biology and Treatment of ITP in Kids and Adults”
January 23	Hematology Grand Rounds, Shiba Medical Center, Tel Aviv, Israel “Biology and Treatment of ITP in Kids and Adults”
January 24	Hematology Grand Rounds, Shiba Medical Center, Kfar Saba, Israel “Biology and Treatment of ITP in Adults”
January 24	Hematology Grand Rounds, Rabin Medical Center, Peta Tikva, Israel “Biology and Treatment of ITP in Adults”
January 24	Israel ITP Patient Association, Peta Tikva, Israel “Questions from Patients”
March 8	9 th Emirates Haematology Conference, Dubai, UAE “The Management of ITP in 2019”
March 8	9 th Emirates Haematology Conference, Dubai, UAE “The Management of Thrombocytopenia in Pregnancy”
April 5	CEMA – 2019 Continuous Education in Medical Advances, Playa del Carmen, Q.R., Mexico “ASH Guidelines: A Focus on Pediatric ITP”
April 6	CEMA – 2019 Continuous Education in Medical Advances, Playa del Carmen, Q.R., Mexico “Individualized Treatment Strategies for Adult ITP Patients”
April 25	BTK Immunology Summit, San Francisco, USA

	"BTK Inhibition in Immune Thrombocytopenia (ITP)"
May 4	Fostamatinib in AIHA Investigators Meeting, Keynote Address, Austin, TX "Warm Autoimmune Hemolytic Anemia (wAIHA)"
May 9	ITP Assembly—Update Day, London, UK "BTK Inhibitors and Other Interesting Ways to Treat ITP"
May 9	ITP Assembly—Update Day, London, UK "Proposed ASH Guidelines 2019"
May 29	CVS Caremark National Pharmacy and Therapeutics Committee Meeting, Chicago, IL "Neutropenia, Anemia, and Thrombocytopenia"
June 13	European Hematology Association 2019, From Guidance to Clinical Practice in ITP Symposium, Amsterdam, NL "ASH ITP Guidelines 2019"
July 5	XVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia "Complicated ITP Cases"
July 6	ITP Australia Patient Meeting, XVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia "What's New in ITP"
July 7	Current Treatment Challenges in ITP Symposium, XVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia "The 2019 Proposed ASH Guidelines"
July 10	State-of-the-Art Session, XVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia

“TPO Receptor Agonists in ITP”

July 27	ITP Conference 2019, Platelet Disorder Support Association, Washington, DC “International Consensus Proposed Guidelines”
July 27	ITP Conference 2019, Platelet Disorder Support Association, Washington, DC “ITP Patient Cases”
July 27	ITP Conference 2019, Platelet Disorder Support Association, Washington, DC “What’s New in ITP 2019”
July 27	ITP Conference 2019, Platelet Disorder Support Association, Washington, DC “Fostamatinib in ITP”
July 27	ITP Conference 2019, Platelet Disorder Support Association, Washington, DC “Interactive Patient ITP Cases”
August 23	HOPE ASIA 2019 – 1 st Highlights of Past EHA (HOPE) in Asia, Kolkata, India “Romiplostim: A New Tool in The Management of Thrombocytopenia”
August 30	24 th Annual Congress of Asia-Pacific Blood and Marrow Transplantation Group (APBMT) 2019, 24 th Annual Congress of Korean Society of Blood and Marrow Transplantation (KSBMT) 2019 & International Congress of Blood and Marrow Transplantation (ICBMT) 2019, Pusan, Korea “The Treatment of ITP with Romiplostim: Bringing New Data to Clinical Practice”
September 20	International ITP Assembly 2019, Amsterdam, Netherlands “ASH ITP Guidelines”
September 21	International ITP Assembly 2019, Amsterdam, Netherlands “Aplastic Anemia”

September 21	International ITP Assembly 2019, Amsterdam, Netherlands “ITP Treatments on the Horizon”
October 18	Chemotherapy-induced Thrombocytopenia (CIT) in Hematologic Malignancies, Lisbon, Portugal “Diagnosis and Treatment of Thrombocytopenia Associated with Cancer Chemotherapy”
October 25	Canadian Conference on ITP, Toronto, Canada “Mechanisms of Platelet Production”
October 25	Canadian Conference on ITP, Toronto, Canada “Consensus Report on Management of ITP”
October 25	Canadian Conference on ITP, Toronto, Canada “Long Term Data on TPO Receptor Agonists”
October 25	Canadian Conference on ITP, Toronto, Canada “Future of ITP Therapy”
November 9	Haematocon 2019, Indian Society of Hematology and Blood Transfusion, Symposium: Romiplostim – A New Armamentarium in the Management of Thrombocytopenia, New Delhi, India “Romiplostim for the Management of Thrombocytopenia”
December 6	ASH Friday Morning ITP Breakfast Symposium, 61 st American Society of Hematology Annual Meeting and Exposition, Orlando, FL “Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia”

- December 6 ASH Friday Morning ITP Breakfast Symposium, 61st American Society of Hematology Annual Meeting and Exposition, Orlando, FL
“Phase I/II, Open-Label, Adoptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary of Secondary Immune Thrombocytopenia”
- December 6 Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematologic Disorders Symposium, 61st American Society of Hematology Annual Meeting and Exposition, Orlando, FL
“Autoimmune Hemolytic Anemia”
- December 7 61st American Society of Hematology Annual Meeting and Exposition, Orlando, FL
“Phase I/II, Open-Label, Adoptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary of Secondary Immune Thrombocytopenia”

2020

- June 18 European Hematology Association 25th Annual Virtual Meeting, Frankfurt, Germany
“Safety and Efficacy of Rilzabrutinib (PRN1008), an Oral Bruton Tyrosine Kinase Inhibitor, in Relapsed/Refractory Patients With Primary or Secondary Immune Thrombocytopenia: Phase I/II Adaptive Study”
- June 18 European Hematology Association 25th Annual Virtual Meeting, Frankfurt, Germany
“Panel Discussion: ITP: What’s New in 2020”
- July 14 Current Perspectives on the Treatment of Primary Chronic ITP in Adults: An Independent Virtual Symposium at the

	International Society of Thrombosis and Hemostasis 2020 Virtual Congress “TPO RAs area as effective in early ITP as in chronic ITP”
July 14	Current Perspectives on the Treatment of Primary Chronic ITP in Adults: An Independent Virtual Symposium at the International Society of Thrombosis and Hemostasis 2020 Virtual Congress “What is the long term safety profile of TPO RAs”
July 14	Current Perspectives on the Treatment of Primary Chronic ITP in Adults: An Independent Virtual Symposium at the International Society of Thrombosis and Hemostasis 2020 Virtual Congress “What Novel Drugs are in the Pipeline to treat ITP”
July 15	Virtual Global ITP Assembly 2020 “Treatment of adult ITP: a guideline to the guidelines”
July 31	ITP Conference 2020, Platelet Disorder Support Association, Virtual Meeting “Current Clinical Trials in ITP 2020”
August 1	ITP Conference 2020, Platelet Disorder Support Association, Virtual Meeting “Treatment of adult ITP: a guideline to the guidelines”
August 1	ITP Conference 2020, Platelet Disorder Support Association, Virtual Meeting “Panel discussion with the experts”
August 19	Australia Virtual Global ITP Assembly 2020 “Meet the Professor”
September 15	Rozanolixizumab ITP Global Scientific Meeting (Global virtual meeting) “The Current ITP Patient Journey”
October 8	2 nd ITP Update Day, London, UK (virtual meeting) “BTK Inhibitors in ITP”

November 6	Global ITP Assembly 2020: TPO-RA Clinical Update. “Meet the Professor Questions”
November 6	Global ITP Assembly 2020: Specialist Sessions. “Chemotherapy-induced thrombocytopenia”
December 4	ASH Friday Morning ITP Breakfast, 62nd ASH Annual Meeting and Exposition, San Diego, CA (virtual meeting) “Oral Riltzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients With Heavily Pretreated Immune Thrombocytopenia”
December 4	Satellite Symposium on Clinical Advances in Immune Thrombocytopenia: Integrating New Therapies, 62 nd ASH Annual Meeting and Exposition, San Diego, CA (virtual meeting) “Therapeutic Options for Patients With Previously Treated ITP”
December 5	62nd ASH Annual Meeting and Exposition, San Diego, CA (virtual meeting) “Oral Riltzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients With Heavily Pretreated Immune Thrombocytopenia”
December 5	62nd ASH Annual Meeting and Exposition, San Diego, CA (virtual meeting) “Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the ENVISION Open-Label Extension”
December 12	Mumbai Hematology Group, Mumbai, India (Virtual Symposium) “Recent Advances in Treatment of Thrombocytopenia”

2021

February 10	Global ITP Assembly Virtual Series: Future Perspectives in ITP (Global virtual symposium) “Future ITP Treatments—Pathways of Interest”
February 11	Haematology Masterclass (Global Haematology Virtual Meeting sponsored by Novartis) “The American Society of Hematology Guidelines for ITP”
February 26	The 8th International Conference of the Jordanian Society of Hematology (Virtual Conference) on Hematological Disorders and Immunotherapy in Malignancies, Amman Jordan “Immune Thrombocytopenia – An Update”
March 10	ITP Assembly – Australia “Future ITP Treatments—Pathways of Interest”
March 17	Qatar ITP Virtual ITP Assembly, Doha, Qatar “The Use of TPO-receptor Agonists in Immune Thrombocytopenia in Adults”
March 20	Kuwait Thrombosis and Hemostasis Conference Symposium (Virtual meeting), Kuwait City, Kuwait The Use of TPO-receptor Agonists in Immune Thrombocytopenia in Adults”
March 24	10 th Emirates Hematology Conference (Virtual meeting), Dubai, UAE “The Use of TPO-receptor Agonists in Immune Thrombocytopenia in Adults”
March 29	Oman and UAE Hematology Conference, Muscat, Oman “The Use of TPO-receptor Agonists in Immune Thrombocytopenia in Adults”

- March 30 Hematology Grand Rounds (Virtual meeting), Northwell Health Cancer Center, New Hyde Park, NY
“Autoimmune Hemolytic Anemia: Focus on CAD”
- April 5 ITP: Meet the Experts Meeting (Virtual meeting), Saudi Arabia
“The Use of TPO-receptor Agonists in Immune Thrombocytopenia in Adults”
- April 7 New Developments in ITP Meeting (Virtual meeting), Riyadh, Saudi Arabia
“The Use of TPO-receptor Agonists in Immune Thrombocytopenia in Adults”
- May 8 UK ITP Support Association – Virtual Convention
“How I Treat ITP”
- May 8 UK ITP Support Association – Virtual Convention
“What Should ITP Patients Know About Vaccines?”
- May 31 Middle East & North Africa Hematology Congress 2021, Al Mukallā, Yemen
“The Use of TPO-receptor Agonists in Immune Thrombocytopenia in Adults”

b. Professional/educational leadership role related to teaching

- 1996 American College of Physicians. Co-organizer, course on “Key Advances in Internal Medicine”. Organized and presented Hematology/Oncology section for this new course of the ACP. The morphology and clinical cases are merged with new clinical stories and medications for internists. This has now become a stable part of the ACP syllabus.
- 1996 International Society of Experimental Hematology (ISEH) Annual Meeting, August 23, New York, NY. Moderator, “Symposium on the Molecular Biology of Platelet Production.” With my co-Chair we organized the first

international meeting on thrombopoietin. Many feel that the discussions at this meeting helped guide the development of this drug for the next several years.

- 1997 American Association of Blood Banks (AABB) Annual Meeting, October 21, Denver, CO. Organizer, Symposium on "Platelet Growth Factors: Impact on Transfusion Medicine." This was the first time that the new concept of "thrombopoietin" had been directed to transfusion medicine experts and stimulated a subsequent trial in stimulating platelet donors with this drug.
- 1997 American Society of Hematology Annual Meeting. Co-Chairman, Session on Growth Factors and Cytokines. Moderated meeting at which novel aspects of hematopoietic growth factors were presented. Subsequent press conference on the new drug, darbepoietin alpha, and new data on the thrombopoietin, PEG-rHuMGDF.
- 1998 Keystone Symposia - Molecular Regulation of Platelet Production, January 10-15, Lake Tahoe, CA. Co-organizer. We obtained NIH funding for this meeting, invited over 50 speakers from around the world. Meeting was the first comprehensive thrombopoietin meeting and was attended by over 500 people. One of few Keystone Meetings to make a profit.
- 1999 4th Annual Conference of Oncology Pharmacy, March 18-21, Orlando, FL. Chairman, "Choosing to Make a Difference with Low-Molecular Weight Heparin." Created an educational symposium for pharmacists on the use and monitoring of the low molecular weight heparins. Invited 5 international experts who provided both lectures and cases to teach this group. A successful meeting that has been

replicated many times over by this group.

- 2000 Consultants Conference, August 11-13, Austin, TX. Chairman, "The Antithrombotic Edge: A Consultant's Forum of Evolving Concepts." Working with an educational grant from Pharmacia, created a thrombosis and hemostasis forum directed at orthopedic surgeons. This successful set of cases and lectures has been repeated many times over for orthopedic surgeons.
- 2000 Consultants Conference, September 22-24, Bermuda. Chairman, "The Antithrombotic Edge: A Consultant's Forum of Evolving Concepts." Working with an educational grant from Pharmacia, created a thrombosis and hemostasis forum directed at cardiac surgeons. This successful set of cases and lectures has been repeated many times over for cardiac surgeons.
- 2002 48th Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis, July 18-20, Boston, MA. Local Organizing Committee member.
- 2002 Organizer, National Anemia Action Council Symposium series on "Current Advances in Oncology Treatment and Supportive Care," September 13, Boston, MA. With an educational grant from this group I organized a two-day symposium with MGH and DFCI oncologists to discuss new MGH developments in oncology and our recent work in supportive care with darbepoetin alpha. 52 physicians attended from New England and allowed us to showcase the MGH cancer effort.
- 2002 Cardiology Consultants Conference

Workshop, October 11-13, Chicago, Co-chairman. Working with an educational grant from Pharmacia, created a thrombosis and hemostasis forum directed at cardiologists. This successful set of cases and lectures has been repeated many times over for cardiologists.

- 2004 American Society of Hematology Annual Meeting, Scientific Subcommittee on Hematopoietic Growth Factors Symposium, "The Role of Chemokines and Their Receptors in Hematopoiesis," December 4-5, San Diego, CA. Chairman. I organized this New symposium topic for ASH with 4 international speakers. Over 1200 people attended both sessions and it was the most highly rated Subcommittee presentation of this meeting.
- 2005 American Society of Hematology Annual Meeting, Scientific Subcommittee on Hematopoietic Growth Factors Symposium, "Cytokine Receptors in Health and Disease," December 2-3, New Orleans, LA. Chairman. I organized this new symposium topic for ASH with 4 international speakers.
- 2006 University of California, Irving School of Medicine and CME Enterprise ITP CME Series, "Immune Thrombocytopenic Purpura: New Concepts and Approaches." Organizer and Chairman. I organized the 300 slide teaching set, gathered 4 other international experts, and arranged 16 sessions around the US.
- 2006 American Society of Hematology Symposium: Thrombocytopenia in the Practice of Hematology and Oncology – Focus on Increasing Platelet Production, Orlando. Organizer and Chairman. I organized the speakers

and topics for this CME symposium attended by about 1200 physicians.

- 2007 Future Directions in Gaucher Disease: Charting New Territories Symposium, Lisbon, Portugal. Co-organizer and Co-chairman. I helped organize this international symposium on Gaucher Disease for about 250 world experts in this field.
- 2007 Meeting the Treatment Challenges of Chronic Immune Thrombocytopenic Purpura: An Interactive Clinical Discussion, European Hematology Association 12th Congress, Vienna, Austria. Organized and chaired this international symposium on new treatments for ITP. Attended by ~600 Hematologists from around the world.
- 2007 Thrombocytopenia Treatment Exposed: Challenging Cases Brought to Life, Symposium at the 49th Annual Meeting of the American Society of Hematology, Atlanta, GA. Organized and co-Chair of this international symposium on the treatment of thrombocytopenia. To be attended by ~1000 hematologists from around the world.
- 2008 The Architecture of Bone Manifestations in Gaucher Disease: Classical Themes Applied to Innovative Concepts, Athens, Greece. Organized and Co-chair of Plenary Session on “Architecture and Design of Bone Manifestations in Gaucher Disease”. Presented to about 250 Gaucher Disease experts from around the world.
- 2008 Targeted Approaches for the Management of ITP, PDSA Annual ITP Conference 2008, Chicago, IL. Co-organizer of this meeting for physicians who treat ITP and patients who have ITP. Presented to over 300 physicians and patients at annual meeting of Platelet Disorder Support Association.

- 2009 Core Lecture Series on ITP, France Foundation, Old Lyme, CT. Co-organizer of core lecture presentation for hematologists about ITP and treatment options. Core lecture prepared for over 50 other specialists to present at various conferences and Grand Rounds.
- 2009 Facing up to Today's Clinical Challenges of Treating Lysosomal Storage Disorders Symposium, at American Society of Human Genetics Annual Meeting, Honolulu, HI. Organizer and chairman of symposium for 200 clinical geneticists on Gaucher Disease and Niemann-Pick C Disease. Gave one lecture and arranged for 5 other lecturers as well as ran panel discussion for this 3 hour meeting.
- 2009 Symposium de lancement Nplate at 7th Annual Lymphoma and Myeloma Conference, New York, NY. Co-organizer and co-chairman of symposium for ~100 French hematologists. Gave core lecture and helped arrange 7 other core lectures on ITP pathophysiology and treatment for this 7 hour symposium.
- 2009 Novel Agents, New Guidance: Standardising the Treatment for ITP, International Symposium, Lisbon, Portugal. Co-organizer and co-chairman of symposium on new treatment guidelines in ITP for ~200 hematologists from over 50 countries. Gave two core lectures and helped arrange for 20 more for this two-day symposium.
- 2009 International ITP Assembly 2009, Lisbon, Portugal. Organizer, Scientific Director, and Chairman. Organized and ran this 2-day symposium for 450 hematologists from around the world. Also gave 6 h of lectures.
- 2010 European School of Haematology International Conference on Immune

- Thrombocytopenia, Lisbon, Portugal. Co-organizer and Co-chairman of three-day international symposium on the biology and treatment of ITP. Gave three lectures and help chair the rest of the meeting.
- 2010 International ITP Symposium 2010, Prague, Czechslovakia. Organizer and Co-chairman for this two-day meeting for 200 European hematologists on advances in ITP pathophysiology, diagnosis and treatment. Organized 48 sessions with 16 faculty. Personally gave plenary address plus three additional lectures. Ran three Meet-the-Professor sessions.
- 2010 The Many Facets of Immune Thrombocytopenia Satellite Symposium, 52nd Annual Meeting American Society of Hematology, Orlando, FL. Organizer and Co-chairman of this 3 hour symposium for 1000 hematologists. 5 faculty and 6 lectures; gave one of the plenary lectures.
- 2011 2011 Highlights of ASH in North America. Organized the section on ITP for this two day review of American Society of Hematology 2010 Annual Meeting. Created core slide set and organized speakers for this 6-site symposium.
- 2011 Gaucher Disease Expert Summit, Zurich Switzerland. Co-Chairman and Co-organizer of this one day symposium on Gaucher Disease attended by 35 world experts on this topic. Arranged core lectures and was co-chairman of the event.
- 2011 3d Middle East and Africa Oncology-Hematology Summit. Dubai, UAE. Co-chairman and Co-organizer of this three day meeting on new developments in oncology and hematology. Selected lectures and

speakers for this event held for 150 physicians from the Middle East and Africa. Also gave three of the lectures.

- | | |
|------|---|
| 2011 | 2011 Australian Haematology and Oncology Symposium. Sydney, Australia. Co-chairman of this two day symposium for all of the hematologists in Australia. Prepared program and gave three major addresses to ~150 hematologists from Australia. |
| 2011 | 16 th Congress of the European Hematology Association, From Paradigm to Practice: Transforming Treatments in ITP Symposium, London, UK. Organizer and Chairman of this two hour symposium on ITP for 600 hematologists from Europe. Developed innovative patient interview format for case discussion and gave two hours of lecture with two colleagues. |
| 2011 | 16 th Congress of the European Hematology Association, ITP Belgian Evening EHA Symposium, London, UK. Developed 90 minute program for 25 hematologists that introduced them to new treatments in ITP. Lecture for 90 minutes. |
| 2011 | 22 nd Congress of the International Society on Thrombosis and Haemostasis, Co-chairman of Plenary Session on Megkaryocyte Biology and Platelet Production. Helped organize and run this 90 minute symposium for 4500 attendees of this international meeting. |
| 2011 | International ITP Assembly 2011, Brussels, Belgium. Organizer and Chairman. Helped organize and run this 2-day symposium for 300 hematologists from around the world. Also gave 5 h of lectures. |
| 2011 | American Society of Hematology 2011 |

Annual Meeting, Symposium on The Care of ITP Patients: Advancing Quality of Life and Improving Treatment Outcomes, San Diego, CA. Organizer and Chairman of this symposium on ITP for 600 hematologists from all over the world. Used patient videos to highlight and outline the multiple aspects of treating ITP. Three hour symposium at which I also gave 1 h of lecture.

- | | |
|------|---|
| 2012 | GD1 Expert Summit 2012: Optimising Therapeutic Approaches with Miglustat in Patients with GD1, Madrid, Spain. Co-Chairman and Co-organizer of this one day symposium on Gaucher Disease attended by ~50 world experts on this topic. Arranged core lectures and was co-chairman of the event. |
| 2012 | ITP Conference 2012, Platelet Disorders Support Association, Denver, CO. Co-chairman and organizer of this symposium on ITP treatment for over 500 patients and their families. Gave 2 h of lectures as well. |
| 2012 | International ITP Assembly 2012, Berlin, Germany. Organizer, Scientific Director, and Chairman. Organized and ran this 2-day symposium for 450 hematologists from around the world. Also gave 6 h of lectures. |
| 2012 | American Society of Hematology 2012 Annual Meeting, Symposium on Unanswered Questions in ITP, Atlanta, GA. Organizer and Chairman of this symposium on ITP for 1000 hematologists from all over the world. Used patient cases and lectures to highlight the multiple aspects of treating ITP. Three hour symposium at which I also gave 1 h of lecture. |
| 2013 | American Society of Hematology 2013 Annual Meeting, Symposium on |

Autoimmune Cytopenias. Designed and organized this symposium on immune cytopenias for 1000 hematologists from all over the world.

- 2014 2014 Winter Oncology Symposium, Holy Cross Hospital, Fort Lauderdale, FL. Co-Director of this symposium for over 250 internists in Florida. Helped develop curriculum for this 6 hour symposium on topics in hematology and medical oncology. Also gave 1 h of lecture.
- 2015 International ITP Assembly 2015, Berlin, Germany. Co-organizer and Co-Chairman. Organized and ran this 2 day symposium for 250 hematologists from around the world. Also gave 6 h of lectures.
- 2016 MDS Summit: Improving MDS Outcomes from Diagnosis to Treatment: A Multidisciplinary Approach at 6th Emirates Haematology Conference 2016), Dubai, UAE. Helped organize this 5 hour program for haematologists in the Middle East to improve the diagnosis and treatment of MDS. Also presented and discussed cases for 2.5 h.
- 2016 International ITP Assembly 2016, Amsterdam, The Netherlands. Co-organizer and Co-Chairman. Organized and ran this 2 Day symposium for 250 hematologists from around the world. Also gave 6 h of lectures.
- 2016 European Hematology Association. Symposium: A new practical tool to help identify Gaucher Disease: Accelerating diagnosis and improving outcome for patients. Madrid, Spain. Co-organizer and Co-Chairman of 2 hour symposium for 100 physicians attending European Hematology Association Meeting. Also gave 1.25 h of lectures and case discussions.

- 2017 International ITP Assembly 2017, Geneva, Switzerland. Co-organizer and Co-Chairman. Organized and ran this 2 Day symposium for 250 hematologists from around the world. Also gave 6 h of lectures.
- 2018 International ITP Assembly 2018, Amsterdam, Netherlands. Co-organizer and Co-Chairman. Organized and ran this 2 Day symposium for 350 hematologists from around the world. Also gave 6 h of lectures.
- 2019 From Guidance to Clinical Practice in ITP EHA Symposium, Amsterdam Netherlands. Co-Chairman and Co-Organizer for this European Hematology Association meeting for over 500 physicians from all over the world. Gave 1 h of lecture.
- 2019 ITP Conference 2019, Platelet Disorder Support Association, Washington, DC. Organized educational conference for 300 ITP patients from around the world. Gave 4 h of lectures.
- 2019 International ITP Assembly 2019, Amsterdam, Netherlands. Co-organizer and Co-Chairman. Organized and chaired this 2 Day symposium for 350 hematologists from around the world. Also gave 6 h of lectures.
- 2019 Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematological Disorders Symposium, 61st American Society of Hematology Annual Meeting and Exposition, Orlando, FL. Organized and chaired this 3 h symposium for practicing hematologists from all over the world. Gave 1 h of lecture.
- 2020 Virtual Global ITP Assembly 2020, Co-organizer and Co-Chairman. Organized and chaired this 4-day virtual symposium for 1000 hematologists from around the world. Also gave 6 h of lectures.

2020	Current Perspectives on the Treatment of Primary Chronic ITP in Adults: An Independent Virtual Symposium at the International Society of Thrombosis and Hemostasis 2020 Virtual Congress. Helped organize this meeting for over 500 attendees of this virtual symposium. Also gave two lectures in it.
2020	ITP Conference 2020, Platelet Disorder Support Association, Virtual Annual Meeting. Organized educational conference for ~700 ITP patients from around the world. Gave 3 h of lectures.
2020	Satellite Symposium on Clinical Advances in Immune Thrombocytopenia: Integrating New Therapies, 62 nd ASH Annual Meeting and Exposition, San Diego, CA (virtual meeting). Organized CME educational conference for >500 hematologists from all over the world for this virtual symposium. Program director and gave 1 h of lectures.
2021	Virtual Global ITP Assembly 2021, Co-organizer and Co-Chairman. Organized and chaired this 4-day virtual symposium for 1000 hematologists from around the world. Also gave 6 h of lectures.
2021	EHA
2021	ISTH

c. Teaching awards

1992	Teaching Excellence Award, Primary Care Internal Medicine Principles and Practice Course, Harvard Medical School
1994	The Alfred Kranes Award for Excellence in Clinical Teaching (awarded by MGH House Staff to best clinical teacher of the year)
1997	I.M. London Teaching Award, Harvard-MIT

Division of Health Sciences and Technology (awarded by medical students to the “faculty member who, through excellence and dedication to teaching in the biomedical sciences curriculum, best exemplifies the goals and philosophy of the Harvard-MIT Division of Health Sciences and Technology”)

- | | |
|------|--|
| 1998 | Best Teacher Award from 1st year Hematology-Oncology Fellows, MGH/BWH/DFCI |
| 2000 | Teaching Excellence Award, Primary Care Internal Medicine Principles and Practice Course, MGH/HMS |
| 2001 | Teaching Excellence Award, Primary Care Internal Medicine Principles and Practice Course, MGH/HMS |
| 2003 | Teaching Award from 1st year Hematology-Oncology Fellows, MGH/BWH/DFCI |
| 2006 | Nominee, Harvard Medical School Prize for Excellence in Teaching (Years 1 & 2) |
| 2007 | Nominee, Harvard Medical School Prize for Excellence in Teaching (Years 1 & 2) |
| 2007 | The Jane Grier Memorial Prize (Recognizing Excellence in Hematology/Oncology Teaching) MGH Cancer Center |
| 2008 | Nominee, Harvard Medical School Prize for Excellence in Teaching (Years 1 & 2) |

d. Major curricula/educational programs developed

- | | |
|-------|--|
| 1984- | “Coagulation I” and “Coagulation II” are the written syllabi for the MGH Internal Medicine Course. Coagulation I is a readable 60 page review of soluble clotting factors, how clots form, how anticoagulants work, and disorders of hemostasis. Coagulation II is a 56 page review of endothelial cell and platelet function. It includes discussion of how platelets form the primary hemostatic plug, |
|-------|--|

- disorders of platelets, and anti-platelet drugs. Updated yearly.
- 1985-2009 “The Platelet” is the written syllabus (68 pages) for the lecture of that name for the HST 080 Hematology course. It reviews all of the history, structure, function, biology, and diseases of platelets. Updated yearly.
- 1985-2009 “The Approach to the Bleeding Patient” is the written syllabus (53 pages) for the lecture of that name for the HST 080 Hematology course. It reviews the symptoms and signs of bleeding disorders, reviews the lab tests that are used, and reviews the major diseases that cause bleeding. Updated yearly.
- 1990-2009 Hematology SlideTeaching Set. Over the past 20 years I have recreated the teaching slide collection for HMS and MGH by obtaining 30 microscope slides each for over 100 interesting teaching cases. Each microscope slide is accompanied by a clinical vignette and description of the salient teaching points to be found on the slide. The last such set was created in 1955.
- 1995-2009 HST 080 Hematology Course Camel and Cases. Over the past 18 years I have developed the entire curriculum, case material, pathology slide set, lecture series for this introductory course in hematology for HST 2nd year students. Updated yearly.
- 1996-2009 “Cellular Hematopoiesis” is the written syllabus (32 pages) for the lecture of that name for the HST 080 Hematology course. It describes the histology of the bone marrow and stem cells, reviews the morphology of all blood cells and their progenitors, describes the evolutionary biology of hematopoiesis. Updated yearly.
- 1996-2009 “Hematopoietic Growth Factors” is the written syllabus (68 pages) for the lecture of that name for the HST 080 Hematology course. It reviews the biochemistry, biology and clinical use of erythropoietin, G-CSF/GM-CSF, thrombopoietin. Updated yearly.

- 1997-2009 “Stem Cell Biology and Hematopoietic Growth Factors” is the 52 page syllabus for the HMS/Partners Cancer Medicine and Hematology Course. After reviewing how stem cells become blood cells, it describes the biochemistry, biology and clinical uses of myeloid, erythroid and platelet growth factors. Updated yearly.
- 2000 The Antithrombotic Edge: Evolving Concepts in Prevention and Treatment. Mount Sinai School of Medicine. With my co-author, developed course, slide set, lecture notes for 4 hours of lecture in this educational program for and international audience of hematologists. Updated yearly.
- 2000-15 “Anticoagulation in Practice: Indication and Options” is the 43 page syllabus for the HMS Primary Care Internal Medicine Principles and Practice course. It reviews for the primary care physician how blood clots, how anticoagulants work, new indications and uses of anticoagulants as well as the anti-platelet agents and their biochemistry and clinical uses. Updated yearly.
- 2001-2015 “Anticoagulation in Practice (Anticoagulation for Idiots)” is the 35 page syllabus for the HMS Primary Care for Subspecialists course. It reviews the current indications for anticoagulation, new drugs that are appearing and the new developments in this area. Updated yearly.
- 2002-2009 “Introduction to Anemia – Iron Deficiency, Normocytic Anemias” is the written syllabus (42 pages) for the lecture of that name for the HST 080 Hematology course. It reviews the several approaches to categorizing the anemias, iron metabolism, and signs and symptoms of anemia. Updated yearly.
- 2002-2009 “Megaloblastic Anemias” is the written syllabus (28 pages) for the lecture of that name for the HST 080 Hematology course. It describes the Harvard history of B12 and its discovery, how B12 and folate work, the symptoms and signs of these anemias. Updated yearly.
- 2006 Immune Thrombocytopenic Purpura: New Concepts and Approaches, CME series.

Sponsored by University of California, Irvine School of Medicine and CME Enterprise. Organized an international panel of experts on ITP to create a teaching slide set on ITP and write a monograph on this topic. In charge of delivering over 20 lectures around the US on this topic to hematologists.

- 2007- Pulmonary and Critical Care Course, HMS CME Course. Created syllabus used to educate ~250 pulmonary/critical care doctors on thrombosis and anticoagulation. Syllabus accompanies yearly one hour lecture on this topic. Updated yearly.
- 2014- ITP Jeopardy Program. Educational program for physicians, students and patients. Formatted after the TV show "Jeopardy," this 1 hour program reviews the history, biology and treatment of ITP. Formatted for three different educational levels, this work consists of three separate programs. Updated yearly.

E. Report of Clinical Activities

1. Clinical Practice

- a. Private Hematology practice (1984-present) limited to unusual platelet problems, coagulation and anticoagulation issues, hematological malignancies, myeloproliferative disorders.
- b. Director of MGH Hematology Outpatient Clinic (1991-present). Supervise and see all referrals and follow-up general hematology patients for the 14-20 Hematology/Oncology Fellows.
- c. Inpatient Consult Service (1984-present). Consult on all general hematology issues for hospital. Admit and supervise hematology patients cared for by the 14 Fellows.
- d. Director MGH Gaucher's Disease Center (1992-present). Regional and national referral center for this disorder. Diagnosis, treatment and rehabilitation services provided by Center.
- e. Director MGH Sickle Cell Center (1991-2012). In collaboration with BWH Sickle Center manage all hospital patients with this disorder.

- f. Attending Physician, Hematology Service (1984-present). One - two months of year attend on wards with Fellows and students and care for all Hematology issues.
 - g. Co-leader, MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center. Help with diagnosis and multi-disciplinary care of patients with HHT. NIH and industry sponsored studies in this patient population
- 2. Patient load.
 - a. Private Hematology practice. 35-50 cases/week (6-8 new). Mostly complicated cases that are usually referrals from other hematologists.
 - b. Director of MGH Hematology Outpatient Clinic. 30-40 cases (6-8 new) per week of all ranges of complexity.
 - c. Inpatient Consult Service. Three to eight patients in hospital at all times, some with participation by Fellows.
 - d. Director MGH Gaucher's Disease Center. Actively treat 4-5 per week.
 - e. Co-leader, MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center. Help with multi-disciplinary care of over 50 families with HHT.
 - f. Attending Physician, Hematology Service. 80-100 new cases per month for two months each year. Range in complexity from simple anemia to acute leukemia.
- 3. Clinical contributions
 - a. Serve as local and national resource for phone consultations regarding issues of coagulation, anticoagulation and platelet disorders. Frequently called on to assist other physicians with the diagnosis and care of patients with immune thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), myeloproliferative diseases, multiple myeloma, and disorders of coagulation.
 - b. Created local guidelines for use of low molecular weight heparin, outpatient treatment of thrombosis, thrombolytic therapy and use of hematopoietic growth factors. Many of these now have spread nationally.

- c. Pioneered use of fondaparinux to treat HIT; used locally and now spreading to most part of the world. Potential to save hundreds of thousands of dollars at MGH alone.
 - d. Conducted clinical trials that helped develop and led to licensure of Velcade (bortezomib) as a new treatment for myeloma.
 - e. Have pioneered the use of AMG531 (thrombopoietin) in treating ITP, MDS, and chemotherapy-related thrombocytopenia
4. Other relevant information about clinical role
- a. Serve as local, national and international consultant on thrombopoietic growth factors.
 - b. Serve as local, national and international consultant on erythroid growth factors.
 - c. Serve as local, national and international consultant on anticoagulants.
 - d. Serve as local, national and international consultant on Gaucher's Disease.
 - e. International leader in developing thrombopoietin and related platelet growth factors.
5. Clinical trials DSMB, oversight committees
- a. Principia Safety Monitoring Committee: PRN1008 -010: An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura (1/17 – present)
 - b. Amgen Advisory Committee for chemotherapy-induced thrombocytopenia studies: NCT:03362177 and NCT: 03937154

Part III Bibliography

Original Articles

1. Weber K, Kuter DJ. Reversible denaturation of enzymes by sodium dodecyl sulfate. J Biol Chem 1971;246:4504-4509.
2. Kuter DJ, Rodgers A. Ribosomal protein differences between animal cells. Exp Cell Res 1974;87:186-194.

3. Kuter DJ, Rodgers A. The synthesis of ribosomal proteins and ribosomal RNA in a rat-mouse hybrid cell line. *Exp Cell Res* 1975; 91:317-325.
4. Kuter DJ, Rodgers A. The protein composition of HeLa ribosomal subunit and nucleolar precursor particles. *Exp Cell Res* 1976;102:205-212.
5. Greenberg SM, Kuter DJ, Rosenberg RD. In vitro stimulation of megakaryocyte maturation by megakaryocyte stimulatory factor. *J. Biol Chem* 1987;262:3269-3277.
6. Bell DF, Harris WH, Kuter DJ, Wessinger SJ. Elevated partial thromboplastin time as an indicator of hemorrhagic risk in post-operative patients on warfarin. *J Arthroplasty* 1988;3:181-184.
7. Kuter DJ, Greenberg SM, Rosenberg RD. The analysis of megakaryocyte ploidy in rat bone marrow cultures. *Blood* 1989; 74:1952-1962.
8. Kuter DJ, Rosenberg RD. The regulation of megakaryocyte ploidy in vivo in the rat. *Blood* 1990;75:74-81.
9. Ravid K, Doi, T, Beeler DL, Kuter DJ, Rosenberg RD. Transcriptional regulation of the rat PF4 gene: interactions between an enhancer/silencer domain and the GATA site. *Molec Cell Biol* 1991;11:6116-6127.
10. Kuter DJ, Gminski D, Rosenberg RD. Transforming growth factor-beta inhibits megakaryocyte growth and endomitosis. *Blood* 1992;79:619-626.
11. Kuter DJ, Gminski D, Rosenberg RD. Botrocetin agglutination of rat megakaryocytes: A rapid method for megakaryocyte isolation. *Exp Hematol* 1992;20:1085-1089.
12. Ravid K, Kuter DJ, Beeler DL, Doi T, Rosenberg RD. Selection of an HEL-derived cell line expressing high levels of platelet factor 4. *Blood* 1993;81:2885-2890.
13. Kuter DJ, Rosenberg RD. Appearance of a megakaryocyte growth promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. *Blood* 1994;84:1464-1472.
14. Kuter DJ, Beeler D, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. *Proc Natl Acad Sci USA* 1994;91:11104-11108.
15. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. *Blood* 1995;85:2720-2730.
16. Ravid K, Kuter DJ, Rosenberg RD. Recombinant murine interleukin-6 stimulates the transcriptional activity of the rat platelet factor 4 gene. *Expt Hematol* 1995;23:397-401.

17. Kuter DJ. The physiology of platelet production. *Stem Cells* 1996;14(Suppl 1):88-101.
18. Kuter DJ. Thrombopoietin: Biology, clinical applications, role in the donor setting. *J Clinical Apheresis* 1996;11:149-159.
19. Sirois MG, Simons M, Kuter DJ, Rosenberg RD, Edelman ER. The rat arterial wall retains myointimal hyperplastic potential long after arterial injury. *Circulation* 1997;96:1291-1298.
20. Head CA, Brugnara C, Martinez-Ruiz R, Kacmarek RM, Bloch KD, Bridges KR, Kuter D, Zapol WM. Low concentrations of nitric oxide increase oxygen affinity of sickle hemoglobin in vitro and in vivo. *J Clin Invest* 1997;100:1193-1198.
21. Vonderheide RH, Thadhani R, Kuter DJ. Association of thrombocytopenia and use of intra-aortic balloon pump. *Am J Med* 1998;105:27-32.
22. Yang C, Li YC, Kuter DJ. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. *Br J Haematol* 1999;105:478-485.
23. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. *Br J Haematol* 1999;106:345-356.
24. Li J, Sabath DF, Kuter DJ. Cloning and functional characterization of a novel c-mpl variant expressed in human CD34 cells and platelets. *Cytokine* 2000;12:835-844.
25. Xia Y, Li J, Bertino A, Kuter DJ. Thrombopoietin and the thrombopoietin receptor during platelet storage. *Transfusion* 2000;40:976-987.
26. Li J, Xia Y, Kuter DJ. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. *Br J Haematol* 2000;111:943-953.
27. Li J, Xia Y, Bertino A, Coburn J, Kuter DJ. The mechanism of apoptosis in human platelets during storage. *Transfusion* 2000;40:1320-1329.
28. Kuter DJ, Goodnough LT, Romo J, DiPersio J, Peterson R, Tomita D, Sheridan W, McCullough J. Thrombopoietin therapy increases platelet yields in healthy platelet donors. *Blood* 2001;98:1339-1345.
29. Goodnough LT, Kuter DJ, McCullough J, Slichter SJ, DiPersio J, Romo J, Peterson R, Smith, KJ, Raife T, Tomita D, Armstrong S. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. *Blood* 2001;98:1346-1351.
30. Allgood GS, Kuter DJ, Roll KT, Taylor SL, Zorich NL. Post-marketing surveillance of new food ingredients: results from the program with the fat replacer Olestra. *Regulatory Toxicology and Pharmacology* 2001;33:224-233.

31. Brown JR, Kuter DJ. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients. *Thrombosis Haemostasis* 2001;85:979-985.
32. Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Saven A, Hynes H, Boccia R., O'Byrne J, Colowick AB. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. *Br J Cancer* 2001;84 (Suppl 1):17-23.
33. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: Focus on the oxazolidinone, linezolid. *Pharmacotherapy*. 2001;21:1010-1013.
34. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ. Thrombocytopenia caused by the development of antibodies to thrombopoietin. *Blood* 2001;98:3241-3248.
35. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter, DJ. Hematologic effects of linezolid: Summary of clinical experience. *Antimicrobial Agents and Chemotherapy* 2002;46:2723-2726.
36. Bertino AM, Qi X, Li J, Xia Y, Kuter DJ. Apoptotic markers are increased in platelets stored at 37°C. *Transfusion* 2003;43:857-866.
37. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter DJ, Limentani SA, Lee, S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson K. A phase II study of bortezomib in patients with relapsed, refractory multiple myeloma. *N Engl J Med* 2003;348:2609-2617.
38. Nasraway SA, Kuter DJ, O'Grady N, Shorr AF, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin. *Clin Infect Dis* 2003;11:1609-1616.
39. Valeri CR, Ragno G, Marks PW, Kuter DJ, Rosenberg RD, Stossel TP. Effect of thrombopoietin alone and a combination of cytochalasin B and ethylene glycol bis(beta-aminoethyl ether) N,N'-tetraacetic acid-AM on the survival and function of autologous baboon platelets stored at 4 degrees C for as long as 5 days. *Transfusion* 2004;44:865-870.
40. Mogues T, Li J, Coburn J, Kuter DJ. IgG antibodies against bovine serum albumin in humans - their prevalence and response to exposure to bovine serum albumin. *J Immunol Methods* 2005;300:1-11.
41. Abel GA, Hays JT, Croghan G, Kuter D, Rigotti NA. Effects of biochemically confirmed smoking cessation on the white blood cell count. *Mayo Clin Proc* 2005;80:1022-1028.

42. Zerem A, Carcao MD, Christensen H, Kuter D, Kahr W, Rand M, Blanchette VS, Freedman MH, Dror Y. Familial non-syndromic thrombocytopenia: a disorder of megakaryopoiesis. *Ped Res* 2007 (In Press).
43. Bussel J, Kuter DJ, George J, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser J, Wiznitzer I, Kelly R, Chen CF, Nichol J. AMG 531, a thrombopoiesis-stimulating protein, for ITP. *New Engl J Med* 2006;355:1672-1681.
44. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Tallman MS. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. *Brit J Haematol* 2006;135:642-650.
45. Kuter DJ, Bussel J, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovic FT, de Wolf JT, Bourgeois E, Guthrie TH, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard J, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol J. Randomized, controlled, 6-month evaluation of AMG531 in patients with chronic immune thrombocytopenic purpura. *The Lancet* 2008;371:395-403.
46. Bussel J, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. *Blood* 2009;113:2161-2171.
47. Davis AK, Makar RS, Stowell CP, Kuter DJ, Dzik WH. ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. *Transfusion* 2009;49:206-213.
48. Soupir CP, Vergilio J, Kelly E, Cin PD, Kuter D, Hasserjian RP. Identification of del(20q) in a subset of patients with presumed idiopathic thrombocytopenic purpura. *Brit J Haematol* 2009;144:800-802.
49. Richardson PG, Xie W, Mitsiades C, Chanan-Khan, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine D, Weller E, Anderson KC, Amato AA. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlates of response and neuropathy. *J Clin Oncol* 2009;27;3518-3525.
50. Kuter DJ, Mufti GJ, Bain B, Hasserjian R, Davis W, Rutstein M. Evaluation of bone marrow reticulin in chronic immune thrombocytopenia patients treated with romiplostim. *Blood* 2009;114:3748-3756.

51. Provan D, Stasi R, Newland A, Blanchette V, Bolton-Maggs P, Bussel J, Chong B, Cines D, Gernsheimer T, Godeau B, Grainger J, Greer I, Hunt B, Imbach P, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter D. International consensus report on the investigation and management of primary immune thrombocytopenia. *Blood* 2010;115:168-186.
52. Kuter DJ, Rummel M, Boccia R, Macik G, Pabinger I, Selleslag D, Rodeghiero F, Chong B, Gehl L, Wang X, Berger D. Romiplostim or standard of care in patients with immune thrombocytopenia. *New Engl J Med* 2010;363:1889-1899.
53. Rabin DU, Kuter DJ, Liebman HA, Bussel JB. What do health care providers ask their patients with immune thrombocytopenia (ITP)? *Am J Hematol* 2010;85:629-631.
54. Cuker A, Arepally G, Crowther M, Rice L, Datko F, Hook K, Probert KJ, Kuter DJ, Ortel TL, Konkole BA, Cines DB. The HIT expert probability (HEP) score: a novel pre-test probability model for HIT based on broad expert opinion. *J Thromb Haemost* 2010;8:2642-2650.
55. Colwell AS, Reish RG, Kuter DJ, Damjanovic B, Austen WG, Fogerty AE. Abdominal contouring procedures are associated with a hypercoagulable state. *Ann Plast Surg* 2012;69:129-133.
56. Kuter DJ, Mathias SD, Rummel M, Mandanas R, Giagounidis AA, Wang X, Dueson RR. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. *Am J Hematol* 2012;87:558-561.
57. Alonzo MT, Lacuesta TL, Dimaano EM, Kurosu T, Suarez LC, Mapua CA, Akeda Y, Matias RR, Kuter DJ, Nagata S, Natividad FF, Oishi K. Platelet apoptosis and apoptotic platelet clearance by macrophages in secondary dengue virus infections. *J Inf Dis* 2012;205:1321-1329.
58. Kuter DJ, Bussel JB, Baker R, Lyons R, Macik G, Newland A, Rummel M, Viallard JF, Wasser J, Jun S, Nie K. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: Safety and efficacy. *Brit J Haematol* 2013;161:411-423.
59. Kuter DJ, Mehta A, Hollak CEM, Giraldo P, Hughes D, Belmatoug N, Brand M, Muller A, Schaaf B, Giorgino R, Zimran A. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. *Blood Cells Mol Dis* 2013;51:116-124.
60. Makar RS, Zhukov OS, Sahud MA, Kuter DJ. Thrombopoietin (TPO) levels may predict responsiveness to therapy with TPO agonists in patients with immune thrombocytopenia. *Am J Hematol* 2013;88:1041-1044.
61. Bussel JB, Kuter DJ, Aledort L, Kessler C, Cuker A, Pendergrass K, Tang S, McIntosh JA. Phase II randomized study of avatrombopag (E5501), a new

- thrombopoietin receptor agonist, in the treatment of patients with chronic immune thrombocytopenia. *Blood* 2014;123:2887-2894.
62. Kuter DJ, Meibohm A, Lopez A. TPO concentrations and response to romiplostim. *Am J Hematol* 2014;89:1155-1156.
 63. Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang F, Dawson KL, Ward M. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. *Int J Hematol* 2015;101:255-263.
 64. Marshall AL, Goodarzi K, Kuter DJ. Romiplostim in the management of the thrombocytopenic surgical patient. *Transfusion* 2015;55:2505-2510.
 65. Marshall AL, Scarpone R, De Greef M, Bird R, Kuter DJ. Remissions after long term use of romiplostim for immune thrombocytopenia. *Haematologica* 2016;101:e476-e478.
 66. Lubbarts B, Pereira, NRP, Kabrhel C, Kuter DJ, DiGiovanni CW. What is the effect of venous thromboembolism and post-thrombotic syndrome on health-related quality of life? A systematic review and meta-analysis. *Thrombosis and Haemostasis* 2016;116:417-431.
 67. Kuter DJ, Konkole BA, Gerstenberger E, Uhl L, Hamza TH, Assmann SF, Kiss JE, Kaufman RM, Key NS, Sachais B, Hess JR, Ness P, McCrae KR, Leissinger C, Strauss RG, McFarland, J, Neufeld E, Ortel TL. Clinical Outcomes in Patients with Heparin-induced Thrombocytopenia. *Am J Hematology* 2017;92:730-738.
 68. Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, Göker-Alpan O, Lukina E, Mengel E, Nakamura K, Pastores GM, Pérez Lopéz J, Schwartz I, Serratrice C, Szer J, Zimran A, Di Rocco M, Panahloo Z, Kuter DJ, Hughes D. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. *Mol Genet Metab* 2017;122:122-129.
 69. Crawford J, Becker PS, Armitage J, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mabry M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA. Myeloid growth factors. *J Natl Compr Canc Netw* 2017;15:1520-1541.
 70. Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumours. *Haematologica* 2018;103:e169-e172.
 71. Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, vom Dahl S, Haussinger D, Muller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM. Hepatocellular carcinoma in Gaucher disease: an international case series. *J Inherited Metab Disease* 2018;41:819-827.

72. Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. Romiplostim for the management of perioperative thrombocytopenia. *Br J Haematol* 2018;182:106-113.
73. Al-Samkari H, Kuter DJ. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag, and romiplostim in a patient with chronic autoimmune thrombocytopenia. *Br J Haematol* 2018;183:168-168.
74. Kuter DJ, Allen LF. Avatrombopag, an oral TPO receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. *Br J Haematol* 2018;183:466-478.
75. Al-Samkari H, Kuter DJ. An alternative intermittent eltrombopag dosing protocol for treatment of chronic immune thrombocytopenia. *Br J Pharmacol* 2018;84:2673-2677.
76. Al-Samkari H & Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. *Am J Hematol* 2018;93:1501-1508.
77. Mehta A, Kuter DJ, Salek SS, Belmatoug N, Bembi B, vom Dahl S, Deodato F, Di Rocco M, Goker-Alpan O, Hughes DA, Lukina EA, Machaczka M, Mengel E, Nagral A, Nakamura K, Narita A, Oliveri B, Pastores G, Pérez-López J, Ramaswami U, Schwartz IV, Szer J, Weinreb NJ, and Zimran A. Consensus on presenting signs and patient co-variables in Gaucher disease: use of the Delphi technique in the Gaucher Earlier Diagnosis Consensus (GED-C) initiative. *Int Medicine J* 2019;49:578-591.
78. Al-Samkari H, Van Cott, E, Kuter DJ. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. *Ann Hematol* 2019;98:581-588.
79. Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, Kuter DJ. Systemic bevacizumab for the treatment of chronic bleeding in hereditary hemorrhagic telangiectasia. *J Int Med* 2019;285:223-231.
80. Guddati AK, Rosovsky RP, van Cott E, Kuter DJ. Quantitative analysis of desmopressin (DDAVP) response in adult patients with Type 1 von Willebrand Disease. *Int J Lab Hematol* 2019;41:325-330.
81. Bianchi P, Fermo E, Glader B, Kanno H, Agarwal A, Barcellini W, Eber S, Hoyer J, Kuter DJ, Magalhães Maia T, Mañu-Pereira M, Kalfa TA, Pissard S, Segovia JC, van Beers E, Gallagher PG, Rees DC, van Wijk R. Addressing the diagnostic gaps in pyruvate kinase (PK) deficiency: Consensus recommendations on the diagnosis of PK deficiency. *Am J Hematol* 2019;94:149-161.
82. Kuter DJ, Newland A, Chong BH, Rodeghiero F, Tejeda Romero M, Pabinger I, Chen Y, Wang K, Mehta B, Eisen M. Romiplostim in adults with ITP for ≤ 1

- and >1 year: analyses from an integrated dataset of completed romiplostim studies. *Br J Haematol* 2019;185:503-513.
83. Grunwald MR, Burke JM, Kuter DJ, Gerds AT, Stein B, Walshauser MA, Parasuraman S, Colucci P, Paranagama D, Savona MR, Mesa R. Symptom burden and blood counts in patients with polycythemia vera in the United States: An analysis from the REVEAL Study. *Clin Lymphoma Myeloma Leuk* 2019;19:579-584.
 84. Al-Samkari H, Kuter DJ. Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. *Brit J Haematol* 2019;187:e61-e64.
 85. Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland A, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong R, Zaja F, Kuter DJ. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Advances* 2019;3:3780-3817.
 86. Hollenhorst MA, Al-Samkari H, Kuter DJ. Markers of autoimmunity in immune thrombocytopenia: Prevalence and prognostic significance. *Blood Advances* 2019;3:3515-3521.
 87. Neunert C, Terrell DR, Arnold DM, Buchanan D, Cines D, Cooper N, Cuker A, Despotovic JM, George JN, Grace R, Kühne T, Kuter DJ, Lim W, McCrae KR, Pruitt B, Shimanek H, Vesely SK. American Society of Hematology 2019 Guideline for Immune Thrombocytopenia. *Blood Advances* 2019;3:3829-3866.
 88. DeFilipp Z, Makar RS, Brown J, Avigan D, Chen Y-B, Cutler CS, Ballen KK, Kuter DJ. Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. *Bone Marrow Transplantation* 2020;55:1178-1180.
 89. Grunwald MR, Kuter DJ, Altomare I, Burke JM, Gerds AT, Walshauser MA, Savona MR, Stein B, Oh ST, Colucci P, Parasuraman S, Paranagama D, Mesa R. Treatment patterns and blood counts in patients with polycythemia vera treated with hydroxyurea in the United States: An analysis from the REVEAL Study. *Clin Lymphoma Myeloma Leuk* 2020;20:219-225.
 90. Jager U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, Jilma B, Kuter DJ, Michel M, Montillo M, Roth A, Zeerleder SS, Berentsen S. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. *Blood Reviews* 2020;41:100648.
 91. Al-Samkari H, Rosovsky RP, Karp Leaf RS, Smith DB, Goodarzi K, Fogerty AE, Sykes DB, Kuter DJ. A Modern Reassessment of Glycoprotein-Specific Direct Platelet Autoantibody Testing in Immune Thrombocytopenia. *Blood Advances* 2020;4:9-18.

92. Bloom PP, Rodriguez-Lopez J, Witkin AS, Al-Samkari H, Kuter DJ, Mojtahed A, Luther J. Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia. *Clinical and Translational Gastroenterology* 2020;11:e00118.
93. Newland AC, Sánchez-González B, Laszlo R, Egyed M, Romanyuk N, Cousin T, Godar M, Verschueren V, Gandini D, Ulrichs P, Beauchamp J, Dreier T, Ward ES, Michel M, Liebman HA, de Haard H, Leupin N, Kuter DJ. Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia. *Am J Hematology* 2020;95:178-187.
94. Kuter DJ, Wajnrajch M, Hernandez B, Wang R, Chertkoff P, Zimran A. Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy. *Blood Cells, Molecules, Diseases* 2020;82:102418.
95. Mytych DT, Park JK, Kim J, Barger TE, Boshier A, Jawa V, Kuter DJ. Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global post-marketing registry. *Brit J Haematol* 2020;190:923-932.
96. Cheloff AZ, Kuter DJ, Al-Samkari H. Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features. *Research and Practice in Thrombosis and Haemostasis* 2020;4:807-812.
97. Kuter DJ, Arnold DM, Rodeghiero F, Janssens A, Selleslag D, Bird R, Newland A, Mayer J, Wang K, Olie R. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. *Am J Hematol* 2020;95:643-651.
98. Al-Samkari H, Karp-Leaf R, Dzik WH, Goodarzi K, Bendapudi PK, Fogerty, AE, Gupta S, Leaf DE, Kuter DJ, Rosovsky R. COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 Infection. *Blood* 2020;136:489-500.
99. Balwani M, Sardh E, Ventura P, Peiró PA, Rees DC, Stölzel U, Bissell DM, Bonkovsky HL, Windyga J, Anderson KE, Parker C, Silver SM, Keel SB, Wang JD, Stein PE, Harper P, Vassiliou D, Wang B, Phillips J, Ivanova A, Langendonk JG, Kauppinen R, Minder E, Horie Y, Penz C, Chen J, Liu S, Ko JJ, Sweetser MT, Garg P, Vaishnav A, Kim JB, Simon AR, Gouya L; ENVISION Investigators (Petrides P, Kuter D, Sasapu A, Ritchie B, Monroy S, Ross G, Oh J, Lee M-J, Kuo H-C, Hother-Nielsen O, Sangro B, Navarro E, Thapar M, Stewart P, Coman D, Adachi T, Goto Y, Takase K-I, Cassiman D, Cappellini M, Singal A, Levy C, Nakahara F, Marcacci M, Celestin B, D'Avola D, Cohen DE, Wittes J, Dienstag JL, Shedlofsky SI). Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. *N Engl J Med*. 2020;382:2289-2301.
100. Mehta A, Rivero-Arias O, Abdelwahab M, Campbell S, McMillan A, Rolfe MJ, Bright JR, Kuter DJ. A scoring system to facilitate diagnosis of Gaucher disease. *Internal Medicine Journal* 2020;50:1538-1546.

101. How J, Leiva JO, Bogue T, Fell GG, Bustoros MW, Connell NT, Connors JM, Ghobrial IM, Kuter DJ, Mullally A, Neuberg D, Styles R, Zwicker J, Fogerty AM, Hobbs G. Pregnancy outcomes, risk factors, and gestational cell count trends in pregnant women with essential thrombocythemia and polycythemia vera. *Leukemia Research* 2020;98:106459.
102. Al-Samkari H, Song F, Kuter DJ, Rosovsky R. Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19). *Am J Hematol* 2020;95:1479-1485.
103. Al-Samkari H, Kasthuri, RS, Parambil JG, Albitar HA, Almodallal YA, Vázquez C, Serra MM, Dupuis-Girod S, Wilsen CB, McWilliams JP, Fountain EH, Gossage JR, Weiss CR, Latif MA, Issachar A, Mei-Zahav M, Meek ME, Conrad M, Rodriguez-Lopez J, Kuter DJ, Iyer VN. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. *Haematologica* 2021 (In Press).
104. Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JL, Connors JM, Kuter DJ. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. *Haematologica* 2021;106:1148-1157.
105. Song AB, Kuter DJ, Al-Samkari H. Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency Anemia. *Am J Hematol* 2021 (In Press).
106. Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Freubis J, Jiang X, Lin S, Reuter C, Morales-Arias J, Hobbs W, Berentsen S. Sutimlimab, a Complement C1s Inhibitor for Patients With Cold Agglutinin Disease: Results From the Pivotal Phase 3 Cardinal Study. *N Engl J Med* 2021;384:1323-1334.
107. Kuter DJ. Exacerbation of immune thrombocytopenia following Covid-19 vaccination. *Brit J Haematol* 2021 (In Press).
108. Waheed A, Kuter DJ. Iron Overload in the Era of Complement Inhibitor Treatment in Paroxysmal Nocturnal Hemoglobinuria. *Am J Hematol* 2021 (In Press).
109. Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Weitz IC, Patel P, Jiang X, Reuter C, Su J, Shafer F, Lee M, Berentsen S. Complement C1s inhibition with sutimlimab in cold agglutinin disease: 1-year follow-up results from the Cardinal study. *Blood* 2021 (Submitted).
110. Röth A, Barcellini W, Tvedt T, Miyakawa Y, Kuter DJ, Su J, Jiang X, Hobbs W, Arias JM, Shafer F, Weitz IC. Sutimlimab improves quality of life in patients with cold agglutinin disease: Cardinal study patient-reported outcomes. *Brit J Haematol* 2021 (Submitted).

111. Ventura P, Bonkovsky HL, Gouya L, Peiró PA, Bissell M, Stein PE, Balwani M, Anderson DK, Parker C, Kuter DJ, Monroy S, Oh J, Ritchie B, Ko JJ, Liu S, Sweetser MT, Simon A, Sardh E; for the ENVISION Investigators. Efficacy and Safety of Givosiran for Acute Hepatic Porphyria: 12-Month Interim Analysis of the ENVISION Study. A Randomized Clinical Trial. JAMA 2021 (Submitted).
112. Broome MA, Röth A, Kuter DJ, Scully M, Smith R, Wang J, Reuter C, Hobbs W, Daak A. Phase 1 Safety and Efficacy of the C1s inhibitor, Sutimlimab, in Patients with Chronic Immune Thrombocytopenia. Blood 2021 (Submitted).
113. Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, M.D., Bird R, M.B.B.S., Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee E-J, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, Oral BTK Inhibitor, in Immune Thrombocytopenia. New Engl J Med 2021 (Submitted).
114. McGrath LJ, Nielson C, Saul B, Breskin A, Yu Y, Nicolaisen S K, Kilpatrick K, Ghanima W, Christiansen CF, Bahmanyar S, Linder M, Eisen M, Wasser J, Altomare I, Kuter D, Sørensen H, Kelsh M, Brookhart M. Lessons learned using real-world data to emulate a randomized controlled trial: a case study of treatment effectiveness for recently diagnosed immune thrombocytopenia. Clinical Pharmacology & Therapeutics 2021 (Submitted).
115. Kuter DJ, Rogers KA, Boxer MA, Choi M, Agajanian R, Arnold D, Broome C, Field JJ, Murakhovskaya I, Numerof B, Tong S. Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Phase 2, Multicenter, Open-Label Study. Blood 2021 (Submitted).
116. Sloan M, Bertino A, Coburn M, Kuter DJ. A proteogenomic analysis of proteins in platelets in patients with ITP. Blood 2020 (Submitted).
117. Park JH, Zhu H, Moore AF, Kuter DJ. Efficacy of long-term enzyme replacement therapy in Gaucher Disease. Eur J Med Res 2019 (Submitted).
118. Bradner J, Goodarzi K, Yeh RW, Hallisey R, Kuter DJ. Fondaparinux in the treatment of heparin-induced thrombocytopenia. Am J Hematol 2020 (Submitted).
119. Kuter DJ, Dale D, Nichol J. Thrombocytopenia resulting from antibodies developed against a recombinant thrombopoietin. Lancet 2020 (Submitted).
120. Rosovsky RP, Abdel-Wahab OI, Van Cott E, Kuter DJ. The incidence of thrombosis in patients with isolated heparin-induced thrombocytopenia. Ann Int Med 2020 (Submitted).
121. AMF thrombin generation in factor X deficient patient
122. JAK2 ms

123. GD and weight

124. GD and spep

Proceedings of Meetings:

1. Kuter DJ, Gminski D, Rosenberg RD. Platelets contain several inhibitors of megakaryocyte growth and ploidization. In: Breton-Gorius J, Levin J, Nurden AT, Williams N, Eds. *Molecular Biology and Differentiation of Megakaryocytes*. New York: Alan R. Liss; 1990 p. 245-257.
2. Kuter DJ. Counterflow centrifugal elutriation. In: Breton-Gorius J, Levin J, Nurden AT, Williams N, Eds. *Molecular Biology and Differentiation of Megakaryocytes*. New York: Alan R. Liss; 1990. p. 351-352.
3. Kuter DJ. Thrombopoietin: from basic biology to clinical applications. In *Eurocancer 1998*. Paris: John Libbey Eurotext; 1998. p. 129-130.
4. Kuter DJ. Apoptosis in transfusion medicine. In *Lifespan*; 2000. p. 120-129.
5. Kuter DJ. Apoptosis in transfusion medicine. In: Blajchman MA, Dzik S, Vamvakas EC, Sweeney J, Snyder EL (eds). *Clinical and molecular basis of transfusion-induced immunomodulation: summary of proceedings of a state-of-the-art conference*. *Transfusion Medicine Reviews* 2001; 15:108-135.
6. Kuter DJ. Apoptosis in platelets during ex vivo storage. *Vox Sang* 2002;83:311-313.
7. Kuter DJ. Can cytokine-based therapy resolve thrombocytopenia? *Hem/Onc Today* 2003;4(suppl):2-10.
8. Kuter DJ. The promise of thrombopoietins in the treatment of ITP. *Clin Adv Hematol Oncol* 2005;6:464-466.
9. McCullough J, Kahn J, Adamson J, Anderlini P, Confer D, Benjamin R, Eapen M, Hirsch B, Kuter DJ, Lazarus E, Pamphilon D, Stroncek D, Sugarman J, Wilson R. Hematopoietic growth factors – Use in normal blood and stem cell donors: Clinical and ethical issues. *Transfusion* 2008;48:2008-25.
10. Kuter DJ. New concepts in conquering ITP. *Physician's Weekly* 2008;25:1.
11. Kuter DJ. The treatment of ITP with romiplostim: Bringing new data to clinical practice. *Blood Research* 2019;54 (Suppl 2):227-229.

Reviews, Chapters, Editorials:

1. Kuter DJ. Hemorrhagic Disorders II - The Platelet. In: Beck WS, Ed. *Hematology*, 5th Ed. Cambridge, MA: MIT Press; 1991. p. 543-575.

2. Kuter DJ, Rosenberg RD. Hemorrhagic Disorders III - Disorders of Primary and Secondary Hemostasis. In: Beck WS, Ed. Hematology, 5th Ed. Cambridge,MA: MIT Press; 1991. p. 577-598.
3. Kuter DJ. Thrombopoietin: biology and clinical applications. The Oncologist 1996;1:98-106.
4. Kuter DJ. In vivo effects of MPL ligand administration and emerging clinical applications for the MPL ligands. Current Opinion Hematol 1997;4:163-170.
5. Sheridan WP, Kuter DJ. Mechanism of action and clinical trials Mpl ligand. Current Opinion Hematol 1997;4:312-316.
6. Kuter DJ. The regulation of platelet production in vivo. In: Kuter DJ, Hunt P, Sheridan WP, Zucker-Franklin D, Eds. Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology. New Jersey: Humana Press; 1997. p 377-395.
7. Kuter DJ, Miyazaki H, Kato T. The purification of thrombopoietin from thrombocytopenic plasma. In: Kuter DJ, Hunt P, Sheridan WP, Zucker-Franklin D, Eds. Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology. New Jersey: Humana Press; 1997. p 143-164.
8. Kuter DJ. The use of PEG-rHuMGDF in platelet apheresis. In: Murphy MJ, Kuter DJ, Eds. Thrombopoietin: From Molecule to Medicine. Miamisburg, OH: AlphaMed Press; 1998. p. 231-242.
9. Kuter DJ. The water color drawings of James Homer Wright. In: Murphy MJ, Kuter DJ, Eds. Thrombopoietin: From Molecule to Medicine. Miamisburg, OH: AlphaMed Press; 1998. p. ix-x.
10. Murphy MJ, Kuter, DJ. Preface. In: Murphy MJ, Kuter DJ, Eds. Thrombopoietin: From Molecule to Medicine. Miamisburg, OH: AlphaMed Press; 1998. p. xi-xii.
11. Kuter DJ. Thrombopoietin and thrombopoiesis: a clinical perspective. Vox Sanguinis 1998;74(Suppl 2):75-86.
12. Goodnough LT, Kuter DJ, McCullough J, Brecher ME. Apheresis platelets: emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. J Clin Apheresis 1998;13:114-119.
13. Kuter DJ, Cebon J, Harker LA, Petz LD, McCullough J. Platelet growth factors: impact on transfusion medicine. Transfusion 1999;39:321-332.
14. Letai A, Kuter DJ. Cancer, coagulation and anticoagulation. The Oncologist 1999;4:443-449.
15. Kuter DJ. Thrombopoietin. In: Oppenheim JJ, Feldmann M, Durum SK, Hirano T, Vilcek J, Nicola NA, eds. Cytokine Reference: A Compendium of

- Cytokines and Other Mediators of Host Defense. New York: Academic Press, 2000; p 965-982.
16. Kuter DJ, Li, J. Thrombopoietin receptor. In: Oppenheim JJ, Feldmann M, Durum SK, Hirano T, Vilcek J, Nicola NA, eds. Cytokine Reference: A Compendium of Cytokines and Other Mediators of Host Defense. New York: Academic Press; 2000, p 1953-1968.
 17. van den Oudenrijn, Kuter DJ. CD110. Protein Reviews on the Web (PROW) 2000.
 18. Kuter DJ. Future directions with platelet growth factors. Seminars in Hematology 2000;37(Suppl 4):41-49.
 19. Snyder EL, Kuter DJ. Apoptosis in transfusion medicine: Of death and dying – is that all there is? Transfusion 2000;40:135-138.
 20. Kuter DJ. Megakaryopoiesis and thrombopoiesis. In: Beutler E, Lichtman MA, Collier BS, Kipps TJ, Seligsohn U, eds. Williams' Hematology, 6th Edition. New York: McGraw-Hill; 2001, p 1339-1356.
 21. Li J, Kuter DJ. The end is just the beginning: megakaryocyte apoptosis and platelet release. International Journal of Hematology 2001;74:365-374.
 22. Kuter DJ. Thrombopoietin. In: Michelson AD, ed. Platelets. San Diego, Academic Press; 2002, p 827-843.
 23. Kuter DJ. Whatever happened to thrombopoietin? Transfusion 2002;42:279-281. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100:3457-3469.
 25. Kuter, DJ. Thrombocytopenia and thrombocytosis. In: Furie B, Cassileth PA, Atkins MB, Mayer RJ, eds. Clinical Hematology and Oncology: Presentation, Diagnosis, and Treatment. Philadelphia: Churchill Livingstone; 2003, p221-231.
 26. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. The Oncologist 2004;9:207-216.
 27. Kuter DJ. Thrombopoietin. In Morstyn G, Foote MA, Lieschke GJ, Eds. Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics. Totowa, NJ: Humana Press; 2004, p125-151.
 28. Rosovsky RP, Kuter DJ. Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis and management. Hematology/Oncology Clinics of North America 2004;19:183-202.
 29. Kuter DJ. Biology and physiology of thrombopoietin. In: Rose BD and Rush JM, eds. UpToDate - Hematology 1999-2021 (updated yearly).

30. Kuter DJ. Clinical applications of thrombopoietin. In: Rose BD and Rush JM, eds. UpToDate - Hematology 1999-2021 (updated yearly).
31. Kuter D.J. Megakaryocyte biology and the production of platelets. In: Rose BD and Rush JM, eds. UpToDate - Hematology 1999-2021 (updated yearly).
32. Kuter DJ. Hemochromatosis. In First Consult. St. Louis: Elsevier, 2004-2007.
33. Kuter DJ. Immune thrombocytopenic purpura. In First Consult. St. Louis: Elsevier, 2004-2007.
34. Kuter DJ. Hemolytic anemia. In First Consult. St. Louis: Elsevier, 2004-2007.
35. Kuter DJ. Hairy cell leukemia. In First Consult. St. Louis: Elsevier, 2004-2007.
36. Kuter DJ. Polycythemia vera. In First Consult. St. Louis: Elsevier, 2004-2007.
37. Kuter DJ. Aplastic anemia. In First Consult. St. Louis: Elsevier, 2004-2007.
38. Kuter DJ. Non-Hodgkins lymphoma. In First Consult. St. Louis: Elsevier, 2004-2007.
39. Kuter DJ. MALT lymphoma. In First Consult. St. Louis: Elsevier, 2005-2007.
40. Kuter DJ. Disseminated intravascular coagulation (DIC). In First Consult. St. Louis: Elsevier, 2007.
41. Kuter DJ. Monoclonal gammopathy of uncertain significance (MGUS). In First Consult. St. Louis: Elsevier, 2005-2007.
42. Kuter DJ. Antiphospholipid antibody syndromes. In First Consult. St. Louis: Elsevier, 2005-2007.
43. Kuter DJ. Myelodysplastic syndromes. In First Consult. St. Louis: Elsevier, 2005-2007.
44. Rosovsky RP, Kuter DJ. Central venous catheters: care and complications. In Chabner BA, Longo DL, Eds. Cancer Chemotherapy and Biotherapy: Principles and Practice, 4th Edition. Baltimore: Lippincott Williams & Wilkins; 2006, 516-528.
45. Kuter DJ. Thrombopoietin: Biology and potential clinical applications. In McCrae KR, Ed. Thrombocytopenia. New York: Taylor & Francis; 2006, p 17-40.
46. Kuter DJ. Platelet growth factors. In: Michelson AD, ed. Platelets, 2nd Ed. San Diego, Academic Press; 2006, p 1211-1236.
47. Kuter DJ. General aspects of thrombocytopenia, platelet transfusions, and thrombopoietic growth factors. In: Kitchens C, Alving B, Kessler C, Eds.

- Consultative Hemostasis and Thrombosis, 2nd Edition, Philadelphia, Elsevier; 2007, 111-122.
48. Kuter DJ. Amyloidosis. In First Consult. St. Louis: Elsevier, 2006-2007.
 49. Kuter DJ. Transfusion reactions. In First Consult. St. Louis: Elsevier, 2006-2007.
 50. Kuter DJ. Anticoagulation. In First Consult. St. Louis: Elsevier, 2006-2007.
 51. Kuter DJ. Hemophilia. In First Consult. St. Louis: Elsevier, 2006-2007.
 52. Kuter DJ. Von Willebrand Disease. In First Consult. St. Louis: Elsevier, 2006-2007.
 53. Kuter DJ. Myelofibrosis. In First Consult. St. Louis: Elsevier, 2006-2007.
 54. Kuter DJ. Porphyria. In First Consult. St. Louis: Elsevier, 2006-2007.
 55. Kuter DJ. Multiple myeloma. In First Consult. St. Louis: Elsevier, 2006-2007.
 56. Kuter DJ. New thrombopoietic growth factors. *Blood* 2007;109:4607-4616.
 57. Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RB. Bone marrow fibrosis: Pathophysiology and clinical significance of increased bone marrow stromal fibers. *Brit J Haematol* 2007;139:351-362.
 58. Kuter DJ. New drugs for familiar therapeutic targets: Thrombopoietin receptor agonists and immune thrombocytopenic purpura. *Eur J Haematol* 2008;80 (s69):9-18.
 59. Kuter DJ. Meeting the treatment challenges of chronic immune thrombocytopenic purpura. *Eur J Haematol* 2008;80 (s69):1-2.
 60. Kuter DJ. The pathophysiology of immune thrombocytopenic purpura. *Clinical Oncology News*. December 2008; 1-12.
 61. Bussel JB, Kuter DJ, Liebman HA. ITP: Clinical companion: An update of evidence from 2008. On line publication at: ITPeducation.com. Nov 1, 2008.
 62. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. *Ann Rev Med* 2009;60:193-206.
 63. Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK. Myeloid growth factors. *J Natl Compr Canc Netw* 2009;7:64-83.
 64. Kuter DJ, Gernsheimer T. Thrombopoietin and platelet production in chronic immune thrombocytopenia. *Hematology-Oncology Clinics of North America* 2009;23:1193-1211.

65. Kuter DJ. Management of ITP: Advantages and disadvantages of standard treatments. In Comprehensive Overview of ITP. HematologyTimes (at hematologytimes.com), August 2009.
66. Kuter DJ. New thrombopoietic growth factors. Clinical Lymphoma and Myeloma 2009;9(Suppl 3);S347-S356.
67. Fleischmann KH, Kuter DJ, Coley CM, Rathmell JP. Practice guidelines often fail to keep pace with the rapid evolution of medicine: a call for clinicians to remain vigilant and revisit their own practice pattern. Reg Anesth Pain Med, 2010;35:4-7.
68. Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol, 2010;47:243-248.
69. Bussel JB, Kuter DJ. New Thrombopoietic Agents: Introduction. Semin Hematol, 2010;47:211.
70. Davids MS, Murali MR, Kuter DJ. Serum free light chain analysis. Am J Hematol 2010;85:787-790.
71. Kuter DJ. Romiplostim. In Lyman GH, Dale DC, Eds. Hematopoietic Growth Factors in Oncology. New York, Springer; 2011, 267-288.
72. Rosovsky RP, Kuter DJ. Intravenous access and catheter management. In Chabner BA, Longo DL, Eds. Cancer Chemotherapy and Biotherapy: Principles and Practice, 5th Edition. Baltimore: Lippincott Williams & Wilkins; 2011, 746-758.
73. Kuter DJ. Standardising the treatment for ITP. In Cines D, Kuter DJ, Newland D, Provan D, Semple J, Eds. The ITP Handbook. Paris: European School of Haematology; 2011, 124-136.
74. Kuter DJ. Thrombopoietin mimetics. Old and New. In Cines D, Kuter DJ, Newland D, Provan D, Semple J, Eds. The ITP Handbook. Paris: European School of Haematology; 2011, 138-157.
75. Kuter DJ. Clinical studies with TPO mimetics. In Cines D, Kuter DJ, Newland D, Provan D, Semple J, Eds. The ITP Handbook. Paris: European School of Haematology; 2011, 158-171.
76. Kuter DJ. Romiplostim. Cancer Treat Res 2011;157:267-88.
77. Belmatoug N, Burlina A, Giraldo P, Hendriksz C, Kuter D, Mengel E, Pastores G. Gastrointestinal disturbances and their management in patients with lysosomal storage disorders treated with miglustat. J Inherit Metab Dis 2011;34:991-1001.
78. Reddy P, Atay J, Selbovitz L, Connors J, Piazza G, Block C, Arpino P, Berliner N, Hutter AM, Fischer MA, Kuter D, Weitzman J, Sherwood GK, Almozlino A,

- Giugliano RP. Dabigatran: a review of clinical and pharmacoeconomic evidence. *Critic Pathway Cardiol* 2011;10:117-127.
79. Kuter DJ. What is the potential for thrombopoietic agents in acute leukemia? *Best Practice & Research Clinical Haematology* 2011;24:553-558.
80. Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M. Myeloid growth factors. *J Natl Compr Canc Netw* 2011;9:914-932.
81. Bendapudi P, Kuter DJ. Disseminated intravascular coagulation. In Parsons PE, Wiener-Kronish JP, Eds. *Critical Care Secrets*, 5th Edition. St. Louis, Mo: Elsevier Bosby; 2012, 397-403.
82. Kuter DJ. Thrombocytopenia and platelet dysfunction. In: Porter RS and Kaplan JL, Eds. *The Merck Manual Professional Edition*. Merck Publishing, Whitehouse Station, NJ; 2012.
83. Kuter DJ. Bleeding due to abnormal blood vessels. In: Porter RS and Kaplan JL, Eds. *The Merck Manual Professional Edition*. Merck Publishing, Whitehouse Station, NJ; 2012.
84. Kuter DJ. Platelet disorders. In: Porter RS and Kaplan JL, Eds. *The Merck Manual Home Health Handbook*. Merck Publishing, Whitehouse Station, NJ; 2012.
85. Kuter DJ. Bleeding due to abnormal blood vessels. In: Porter RS and Kaplan JL, Eds. *The Merck Manual Home Health Handbook*. Merck Publishing, Whitehouse Station, NJ; 2012.
86. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. *Int J Hematol* 2013;98:10-23.
87. Kuter DJ. Thrombopoietic growth factors. In: Michelson AD, Ed. *Platelets*, 3d Ed. San Diego: Elsevier/Academic Press; 2013, 1217-1242.
88. Kuter DJ. General aspects of thrombocytopenia, platelet transfusions, and thrombopoietic growth factors. In: Kitchens C, Kessler C, Konkle B, Eds. *Consultative Hemostasis and Thrombosis*, 3d Edition. Philadelphia: Elsevier Saunders; 2013, 103-116.
89. Crawford J, Armitage J, Balducci L, Becker, PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P. Myeloid growth factors. *J Natl Compr Canc Netw* 2013;11:1266-1290.
90. Kuter DJ. Milestones in understanding platelet production – A historical review. *Br J Haematol* 2014;165:248-258.

91. Kuter DJ. Thrombocytopenia and platelet dysfunction. In: Porter RS and Kaplan JL, Eds. The Merck Manual Professional Edition. Merck Publishing, Whitehouse Station, NJ; 2014 (updated yearly).
92. Kuter DJ. Bleeding due to abnormal blood vessels. In: Porter RS and Kaplan JL, Eds. The Merck Manual Professional Edition. Merck Publishing, Whitehouse Station, NJ; 2014 (updated yearly).
93. Kuter DJ. Platelet disorders. In: Porter RS and Kaplan JL, Eds. The Merck Manual Home Health Handbook. Merck Publishing, Whitehouse Station, NJ; 2014 (updated yearly).
94. Kuter DJ. Bleeding due to abnormal blood vessels. In: Porter RS and Kaplan JL, Eds. The Merck Manual Home Health Handbook. Merck Publishing, Whitehouse Station, NJ; 2014 (updated yearly).
95. Kuter DJ. Overview of blood disorders. In: Porter RS and Kaplan JL, Eds. The Merck Manual Home Health Handbook. Merck Publishing, Whitehouse Station, NJ; 2014 (updated yearly).
96. Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. *Oncology* 2015;29:282-294.
97. Kuter DJ. Hematopoietic growth factors. In: Simon TL, McCullough J, Snyder EL, Solheim BG, Strauss, RG, Eds. Rossi's Principles of Transfusion Medicine, 5th Edition. John Wiley and Sons, Hoboken, NJ; 2016;418-429.
98. Kuter DJ. What is the role of novel thrombopoietic agents in the management of acute leukemia. *Best Practice and Research: Clinical Haematology* 2016;29:372-378.
99. Kuter DJ. General aspects of thrombocytopenia, platelet transfusions, and thrombopoietic growth factors. In: Kitchens C, Kessler C, Konkle B, Eds. Consultative Hemostasis and Thrombosis, 4th Edition. Philadelphia: Elsevier; 2019;108-126.
100. Kritharis A, Al-Samkari H, Kuter DJ. Hereditary hemorrhagic telangiectasia: Diagnosis and management from the hematologist's perspective. *Haematologica* 2018;103:1433-1443.
101. Nagrebetsky A, Al-Samkari H, Kuter DJ, Wiener-Kronish JP. Perioperative thrombocytopenia. *Brit J Anaesthesia* 2019;122:19-31.
102. Kuter DJ. Thrombopoietin receptor agonists. In: Michelson AD, Cattaneo M, Frelinger AL, Newman PJ, Eds. Platelets, 4th Edition. St. Louis, MO:Academic Press;2019;1085-1110.
103. Bendapudi P, Kuter DJ. Disseminated intravascular coagulation. In: Parsons PE, Wiener-Kronish JP, Stapleton RD, Berra L, Eds. Critical Care Secrets, 6th Edition. Philadelphia, PA: Elsevier; 2019;386-391.

104. Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. *Therapeutic Adv Hematol* 2019;10:2040620719841735.
105. Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: Modern approaches to diagnosis and treatment. *Seminars Thrombosis Hemostasis* 2020; 46:275-288.
106. Al-Samkari, Grace RF, Kuter DJ. The role of romiplostim for pediatric patients with immune thrombocytopenia. *Ther Adv Hematol* 2020;11: 2040620720912992.
107. Bussel J, Kuter DJ. Preparing patients with immune thrombocytopenia for surgery: what are the options? *Lancet Haematology* 2020;7:e626-e627.
108. Lozano ML, Godeau B, Grainger J, Matzdorff A, Rodeghiero F, Hippenmeyer J, Kuter DJ. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. *Expert Review Hematol* 2020;13:1319-1332.
109. Kuter DJ, Tarantino MD, Lawrence T. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. *Blood Reviews* 2021 (**In Press**).
110. Ghanima W, Gernsheimer T, Kuter DJ. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. *Blood* 2021;137:2736-2744.
111. Kuter DJ. The Treatment of Immune Thrombocytopenia (ITP)– Focus on Thrombopoietin Receptor Agonists. *Annals of Blood* 2021;6: <https://aob.amegroups.com/article/view/6335>.
112. Karp Leaf R, Kuter DJ. Immune thrombocytopenia. In Boyiadzis MM, Frame JN, Kohler DR, Fojo T, Eds. *Hematology Oncology Therapy*, 3d Edition. New York: McGraw-Hill Education/Medical;2021,xxx.
113. Virk ZM, Kuter DJ, Al-Samkari H. An evaluation of avatrombopag for the treatment of thrombocytopenia. *Expert Opinion on Pharmacotherapy* 2021;22:273-280.

Books, Monographs, Text Books:

1. Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D, Eds. *Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical and Clinical Biology*. Totowa, NJ: Humana Press, 1997.
2. Murphy MJ, Kuter DJ, Eds. *Thrombopoietin: From Molecule to Medicine*. Miamisburg, OH: AlphaMed Press, 1998.
3. Kuter DJ, Ed. *Meeting the Treatment Challenges of Chronic Immune Thrombocytopenic Purpura*. Edinburgh, UK: Blackwell Publishing, 2008.

4. Bussel JB, Kuter DJ, Guest Eds. Seminars in Hematology-New Thrombopoietic Agents, Vol 47, No 3. Philadelphia, PA: Elsevier, July 2010.
5. Cines D, Kuter DJ, Newland D, Provan D, Semple J, Eds. The ITP Handbook. European School of Haematology, Paris, 2011.

Clinical Communications:

1. Kuter DJ, Ellman L, McCluskey RT. CPC – An 85-year-old woman with renal failure, neurological deterioration, and seizures. *New Engl J Med* 1991;325:266-273.
2. Kuter DJ and Harris N. CPC – A 57-year-old man with a 20-year history of episodic headache flushing, hypotension, and occasional seizure. *New Eng J Med* 1992;326:472-481.
3. Kakkar AK, Levine MN, Prandoni P, Lee AY, Rasmussen MS, Kuter D. What is the role for antithrombotics in cancer care? *Cancer Treatment Reviews* 2002;28:157-159.
4. Yee A, Kuter DJ. Successful recovery after an overdose of argatroban. *Annals Pharmacotherapy* 2006;40:336-339.
5. Moore A, Lau E, Yang C, Mackool B, Kuter DJ. Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma. *Am J Clinical Oncol* 2006;30:329-331.
6. Park JH, Spitzer T, Kuter DJ. Successful treatment of pure red cell aplasia with autologous stem cell transplantation. *Am J Hematol* 2007;82:814-814.
7. Lennerz JK, Kuter DJ, Hasserjian R, Iafrate J. Massive hepatomegaly and involvement by Janus kinase 2-positive myeloproliferative neoplasm. *Hepatology* 2010;52:1855-1856.
8. Schulman S, Awad MM, Kuter DJ. Neutrophil erythrocyte rosettes in autoimmune hemolytic anemia. *Am J Hematol* 2013;88:333-334.
9. Fitzsimmons MG, Walton K, Makar R, Dzik W, Kuter D, Vlahakes GJ. Redo aortic valve replacement in a patient with IgA deficiency and hemophilia A. *Ann Thor Surg* 2013;96:311-313.
10. Guddati AK, Kuter DJ. Rituximab therapy for factor II inhibitor in a patient with anti-phospholipid antibody syndrome. *Blood Coagul Fibrinolysis* 2014;25:289-291.
11. Kim PG, Suh J, Adelman MW, Oduro K, Williams E, Brunner A, Kuter DJ. Pure white cell aplasia and necrotizing myositis. *Case Reports in Hematology* 2016;2016: 4161679.

12. Rosen EA, Vallurupalli M, Choy E, Lennerz JK, Kuter DJ. Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma: A case report. *Medicine (Baltimore)* 2018;97:e13321.
13. Al-Samkari H, Patel, AA, Schiano TD, Kuter DJ. Recurrence of acute intermittent porphyria after liver transplantation. *Ann Int Med* 2019;170:904-905.
14. Soffer MD, Bendapudi PK, Roberts DJ, Edelson PK, Kuter DJ, Ecker J, Bryant AS, Goldfarb IT. Congenital thrombotic thrombocytopenic purpura (TTP) in pregnancy with subsequent placental abruption despite maternal improvement. *BMC Pregnancy and Childbirth* 2020;20:365.
15. Marinacci LX, Simeone FJ, Lundquist AL, Kuter DJ, Mahowald GK. Case 38-2020: A 55-year-old man with cancer and acute hypoxemia". *New Engl J Med* 2020;383:2372-2383.

Letter to the Editor:

1. Kuter DJ, Goodnough LT. Response: Thrombopoietin therapy increases platelet yields in healthy platelet donors. *Blood* 2002;99:3867-3868.
2. Kuter DJ. In Reply: Low dose warfarin prophylaxis for catheter-associated thrombosis in cancer patients. Can it be safely associated with 5-fluorouracil-based chemotherapy? *The Oncologist* 2004;9:596.
3. Bussel JB, Kuter DJ, Nichol JM. AMG 531 for chronic ITP. *New Engl J Med* 2007;356:307-308.
4. Al-Samkari H, Kritharis, A, Kuter DJ. Infections and vaccination in hereditary hemorrhagic telangiectasia: Microbiological evidence-based considerations. *Haematologica* 2018;103:e492-e495.

Educational Material:

1. Kuter DJ. Coagulation I, 1984-2021 (updated yearly).
2. Kuter DJ. Coagulation II, 1985-2021 (updated yearly).
3. Kuter DJ. The Platelet, 1985-2021 (updated yearly).
4. Kuter DJ. The Approach to the Bleeding Patient, 1985-2021 (updated yearly).
5. Kuter DJ. Hematology Slide Teaching Set, 1999-2009 (updated yearly).
6. Kuter DJ. HST Core Hematology Curriculum - Case Studies in Hematology, 1995-2009 (updated yearly).
7. Kuter DJ. HST Core Hematology Curriculum – Syllabus, 1995-2009 (updated yearly).

8. Kuter DJ. Cellular Hematopoiesis, 1996-2021 (updated yearly).
9. Kuter DJ. Hematopoietic Growth Factors, 1996-2021 (updated yearly).
10. Kuter DJ. Stem Cell Biology and Hematopoietic Growth Factors, 1997-2021 (updated yearly).
11. Kuter DJ. Low-molecular weight heparin – evolving role in clinical practice, Speakers Program slides and notes (Pharmacia, Pfizer), 1999-2007 (updated yearly).
12. Kuter DJ. Anticoagulation in Practice: Indication and Options, 2000-2021 (updated yearly).
13. Kuter DJ. Anticoagulation in Practice (Anticoagulation for Idiots), 2001-2021 (updated yearly).
14. Kuter DJ. Introduction to Anemia – Iron Deficiency, Normocytic Anemias, 2002-2021 (updated yearly).
15. Kuter DJ. Megaloblastic Anemias, 2002-2021 (updated yearly).
16. Kuter DJ. Thrombotic Mechanisms and Thrombotic Drugs, 2008-2021 (updated yearly).

Up-to-date Chapters:

1. Megakaryocyte biology and the production of platelets (Updated 6/30/2021).
2. Clinical applications of thrombopoietic growth factors (Updated 6/30/2021).
3. Biology and physiology of thrombopoietin (Updated 6/30/2021).

Thesis:

1. Kuter DJ. The ribosomal proteins of eukaryotic cells. Oxford, England: Bodleian Library, Oxford University; 1976.

Patents:

1. Rosenberg RD, Kuter DJ, Beeler D. Method of using megapoietin for prolonging the survival and viability of platelets. United States Patent 5,571,686 (November 5, 1996).